

Pembrolizumab plus Axitinib versus Sunitinib for Adva

New England Journal of Medicine

380, 1116-1127

DOI: [10.1056/nejmoa1816714](https://doi.org/10.1056/nejmoa1816714)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1370-1385.	5.1	594
2	Treatment of advanced renal cell carcinoma patients with cabozantinib, an oral multityrosine kinase inhibitor of MET, AXL and VEGF receptors. <i>Future Oncology</i> , 2019, 15, 2337-2348.	1.1	15
3	Diagnostic role of kidney injury molecule-1 in renal cell carcinoma. <i>International Urology and Nephrology</i> , 2019, 51, 1893-1902.	0.6	6
4	Toward a genome-based treatment landscape for renal cell carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 142, 141-152.	2.0	15
5	Immune checkpoint inhibitorsâ€”induced neuromuscular toxicity: From pathogenesis to treatment. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, S74-S85.	1.4	42
6	Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial. <i>Oncologist</i> , 2019, 24, 1497-1501.	1.9	22
7	Renal cell carcinoma treatment after first-line combinations. <i>Lancet Oncology</i> , The, 2019, 20, 1332-1334.	5.1	8
8	Results from a meta-analysis of immune checkpoint inhibitors in first-line renal cancer patients: does PD-L1 matter?. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591986190.	1.4	31
9	Should we use combination therapy for all advanced renal cell carcinoma?. <i>Lancet Oncology</i> , The, 2019, 20, 1331-1332.	5.1	3
13	Do biomarkers play a predictive role for response to novel immunotherapeutic agents in metastatic renal cell carcinoma?. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 1107-1110.	1.4	6
14	Enhanced efficacy of sitravatinib in metastatic models of antiangiogenic therapy resistance. <i>PLoS ONE</i> , 2019, 14, e0220101.	1.1	22
15	A Phase II, single-arm trial of neoadjuvant axitinib plus avelumab in patients with localized renal cell carcinoma who are at high risk of relapse after nephrectomy (NEOAVAX). <i>Future Oncology</i> , 2019, 15, 2203-2209.	1.1	19
16	Tumor Vasculatures: A New Target for Cancer Immunotherapy. <i>Trends in Pharmacological Sciences</i> , 2019, 40, 613-623.	4.0	79
17	Time on Therapy for at Least Three Months Correlates with Overall Survival in Metastatic Renal Cell Carcinoma. <i>Cancers</i> , 2019, 11, 1000.	1.7	17
18	Sunitinib for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World and Clinical Trials Data. <i>Targeted Oncology</i> , 2019, 14, 405-416.	1.7	35
19	Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma. <i>European Urology</i> , 2019, 76, 151-156.	0.9	190
20	New emerging targets in cancer immunotherapy: the role of TIM3. <i>ESMO Open</i> , 2019, 4, e000497.	2.0	72
21	Ramucirumab plus pembrolizumab: can we make the maths work?. <i>Lancet Oncology</i> , The, 2019, 20, 1041-1043.	5.1	1

#	ARTICLE	IF	CITATIONS
22	Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial. <i>Lancet Oncology</i> , The, 2019, 20, 1109-1123.	5.1	193
23	Validation of the IMDC Prognostic Model in Patients With Metastatic Renal-Cell Carcinoma Treated With First-Line Axitinib: A Multicenter Retrospective Study. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e1080-e1089.	0.9	10
24	Câ€reactive protein/albumin ratio is a predictive factor for prognosis in patients with metastatic renal cell carcinoma. <i>International Journal of Urology</i> , 2019, 26, 992-998.	0.5	16
25	Immune checkpoint inhibitors: The linchpins of modern immunotherapy. <i>Immunological Reviews</i> , 2019, 290, 6-23.	2.8	150
26	<p>Co-delivery of everolimus and vinorelbine via a tumor-targeted liposomal formulation inhibits tumor growth and metastasis in RCC</p>. <i>International Journal of Nanomedicine</i> , 2019, Volume 14, 5109-5123.	3.3	30
27	Immune checkpoint inhibitor combinations: Current efforts and important aspects for success. <i>Drug Resistance Updates</i> , 2019, 45, 13-29.	6.5	82
28	Cost-effectiveness Analysis of Pembrolizumab Plus Axitinib Versus Sunitinib in First-line Advanced Renal Cell Carcinoma in China. <i>Clinical Drug Investigation</i> , 2019, 39, 931-938.	1.1	27
29	Inhibition of Tumor Growth and Sensitization to Sunitinib by RNA Interference Targeting Programmed Death-ligand 1 in Mouse Renal Cell Carcinoma RenCa Model. <i>Anticancer Research</i> , 2019, 39, 4737-4742.	0.5	8
30	Augmenting the randomized controlled trial with real-world data to aid clinical decision making in metastatic renal cell carcinoma: a systematic review and meta-analysis. <i>Future Oncology</i> , 2019, 15, 3987-4001.	1.1	6
31	Current Concepts of Non-Coding RNAs in the Pathogenesis of Non-Clear Cell Renal Cell Carcinoma. <i>Cancers</i> , 2019, 11, 1580.	1.7	36
32	A Time to Ignore â€œNo Meat, No Treatâ€•. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 245-246.	0.4	0
33	Management of Advanced Kidney Cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2019. <i>Canadian Urological Association Journal</i> , 2019, 13, 343-54.	0.3	10
34	Response of Primary Renal Cell Carcinoma to Systemic Therapy. <i>European Urology</i> , 2019, 76, 852-860.	0.9	9
35	Preclinical rationale and clinical efficacy of antiangiogenic therapy and immune checkpoint blockade combination therapy in urogenital tumors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 3021-3036.	1.2	20
36	First-Line Systemic Therapy for Metastatic Clear-Cell Renal Cell Carcinoma: Critical Appraisal of Emerging Options. <i>Targeted Oncology</i> , 2019, 14, 639-645.	1.7	14
37	Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer. <i>JAMA Oncology</i> , 2019, 5, 1731.	3.4	150
38	Renal Cell Carcinoma: the Oncologist Asks, Can PSMA PET/CT Answer?. <i>Current Urology Reports</i> , 2019, 20, 68.	1.0	27
39	Factors Influencing the Efficacy of Anti-PD-1 Therapy in Chinese Patients with Advanced Melanoma. <i>Journal of Oncology</i> , 2019, 2019, 1-8.	0.6	9

#	ARTICLE	IF	CITATIONS
40	Inflammatory Biomarkers as Predictors of Response to Immunotherapy in Urological Tumors. <i>Journal of Oncology</i> , 2019, 2019, 1-11.	0.6	6
41	Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial. , 2019, 7, 275.		48
42	Targeted Therapies Following First-Line Immune Checkpoint Inhibitor Combination in Metastatic Renal Cell Carcinoma: A Single Center Experience. <i>Kidney Cancer</i> , 2019, 3, 171-176.	0.2	3
43	Evaluation of clear cell subtypes of ovarian and uterine malignancies with anti-PD-L1 and anti-PD1 immunohistochemical expression and their association with stage and survival. <i>Gynecologic Oncology</i> , 2019, 155, 483-488.	0.6	10
44	Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice. <i>Immunotherapy</i> , 2019, 11, 1507-1521.	1.0	17
45	Effect of third- and fourth-line systemic therapies for metastatic renal cell carcinoma. <i>Scientific Reports</i> , 2019, 9, 15451.	1.6	8
46	Adverse Events of Concurrent Immune Checkpoint Inhibitors and Antiangiogenic Agents: A Systematic Review. <i>Frontiers in Pharmacology</i> , 2019, 10, 1173.	1.6	35
47	Incidence of Immune Checkpoint Inhibitor-Associated Diabetes: A Meta-Analysis of Randomized Controlled Studies. <i>Frontiers in Pharmacology</i> , 2019, 10, 1453.	1.6	24
49	Therapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors. <i>Antibodies</i> , 2019, 8, 51.	1.2	32
50	Vascular endothelial growth factor and programmed death-1 pathway inhibitors in renal cell carcinoma. <i>Cancer</i> , 2019, 125, 4148-4157.	2.0	21
51	PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN. <i>Clinical Cancer Research</i> , 2019, 25, 6080-6088.	3.2	50
52	Cytoreductive nephrectomy in the current treatment algorithm. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591987902.	1.4	13
54	Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 22699-22709.	3.3	226
55	The Changing Therapeutic Landscape of Metastatic Renal Cancer. <i>Cancers</i> , 2019, 11, 1227.	1.7	49
56	Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2019, 20, 1386-1394.	5.1	69
57	Role of immune checkpoint inhibitor-based therapies for metastatic renal cell carcinoma in the first-line setting: A Bayesian network analysis. <i>EBioMedicine</i> , 2019, 47, 78-88.	2.7	24
58	First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium. <i>European Urology</i> , 2019, 76, 861-867.	0.9	71
60	The Evaluation of Response to Immunotherapy in Metastatic Renal Cell Carcinoma: Open Challenges in the Clinical Practice. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4263.	1.8	17

#	ARTICLE	IF	CITATIONS
61	Emerging therapeutic agents for genitourinary cancers. <i>Journal of Hematology and Oncology</i> , 2019, 12, 89.	6.9	33
62	Game of thrones: immunotherapy versus molecular targeted therapy in renal cell cancer scenarios. <i>International Urology and Nephrology</i> , 2019, 51, 2107-2117.	0.6	2
63	Management of metastatic renal cell carcinoma: The complexity of choice. <i>EBioMedicine</i> , 2019, 47, 2-3.	2.7	1
64	Tumor Microenvironment Dynamics in Clear-Cell Renal Cell Carcinoma. <i>Cancer Discovery</i> , 2019, 9, 1349-1357.	7.7	226
65	Towards Comprehensive Clinical Trial Reporting: The Value of Unpublished Data to Inform Therapeutic Decision-Making in Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e1181-e1184.	0.9	0
66	The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy. <i>Journal of Clinical Medicine</i> , 2019, 8, 1534.	1.0	41
67	Current Perspectives in Cancer Immunotherapy. <i>Cancers</i> , 2019, 11, 1472.	1.7	149
68	Investigational MET inhibitors to treat Renal cell carcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 851-860.	1.9	19
69	First-line Treatment of Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. <i>European Urology Oncology</i> , 2019, 2, 708-715.	2.6	64
70	Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT Study. <i>European Urology Oncology</i> , 2019, 2, 699-707.	2.6	38
71	<p>Tivozanib for the treatment of renal cell carcinoma: patient selection and perspectives</p>. <i>International Journal of Nephrology and Renovascular Disease</i> , 2019, Volume 12, 137-141.	0.8	0
72	What Comes After Immuno-Oncology Therapy for Kidney Cancer?. <i>Kidney Cancer</i> , 2019, 3, 93-102.	0.2	4
73	Targeting the Tumor Microenvironment in Renal Cell Cancer Biology and Therapy. <i>Frontiers in Oncology</i> , 2019, 9, 490.	1.3	85
74	Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor. <i>Cancers</i> , 2019, 11, 830.	1.7	29
75	Uveal Melanoma, Angiogenesis and Immunotherapy, Is There Any Hope?. <i>Cancers</i> , 2019, 11, 834.	1.7	41
76	Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019. <i>European Urology</i> , 2019, 76, 368-380.	0.9	48
77	Clear-cell Renal Cell Carcinoma: Molecular Characterization of IMDC Risk Groups and Sarcomatoid Tumors. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e981-e994.	0.9	34
78	Personalized approach to systemic therapy of renal cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2019, 4, 179-188.	0.4	0

#	ARTICLE	IF	CITATIONS
79	Immune Checkpoint Blockade plus Axitinib for Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2019, 380, 2581-2582.	13.9	8
80	Immunotherapy for renal cell carcinoma. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 897-905.	1.4	14
81	Durable complete response in renal cell carcinoma clinical trials. <i>Lancet, The</i> , 2019, 393, 2362-2364.	6.3	7
82	Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2019, 114, 67-75.	1.3	88
83	Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 165-174.	1.8	123
84	Early Changes in CT Perfusion Parameters: Primary Renal Carcinoma Versus Metastases After Treatment with Targeted Therapy. <i>Cancers</i> , 2019, 11, 608.	1.7	5
85	Low-dose axitinib rechallenge with positive outcomes in a patient with metastatic renal cell carcinoma refractory to interferon α , sunitinib, axitinib, and nivolumab therapies: a case report. <i>Journal of Medical Case Reports</i> , 2019, 13, 98.	0.4	4
86	Efficacy and safety of combination immunotherapy for malignant solid tumors: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 138, 178-189.	2.0	31
87	Targeting Tyrosine kinases in Renal Cell Carcinoma: "New Bullets against Old Guys". <i>International Journal of Molecular Sciences</i> , 2019, 20, 1901.	1.8	41
88	Perspectives on Geriatric Oncology Research presented at the 2019 American Society of Clinical Oncology Genitourinary Cancers Symposium. <i>Journal of Geriatric Oncology</i> , 2019, 10, 523-525.	0.5	0
89	Enhancing Antitumor Immunity with Antiangiogenic Therapy: A Clinical Model in Renal Cell Carcinoma?. <i>Oncologist</i> , 2019, 24, 725-727.	1.9	5
90	Towards individualized therapy for metastatic renal cell carcinoma. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 621-633.	12.5	148
91	Immune-based combination therapy for metastatic kidney cancer. <i>Nature Reviews Nephrology</i> , 2019, 15, 324-325.	4.1	3
92	Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1692.	1.8	61
93	Re: Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. <i>European Urology</i> , 2019, 76, 126-127.	0.9	3
94	Axitinib "ICIs boost the RCC armamentarium. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 207-207.	12.5	0
95	Prognostic Markers for Refined Stratification of IMDC Intermediate-Risk Metastatic Clear Cell Renal Cell Carcinoma Treated with First-Line Tyrosine Kinase Inhibitor Therapy. <i>Targeted Oncology</i> , 2019, 14, 179-186.	1.7	14
96	Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution. <i>Clinical Drug Investigation</i> , 2019, 39, 503-519.	1.1	26

#	ARTICLE	IF	CITATIONS
97	The Intersection between Tumor Angiogenesis and Immune Suppression. <i>Clinical Cancer Research</i> , 2019, 25, 5449-5457.	3.2	300
98	Combination Therapy as First-Line Treatment in Metastatic Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2019, 380, 1176-1178.	13.9	54
99	Neoadjuvant anti-PD-1 immunotherapy for recurrent glioblastoma. <i>Translational Cancer Research</i> , 2019, 8, S577-S579.	0.4	2
100	Immune Checkpoint Inhibition, the Key to Success in Renal Cell Carcinoma?. <i>Kidney Cancer</i> , 2019, 3, 199-211.	0.2	0
102	Individualization of Dose and Schedule Based On Toxicity for Oral VEGF Drugs in Kidney Cancer. <i>Kidney Cancer</i> , 2019, 3, 213-225.	0.2	3
104	Evolving Epidemiologic Trends of Renal Cell Cancer by Histologic Subtype: An Updated Analysis of the California Cancer Registry. <i>Kidney Cancer</i> , 2019, 3, 189-196.	0.2	0
105	Real-World Results from One Year of Therapy with Tivozanib. <i>Kidney Cancer</i> , 2019, 3, 235-239.	0.2	2
106	Avelumab plus axitinib vs. sunitinib for advanced renal-cell carcinoma. <i>Translational Cancer Research</i> , 2019, 8, S585-S588.	0.4	1
107	Immunotherapy combinations transform the treatment paradigm for advanced renal cell carcinoma. <i>Annals of Translational Medicine</i> , 2019, 7, S385-S385.	0.7	2
108	Can immune biomarkers predict benefit from targeted agents in metastatic renal cell carcinoma?. <i>Annals of Translational Medicine</i> , 2019, 7, S275-S275.	0.7	0
109	Role of immunotherapy in metastatic renal cell cancer: past, present and future. <i>Annals of Translational Medicine</i> , 2019, 7, S349-S349.	0.7	5
110	Sequential treatment of metastatic renal cancer in a complex evolving landscape. <i>Annals of Translational Medicine</i> , 2019, 7, S272-S272.	0.7	6
113	Combination with Stereotactic Body Radiotherapy Offers a Promising Strategy to Overcome Resistance to Immunotherapy in Advanced Renal Cell Cancer. <i>Journal of Oncology</i> , 2019, 2019, 1-12.	0.6	17
115	First-line treatment of metastatic renal cell carcinoma: current standard of care. <i>Memo - Magazine of European Medical Oncology</i> , 2019, 12, 334-338.	0.3	1
116	BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma. <i>Journal of Translational Medicine</i> , 2019, 17, 386.	1.8	32
117	Immune checkpoint inhibitors in gastrointestinal malignancies: what can we learn from experience with other tumors?. <i>Translational Gastroenterology and Hepatology</i> , 2019, 4, 73-73.	1.5	4
118	New immunotherapy in the treatment of advanced renal cancer. <i>Expert Opinion on Emerging Drugs</i> , 2019, 24, 233-237.	1.0	10
119	Is immunotherapy the holy grail for pancreatic cancer?. <i>Immunotherapy</i> , 2019, 11, 1435-1438.	1.0	11

#	ARTICLE	IF	CITATIONS
120	Contemporary Renal Tumor Categorization With Biomarker and Translational Updates: A Practical Review. <i>Archives of Pathology and Laboratory Medicine</i> , 2019, 143, 1477-1491.	1.2	9
121	Treatment selection for first-line metastatic renal cell carcinoma in Australia: Impact of new therapy options. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019, 15, 3-10.	0.7	3
122	A view on drug resistance in cancer. <i>Nature</i> , 2019, 575, 299-309.	13.7	1,391
123	Pharmacodynamics, clinical findings and approval status of current and emerging tyrosine-kinase inhibitors for pancreatic neuroendocrine tumors. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 993-1004.	1.5	15
124	Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway. <i>Journal of Biomedical Science</i> , 2019, 26, 96.	2.6	26
125	The Interplay between Inflammation, Anti-Angiogenic Agents, and Immune Checkpoint Inhibitors: Perspectives for Renal Cell Cancer Treatment. <i>Cancers</i> , 2019, 11, 1935.	1.7	21
126	Is cytoreductive nephrectomy relevant in the immunotherapy era?. <i>Current Opinion in Urology</i> , 2019, 29, 526-530.	0.9	12
127	The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC). , 2019, 7, 354.		182
128	Novel therapy for pediatric and adolescent kidney cancer. <i>Cancer and Metastasis Reviews</i> , 2019, 38, 643-655.	2.7	11
129	Second-line therapy in metastatic renal cell cancer—how do we treat after immuno-oncology drugs?. Memo - Magazine of European Medical Oncology, 2019, 12, 339-341.	0.3	1
130	Synchronous inhibition of mTOR and VEGF/NRP1 axis impedes tumor growth and metastasis in renal cancer. <i>Npj Precision Oncology</i> , 2019, 3, 31.	2.3	31
131	Development of a prognostic composite cytokine signature based on the correlation with nivolumab clearance: translational PK/PD analysis in patients with renal cell carcinoma. , 2019, 7, 348.		17
132	The pro-tumorigenic host response to cancer therapies. <i>Nature Reviews Cancer</i> , 2019, 19, 667-685.	12.8	135
133	Three case reports. <i>Medicine (United States)</i> , 2019, 98, e18098.	0.4	7
134	Patient selection for cytoreductive nephrectomy in combination with targeted therapies or immune checkpoint inhibitors. <i>Current Opinion in Urology</i> , 2019, 29, 513-520.	0.9	9
135	The current role for adjuvant and neoadjuvant therapy in renal cell cancer. <i>Current Opinion in Urology</i> , 2019, 29, 636-642.	0.9	12
136	Cabozantinib in Combination with Immunotherapy for Advanced Renal Cell Carcinoma and Urothelial Carcinoma: Rationale and Clinical Evidence. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 2185-2193.	1.9	84
137	Are targeted agents the key to unlock the code for immune checkpoint inhibitors in soft-tissue sarcomas?. <i>Future Oncology</i> , 2019, 15, 3185-3187.	1.1	1

#	ARTICLE	IF	CITATIONS
138	Biomarkers of Prognosis and Efficacy of Anti-angiogenic Therapy in Metastatic Clear Cell Renal Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 1400.	1.3	39
139	Nicht metastasiertes Nierenzellkarzinom mit Tumorthrombus: Sunitinib und Sorafenib in der neoadjuvanten Therapie. <i>Karger Kompass Onkologie</i> , 2019, 6, 98-99.	0.0	0
140	Outcomes of combination therapy with tyrosine kinase inhibitors and immune checkpoint inhibitors in metastatic renal cell carcinoma – A retrospective study. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 556-563.	0.5	3
141	The Role of PD-L1 Testing in Advanced Genitourinary Malignancies. <i>European Urology Focus</i> , 2020, 6, 11-13.	1.6	6
142	C-reactive protein and the neutrophil-to-lymphocyte ratio are prognostic biomarkers in metastatic renal cell carcinoma patients treated with nivolumab. <i>International Journal of Clinical Oncology</i> , 2020, 25, 135-144.	1.0	38
143	Improving IMDC Prognostic Prediction Through Evaluation of Initial Site of Metastasis in Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e83-e90.	0.9	17
144	Complete response to combination therapy with nivolumab and ipilimumab for metastatic collecting duct carcinoma of the kidney. <i>International Cancer Conference Journal</i> , 2020, 9, 32-35.	0.2	22
145	Prognostic and predictive molecular biomarkers in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors: a systematic review. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 169-185.	1.5	21
146	Immune checkpoint inhibition for the treatment of renal cell carcinoma. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 83-94.	1.4	14
147	Patterns of treatment in metastatic renal cell carcinoma for older versus younger patients. <i>Journal of Geriatric Oncology</i> , 2020, 11, 724-726.	0.5	2
148	The antibody-based delivery of interleukin-12 to solid tumors boosts NK and CD8 ⁺ T cell activity and synergizes with immune checkpoint inhibitors. <i>International Journal of Cancer</i> , 2020, 146, 2518-2530.	2.3	39
149	Identification of methylation-driven genes related to prognosis in clear-cell renal cell carcinoma. <i>Journal of Cellular Physiology</i> , 2020, 235, 1296-1308.	2.0	22
150	Long survival of patients with metastatic clear cell renal cell carcinoma. Results of real life study of 344 patients. <i>International Journal of Cancer</i> , 2020, 146, 1643-1651.	2.3	5
151	A Phase I Study of Alpha-1,3-Galactosyltransferase-Expressing Allogeneic Renal Cell Carcinoma Immunotherapy in Patients with Refractory Metastatic Renal Cell Carcinoma. <i>Oncologist</i> , 2020, 25, 121-e213.	1.9	28
152	The impact of neutrophil-lymphocyte ratio on risk reclassification of patients with advanced renal cell cancer to guide risk-directed therapy. <i>Acta Oncologica</i> , 2020, 59, 20-27.	0.8	3
153	Hyperprogressive Disease in Patients With Urothelial Carcinoma or Renal Cell Carcinoma Treated With PD-1/PD-L1 Inhibitors. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e122-e133.	0.9	32
154	What Do International Guidelines Say About First-line Therapy for Clear-cell Metastatic Renal Cell Carcinoma?. <i>European Urology Focus</i> , 2020, 6, 48-52.	1.6	5
155	Setting the Dose of Checkpoint Inhibitors: The Role of Clinical Pharmacology. <i>Clinical Pharmacokinetics</i> , 2020, 59, 287-296.	1.6	8

#	ARTICLE	IF	CITATIONS
156	Fertility Challenges and Solutions in Women with Cancer. , 2020, , .		0
157	Health technology assessment methodology in metastatic renal cell carcinoma. Nature Reviews Urology, 2020, 17, 3-5.	1.9	4
158	Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features. Journal of Clinical Oncology, 2020, 38, 63-70.	0.8	109
159	Association of PD-1 expression status with the efficacy of PD-1/PD-L1 inhibitors and overall survival in solid tumours: A systematic review and meta-analysis. International Journal of Cancer, 2020, 147, 116-127.	2.3	53
160	A review of checkpoint inhibitors in the management of renal cell carcinoma. Journal of Oncology Pharmacy Practice, 2020, 26, 445-458.	0.5	9
161	Oncologic Outcomes in Young Adults With Kidney Cancer Treated During the Targeted Therapy Era. Clinical Genitourinary Cancer, 2020, 18, e134-e144.	0.9	3
162	Current issues and perspectives in PD-1 blockade cancer immunotherapy. International Journal of Clinical Oncology, 2020, 25, 790-800.	1.0	120
163	Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2020, 18, 322-331.e2.	0.9	30
164	Sarcomatoid Dedifferentiation in Renal Cell Carcinoma: From Novel Molecular Insights to New Clinical Opportunities. Cancers, 2020, 12, 99.	1.7	23
165	Recent advancements in the treatment of metastatic clear cell renal cell carcinoma: A review of the evidence using second-generation p-values. Cancer Treatment and Research Communications, 2020, 23, 100166.	0.7	23
166	Novel immunotherapy combinations for genitourinary cancers. Expert Opinion on Biological Therapy, 2020, 20, 253-262.	1.4	11
167	Lenvatinib in Management of Solid Tumors. Oncologist, 2020, 25, e302-e310.	1.9	80
168	Comparable efficacy and safety between second-line and later-line nivolumab therapy for metastatic renal cell carcinoma. International Journal of Clinical Oncology, 2020, 25, 705-712.	1.0	3
169	Vessel co-option and resistance to anti-angiogenic therapy. Angiogenesis, 2020, 23, 55-74.	3.7	77
170	Understanding genetic determinants of resistance to immune checkpoint blockers. Seminars in Cancer Biology, 2020, 65, 123-139.	4.3	9
171	Predictive impact of an early change in serum C-reactive protein levels in nivolumab therapy for metastatic renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 526-532.	0.8	18
172	Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer. JAMA Oncology, 2020, 6, 375.	3.4	215
173	Real-world Clinical Outcomes of Pazopanib Immediately After Discontinuation of Immunotherapy for Advanced Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2020, 18, e37-e45.	0.9	14

#	ARTICLE	IF	CITATIONS
174	Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214. <i>European Urology</i> , 2020, 77, 449-453.	0.9	52
175	Re: Brian I. Rini, Thomas Powles, Michael B. Atkins, et al. Atezolizumab plus Bevacizumab Versus Sunitinib in Patients with Previously Untreated Metastatic Renal Cell Carcinoma (IMmotion151): A Multicentre, Open-label, Phase 3, Randomised Controlled Trial. <i>Lancet</i> 2019;393:2404-15. <i>European Urology</i> , 2020, 77, e168-e169.	0.9	1
176	Exposing Hidden Targets: Combining epigenetic and immunotherapy to overcome cancer resistance. <i>Seminars in Cancer Biology</i> , 2020, 65, 114-122.	4.3	45
177	Concordance of PD-L1 and PD-L1 (B7-H1) in paired primary and metastatic clear cell renal cell carcinoma. <i>Cancer Medicine</i> , 2020, 9, 1152-1160.	1.3	17
178	Efficacy and Safety of Approved First-Line Tyrosine Kinase Inhibitor Treatments in Metastatic Renal Cell Carcinoma: A Network Meta-Analysis. <i>Advances in Therapy</i> , 2020, 37, 730-744.	1.3	16
179	Novel Risk Scoring System for Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. <i>Oncologist</i> , 2020, 25, e484-e491.	1.9	29
180	The covalent CDK7 inhibitor THZ1 enhances temsirolimus-induced cytotoxicity via autophagy suppression in human renal cell carcinoma. <i>Cancer Letters</i> , 2020, 471, 27-37.	3.2	17
181	Combining Immune Checkpoint and VEGFR Inhibition in Favorable Risk and Elderly Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 179-184.e3.	0.9	6
182	Cytoreductive nephrectomy. <i>Current Opinion in Urology</i> , 2020, 30, 36-40.	0.9	4
183	Prognostic analysis of postoperative clinically nonmetastatic renal cell carcinoma. <i>Cancer Medicine</i> , 2020, 9, 959-970.	1.3	14
184	Clinical Outcomes of First-line Sunitinib Followed by Immuno-oncology Checkpoint Inhibitors in Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e350-e359.	0.9	3
185	A closer look at immune-mediated myocarditis in the era of combined checkpoint blockade and targeted therapies. <i>European Journal of Cancer</i> , 2020, 124, 15-24.	1.3	31
186	Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy. <i>Oncologist</i> , 2020, 25, e398-e404.	1.9	10
187	Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer. <i>Cancer Discovery</i> , 2020, 10, 40-53.	7.7	219
188	Progress Toward Precision Medicine in Frontline Treatment of Metastatic Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2020, 6, 25.	3.4	5
189	Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. <i>Lancet Oncology</i> , The, 2020, 21, 95-104.	5.1	160
190	Sequencing therapy for advanced renal cancer. <i>Lancet Oncology</i> , The, 2020, 21, 9-11.	5.1	5
191	Important Considerations Regarding the Impact of Patients' Gender on Efficacy of Immunotherapy in Patients With Metastatic Kidney Cancer: A Systematic Review and Meta-analysis. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e293-e294.	0.9	0

#	ARTICLE	IF	CITATIONS
192	Rational Approaches to Treatment Duration with Immunotherapy in Metastatic Renal Cell Carcinoma. <i>European Urology Focus</i> , 2020, 6, 31-33.	1.6	4
193	Comparative analysis of programmed cell death ligand 1 assays in renal cell carcinoma. <i>Histopathology</i> , 2020, 77, 67-78.	1.6	4
194	Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors. <i>Cancers</i> , 2020, 12, 84.	1.7	22
195	Treatment-related adverse events as surrogate to response rate to immune checkpoint blockade. <i>Medicine (United States)</i> , 2020, 99, e22153.	0.4	7
196	Editorial Comment to Efficacy and safety of first-line nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma: A multicenter retrospective study. <i>International Journal of Urology</i> , 2020, 27, 1100-1101.	0.5	0
197	Race/Ethnicity and Survival in Metastatic Renal Cell Carcinoma: Outcomes for Patients Receiving First Line Targeted Therapies. <i>Kidney Cancer</i> , 2020, 4, 159-166.	0.2	1
198	Circulating Non-coding RNAs in Renal Cell Carcinoma—Pathogenesis and Potential Implications as Clinical Biomarkers. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 828.	1.8	22
199	RCC Immune Microenvironment Subsequent to Targeted Therapy: A Friend or a Foe?. <i>Frontiers in Oncology</i> , 2020, 10, 573690.	1.3	6
200	Integrating Phenotypic Search and Phosphoproteomic Profiling of Active Kinases for Optimization of Drug Mixtures for RCC Treatment. <i>Cancers</i> , 2020, 12, 2697.	1.7	11
201	Treatment Combinations with DNA Vaccines for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC). <i>Cancers</i> , 2020, 12, 2831.	1.7	12
203	Smoking status-based efficacy difference in anti-PD-1/PD-L1 immunotherapy: a systematic review and meta-analysis. <i>Immunotherapy</i> , 2020, 12, 1313-1324.	1.0	5
204	Targeted therapy for metastatic renal cell carcinoma. <i>The Cochrane Library</i> , 2020, 2020, CD012796.	1.5	23
207	Eligibility Criteria and Endpoints in Metastatic Renal Cell Carcinoma Trials. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 559-566.	0.6	3
208	Association between copy-number alteration of +20q, 14q and 18p and cross-sensitivity to tyrosine kinase inhibitors in clear-cell renal cell carcinoma. <i>Cancer Cell International</i> , 2020, 20, 482.	1.8	3
209	Potential Application of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Renal Cell Tumors. <i>Frontiers in Oncology</i> , 2020, 10, 565857.	1.3	14
210	Consensus paper: current state of first- and second-line therapy in advanced clear-cell renal cell carcinoma. <i>Future Oncology</i> , 2020, 16, 2307-2328.	1.1	17
211	No-cytoreductive nephrectomy should no longer be routinely performed. <i>Current Opinion in Urology</i> , 2020, Publish Ahead of Print, 743-745.	0.9	1
212	Prognostic and Predictive Factors in Metastatic Renal Cell Carcinoma. <i>Cancer Journal (Sudbury, Mass)</i> Tj ETQq1 1 0,784314 rgBT /Overl	1.0	10

#	ARTICLE	IF	CITATIONS
213	The von Hippel-Lindau Tumor Suppressor Gene. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 390-398.	1.0	123
214	Avelumab and axitinib combination therapy for the treatment of advanced renal cell carcinoma. <i>Future Oncology</i> , 2020, 16, 3021-3034.	1.1	3
215	Tumor Cellâ€‘Derived TGFÎ²1 Attenuates Antitumor Immune Activity of T Cells via Regulation of PD-1 mRNA. <i>Cancer Immunology Research</i> , 2020, 8, 1470-1484.	1.6	28
216	Cytoreductive Nephrectomy in Patients Presenting With Advanced Disease. <i>Cancer Journal (Sudbury,)</i> Tj ETQq1 1 0,784314 rgBT /Overl	1.0	1
217	Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1. <i>Biomedicine and Pharmacotherapy</i> , 2020, 130, 110621.	2.5	8
218	PBA2, a novel compound, enhances radiosensitivity in various carcinoma cells by activating the p53 pathway in vitro and in vivo. <i>Free Radical Biology and Medicine</i> , 2020, 161, 224-233.	1.3	1
219	Efficacy and safety of combination PDâ€‘1/PDâ€‘L1 checkpoint inhibitors for malignant solid tumours: A systematic review. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 13494-13506.	1.6	4
220	Designing novel immunocombinations in metastatic renal cell carcinoma. <i>Immunotherapy</i> , 2020, 12, 1257-1268.	1.0	6
221	Trends in Initial Systemic Therapy for Elderly Patients with Metastatic Clear Cell Renal Cell Carcinoma. <i>Kidney Cancer</i> , 2020, 4, 131-137.	0.2	2
222	Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , 2020, 21, 1563-1573.	5.1	466
223	The Reintroduction of Radiotherapy Into the Integrated Management of Kidney Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 448-459.	1.0	1
224	Deep immunophenotyping at the single-cell level identifies a combination of anti-IL-17 and checkpoint blockade as an effective treatment in a preclinical model of data-guided personalized immunotherapy. , 2020, 8, e001358.		44
225	The Role of Targeted Therapy in the Management of High-Risk Resected Kidney Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 376-381.	1.0	5
226	The Immunotherapy Revolution in Kidney Cancer Treatment. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 419-431.	1.0	17
227	Immunotherapy in older patients with cancer. <i>Biomedical Journal</i> , 2021, 44, 260-271.	1.4	19
228	A Perspective on Therapeutic Pan-Resistance in Metastatic Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7304.	1.8	11
229	Sarcomatoid renal cell carcinoma: biology, natural history and management. <i>Nature Reviews Urology</i> , 2020, 17, 659-678.	1.9	76
230	Novel Therapeutic Approaches and the Evolution of Drug Development in Advanced Kidney Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 464-470.	1.0	18

#	ARTICLE	IF	CITATIONS
231	The Immunotherapy Landscape in Renal Cell Carcinoma. <i>BioDrugs</i> , 2020, 34, 733-748.	2.2	27
232	Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors. <i>JHEP Reports</i> , 2020, 2, 100170.	2.6	86
233	Current Multimodality Treatments against Brain Metastases from Renal Cell Carcinoma. <i>Cancers</i> , 2020, 12, 2875.	1.7	14
234	Discontinuation of first-line molecular-targeted therapy and prognosis in patients with metastatic renal cell carcinoma: Impact of disease progression vs. adverse events. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 937.e19-937.e25.	0.8	2
235	Cultivation of Clear Cell Renal Cell Carcinoma Patient-Derived Organoids in an Air-Liquid Interface System as a Tool for Studying Individualized Therapy. <i>Frontiers in Oncology</i> , 2020, 10, 1775.	1.3	24
236	Renal Cell Tumors: Molecular Findings Reshaping Clinico-pathological Practice. <i>Archives of Medical Research</i> , 2020, 51, 799-816.	1.5	3
237	Impact of concomitant systemic treatments on toxicity and intracerebral response after stereotactic radiotherapy for brain metastases. <i>BMC Cancer</i> , 2020, 20, 991.	1.1	13
238	Kidney Cancer. <i>Urologic Clinics of North America</i> , 2020, 47, 419-431.	0.8	84
239	Immunotherapy for Metastatic Prostate Cancer: Current and Emerging Treatment Options. <i>Urologic Clinics of North America</i> , 2020, 47, 487-510.	0.8	10
240	Targeting the HIF2-VEGF axis in renal cell carcinoma. <i>Nature Medicine</i> , 2020, 26, 1519-1530.	15.2	248
241	Significance of tumor microenvironment in acquiring resistance to vascular endothelial growth factor-tyrosine kinase inhibitor and recent advance of systemic treatment of clear cell renal cell carcinoma. <i>Pathology International</i> , 2020, 70, 712-723.	0.6	5
242	Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. , 2020, 8, e000891.		160
243	Correlates of clinical benefit from immunotherapy and targeted therapy in metastatic renal cell carcinoma: comprehensive genomic and transcriptomic analysis. , 2020, 8, e000953.		32
244	Angiogenesis and Its Role in the Tumour Microenvironment: A Target for Cancer Therapy. , 2020, , .		2
245	Research progress of PD-1/PD-L1 immunotherapy in gastrointestinal tumors. <i>Biomedicine and Pharmacotherapy</i> , 2020, 129, 110504.	2.5	26
246	Resistance to immune checkpoint inhibitors in non-small cell lung cancer: biomarkers and therapeutic strategies. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592093790.	1.4	49
247	Characteristics and Outcome of Children with Renal Cell Carcinoma: A Narrative Review. <i>Cancers</i> , 2020, 12, 1776.	1.7	29
248	Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis. <i>Targeted Oncology</i> , 2020, 15, 495-501.	1.7	28

#	ARTICLE	IF	CITATIONS
249	Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies. Drug Resistance Updates, 2020, 53, 100718.	6.5	103
250	Randomised Phase II study comparing alternating cycles of sunitinib and everolimus vs standard sequential administration in first-line metastatic renal carcinoma (SUNRISES study). BJU International, 2020, 126, 559-567.	1.3	5
251	Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort. Frontiers in Oncology, 2020, 10, 581189.	1.3	11
252	Targeting the Deterministic Evolutionary Trajectories of Clear Cell Renal Cell Carcinoma. Cancers, 2020, 12, 3300.	1.7	6
253	Tyrosine Kinase Receptors in Oncology. International Journal of Molecular Sciences, 2020, 21, 8529.	1.8	46
255	Pathological complete response after nivolumab therapy following angiogenesis inhibitors in a patient with metastatic renal cell carcinoma. IJU Case Reports, 2020, 3, 287-290.	0.1	6
256	First-line axitinib therapy is less effective in metastatic renal cell carcinoma with spindle histology. Scientific Reports, 2020, 10, 20089.	1.6	2
257	A Lymphocyte MicroRNA Signature as Predictive Biomarker of Immunotherapy Response and Plasma PD-1/PD-L1 Expression Levels in Patients with Metastatic Renal Cell Carcinoma: Pointing towards Epigenetic Reprogramming. Cancers, 2020, 12, 3396.	1.7	41
258	Advances in urologic oncology – OncoForum – The best of 2019. Actas Urológicas Españolas (English) TjETQo0 0 0 rgBT /Overlo	0.2	1
259	A Window of Opportunity: Targeting Cancer Endothelium to Enhance Immunotherapy. Frontiers in Immunology, 2020, 11, 584723.	2.2	22
260	Bilateral Posterior Uveitis and Retinal Detachment During Immunotherapy: A Case Report and Literature Review. Frontiers in Oncology, 2020, 10, 549168.	1.3	9
261	Immunotherapeutic Targets and Therapy for Renal Cell Carcinoma. ImmunoTargets and Therapy, 2020, Volume 9, 273-288.	2.7	9
262	Construction of a Novel Multigene Panel Potently Predicting Poor Prognosis in Patients with Clear Cell Renal Cell Carcinoma. Cancers, 2020, 12, 3471.	1.7	8
263	The human microbiome and genitourinary malignancies. Annals of Translational Medicine, 2020, 8, 1245-1245.	0.7	17
264	Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma. , 2020, 8, e001467.		22
265	Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial. Breast Cancer Research, 2020, 22, 124.	2.2	21
266	Immune checkpoints and their inhibitors: Reappraisal of a novel diagnostic and therapeutic dimension in the urologic malignancies. Seminars in Oncology, 2020, 47, 367-379.	0.8	6
267	A Durable Response With the Combination of Nivolumab and Cabozantinib in a Patient With Metastatic Paraganglioma: A Case Report and Review of the Current Literature. Frontiers in Endocrinology, 2020, 11, 594264.	1.5	10

#	ARTICLE	IF	CITATIONS
268	Immunotherapy for extensive stage small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2020, 12, 6212-6224.	0.6	3
269	The Impact of Renal Impairment on Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With Tyrosine Kinase Inhibitors. <i>Cancer Control</i> , 2020, 27, 107327482097714.	0.7	2
270	Treatment of epithelial ovarian cancer. <i>BMJ, The</i> , 2020, 371, m3773.	3.0	359
271	The Immune Checkpoint PD-1 in Natural Killer Cells: Expression, Function and Targeting in Tumour Immunotherapy. <i>Cancers</i> , 2020, 12, 3285.	1.7	85
272	Therapy-Induced Modulation of the Tumor Microenvironment: New Opportunities for Cancer Therapies. <i>Frontiers in Oncology</i> , 2020, 10, 582884.	1.3	23
273	Avances en uro-oncologÃa Â«OncoForumÃ»: lo mejor del 2019. <i>Actas UrolÃ³gicas EspaÃ±olas</i> , 2020, 44, 586-596.	0.3	0
274	Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions. <i>Oncolimmunology</i> , 2020, 9, 1832348.	2.1	55
275	lncRNA and Mechanisms of Drug Resistance in Cancers of the Genitourinary System. <i>Cancers</i> , 2020, 12, 2148.	1.7	27
276	First-in-human, dose-escalation, phase 1 study of anti-angiopoietin-2 LY3127804 as monotherapy and in combination with ramucirumab in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2020, 123, 1235-1243.	2.9	12
277	Genetic Alterations in Renal Cancers: Identification of The Mechanisms Underlying Cancer Initiation and Progression and of Therapeutic Targets. <i>Medicines (Basel, Switzerland)</i> , 2020, 7, 44.	0.7	13
278	Treating metastatic clear-cell renal cell carcinoma: beyond immunotherapy. <i>Medical Oncology</i> , 2020, 37, 81.	1.2	7
279	Complete response to immune checkpoint inhibitors-based therapy in advanced renal cell carcinoma patients. A meta-analysis of randomized clinical trials. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 798.e17-798.e24.	0.8	6
280	Comparative risk of serious and fatal treatment-related adverse events caused by 19 immune checkpoint inhibitors used in cancer treatment: a network meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592094092.	1.4	11
281	Pattern and impact of hepatic adverse events encountered during immune checkpoint inhibitors â€“ A territory-wide cohort study. <i>Cancer Medicine</i> , 2020, 9, 7052-7061.	1.3	14
282	Differential risks of immune-related colitis among various immune checkpoint inhibitor regimens. <i>International Immunopharmacology</i> , 2020, 87, 106770.	1.7	7
283	Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade. <i>Frontiers in Immunology</i> , 2020, 11, 1590.	2.2	50
284	Systemic Therapy of Common Tumours in Older Patients: Challenges and Opportunities. A Young International Society of Geriatric Oncology Review Paper. <i>Current Oncology Reports</i> , 2020, 22, 98.	1.8	3
285	Synergies of Antiangiogenic Therapy and Immune Checkpoint Blockade in Renal Cell Carcinoma: From Theoretical Background to Clinical Reality. <i>Frontiers in Oncology</i> , 2020, 10, 1321.	1.3	22

#	ARTICLE	IF	CITATIONS
286	Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 137.	7.1	79
287	Resistance to Anti-angiogenic Therapies: A Mechanism Depending on the Time of Exposure to the Drugs. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 584.	1.8	40
288	Evolving Frontline Treatment Landscape for Advanced or Metastatic Renal Cell Carcinoma. <i>Kidney Cancer</i> , 2020, 4, 71-79.	0.2	2
289	Are we ready to accept intermediate outcome measures in clinical cancer trials?. <i>Annals of Oncology</i> , 2020, 31, 973-975.	0.6	1
290	Anti-angiogenesis: Opening a new window for immunotherapy. <i>Life Sciences</i> , 2020, 258, 118163.	2.0	33
291	The immunology of renal cell carcinoma. <i>Nature Reviews Nephrology</i> , 2020, 16, 721-735.	4.1	229
292	Regulatory Considerations for Contribution of Effect of Drugs Used in Combination Regimens: Renal Cell Cancer Case Studies. <i>Clinical Cancer Research</i> , 2020, 26, 6406-6411.	3.2	5
293	Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research. <i>Lancet Oncology</i> , The, 2020, 21, e398-e404.	5.1	74
294	Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy. <i>Oncologist</i> , 2020, 25, 878-885.	1.9	28
295	Prognostic Value of Vimentin Is Associated With Immunosuppression in Metastatic Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 1181.	1.3	12
296	Clinical and molecular characteristics associated with survival among cancer patients receiving first-line anti-PD-1/PD-L1-based therapies. <i>Biomarkers</i> , 2020, 25, 441-448.	0.9	1
297	The Value of PD-L1 Expression as Predictive Biomarker in Metastatic Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials. <i>Cancers</i> , 2020, 12, 1945.	1.7	49
298	Patients with sarcomatoid renal cell carcinoma “ re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2020, 136, 195-203.	1.3	47
299	Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma. <i>Current Medical Research and Opinion</i> , 2020, 36, 1507-1517.	0.9	11
300	Targeting the immune milieu in gastrointestinal cancers. <i>Journal of Gastroenterology</i> , 2020, 55, 909-926.	2.3	7
301	Complete response to pembrolizumab in a patient with extensive-stage small-cell lung cancer: a case report. <i>Annals of Palliative Medicine</i> , 2020, 9, 2347-2352.	0.5	4
302	Normalizing the Tumor Microenvironment for Radiosensitization. <i>Cancer Drug Discovery and Development</i> , 2020, , 301-338.	0.2	4
303	Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade. <i>Cancer Discovery</i> , 2020, 10, 1842-1853.	7.7	179

#	ARTICLE	IF	CITATIONS
304	Cabozantinib in advanced renal cell carcinoma: A phase III, open-label, single-arm study of Japanese patients. <i>International Journal of Urology</i> , 2020, 27, 952-959.	0.5	17
305	Distinct Expression Patterns of VEGFR 1-3 in Gastroenteropancreatic Neuroendocrine Neoplasms: Supporting Clinical Relevance, but not a Prognostic Factor. <i>Journal of Clinical Medicine</i> , 2020, 9, 3368.	1.0	2
306	BIONIKK: A phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer. <i>Bulletin Du Cancer</i> , 2020, 107, eS22-eS27.	0.6	37
307	An updated cost-effectiveness analysis of pazopanib versus sunitinib as first-line treatment for locally advanced or metastatic renal cell carcinoma in Italy. <i>Journal of Medical Economics</i> , 2020, 23, 1579-1587.	1.0	4
308	Adoptive transfer of TILs plus anti-PD1 therapy: An alternative combination therapy for treating metastatic osteosarcoma. <i>Journal of Bone Oncology</i> , 2020, 25, 100332.	1.0	19
309	Advanced Non-Clear Cell Kidney Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 441-447.	1.0	1
310	Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma. <i>ESMO Open</i> , 2020, 5, e000852.	2.0	18
311	Retrospective Analysis of Adoptive TIL Therapy plus Anti-PD1 Therapy in Patients with Chemotherapy-Resistant Metastatic Osteosarcoma. <i>Journal of Immunology Research</i> , 2020, 2020, 1-12.	0.9	16
312	Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020). <i>Journal of Hematology and Oncology</i> , 2020, 13, 143.	6.9	226
313	<p>High Expression of CD39 is Associated with Poor Prognosis and Immune Infiltrates in Clear Cell Renal Cell Carcinoma</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 10453-10464.	1.0	11
314	Cost-effectiveness of pembrolizumab plus axitinib as first-line therapy for advanced renal cell carcinoma. <i>Immunotherapy</i> , 2020, 12, 1237-1246.	1.0	6
315	Old Player-New Tricks: Non Angiogenic Effects of the VEGF/VEGFR Pathway in Cancer. <i>Cancers</i> , 2020, 12, 3145.	1.7	42
316	Clinical Impact of Tumor-Infiltrating Lymphocytes and PD-L1-Positive Cells as Prognostic and Predictive Biomarkers in Urological Malignancies and Retroperitoneal Sarcoma. <i>Cancers</i> , 2020, 12, 3153.	1.7	15
317	Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial. <i>Cancers</i> , 2020, 12, 2985.	1.7	21
318	Combination therapy in metastatic renal cell carcinoma: Back to the future?. <i>Seminars in Oncology</i> , 2020, 47, 361-366.	0.8	11
319	Tailoring precision immunotherapy: coming to a clinic soon?. <i>ESMO Open</i> , 2020, 5, e000631.	2.0	8
320	Adjuvant therapy for high-risk renal cell carcinoma after nephrectomy how many trials are positive? Only one or more than one. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 12-17.	0.7	1
321	Roles of N ⁶ -methyladenosine (m ⁶ A) RNA modifications in urological cancers. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 10302-10310.	1.6	10

#	ARTICLE	IF	CITATIONS
322	What is the optimum systemic treatment for advanced/metastatic renal cell carcinoma of favourable, intermediate and poor risk, respectively? A systematic review and network meta-analysis. <i>BMJ Open</i> , 2020, 10, e034626.	0.8	13
323	Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment. <i>Frontiers in Immunology</i> , 2020, 11, 1956.	2.2	143
324	Pediatric and young adult renal cell carcinoma. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28675.	0.8	14
325	Association between tyrosine kinase inhibitor induced hypertension and treatment outcomes in metastatic renal cancer. <i>Cancer Reports</i> , 2020, 3, e1275.	0.6	6
326	The clinical significance of routine risk categorization in metastatic renal cell carcinoma and its impact on treatment decision-making: a systematic review. <i>Future Oncology</i> , 2020, 16, 2879-2896.	1.1	3
327	Impact of PD-L1 Scores and Changes on Clinical Outcome in Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiotherapy. <i>Journal of Clinical Medicine</i> , 2020, 9, 2775.	1.0	10
328	<p>Pembrolizumab in Combination with Axitinib as First-Line Treatment for Patients with Renal Cell Carcinoma (RCC): Evidence to Date</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 7321-7330.	0.9	24
329	First-line treatments for advanced renal-cell carcinoma with immune checkpoint inhibitors: systematic review, network meta-analysis and cost-effectiveness analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592095019.	1.4	21
330	Immunogenic Cell Death and Elimination of Immunosuppressive Cells: A Double-Edged Sword of Chemotherapy. <i>Cancers</i> , 2020, 12, 2637.	1.7	40
331	Predicting Response to Immunotherapy in Metastatic Renal Cell Carcinoma. <i>Cancers</i> , 2020, 12, 2662.	1.7	31
333	Tumour vasculature: Friend or foe of oncolytic viruses?. <i>Cytokine and Growth Factor Reviews</i> , 2020, 56, 69-82.	3.2	12
334	Beyond Antoni: A Surgeon's Guide to the Vestibular Schwannoma Microenvironment. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2022, 83, 001-010.	0.4	4
335	Immune Related Adverse Events. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 432-440.	1.0	4
336	Treatment sequencing strategies in metastatic renal cell carcinoma: A critical interpretation of available data. <i>Journal of Onco-Nephrology</i> , 2020, 4, 153-164.	0.3	0
337	Camrelizumab plus apatinib successfully treated a patient with advanced esophageal squamous cell carcinoma. <i>Immunotherapy</i> , 2020, 12, 1161-1166.	1.0	7
338	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors. <i>Supportive Care in Cancer</i> , 2020, 28, 6129-6143.	1.0	28
340	Too good for CARMENA: criteria associated with long systemic therapy free intervals post cytoreductive nephrectomy for metastatic clear cell renal cell carcinoma. <i>Scandinavian Journal of Urology</i> , 2020, 54, 493-499.	0.6	12
341	Prospective Translational Study Investigating Molecular PrEdictors of Resistance to First-Line Pazopanib in Metastatic reNal Cell Carcinoma (PIPELINE Study). <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 621-627.	0.6	4

#	ARTICLE	IF	CITATIONS
342	A novel scoring method based on RNA-seq immunograms describing individual cancer-immunity interactions. <i>Cancer Science</i> , 2020, 111, 4031-4040.	1.7	32
344	Patient selection and risk factors in the changing treatment landscape of metastatic renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 831-840.	1.1	3
345	Treatment patterns, outcomes and clinical characteristics in advanced renal cell carcinoma: a real-world US study. <i>Future Oncology</i> , 2020, 16, 3045-3060.	1.1	7
346	Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial. <i>Nature Medicine</i> , 2020, 26, 1733-1741.	15.2	282
347	Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1644.	1.3	48
348	Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors. <i>Journal of Clinical Oncology</i> , 2020, 38, 3672-3684.	0.8	78
349	Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 3625-3649.	2.0	80
350	Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity. <i>Experimental and Molecular Medicine</i> , 2020, 52, 1475-1485.	3.2	306
352	Association of Sex, Age, and Eastern Cooperative Oncology Group Performance Status With Survival Benefit of Cancer Immunotherapy in Randomized Clinical Trials. <i>JAMA Network Open</i> , 2020, 3, e2012534.	2.8	72
353	Safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma: a systematic review and meta-analysis. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1329-1338.	1.0	64
354	Second-line tyrosine kinase inhibitor-therapy after immunotherapy-failure. <i>Current Opinion in Supportive and Palliative Care</i> , 2020, 14, 276-285.	0.5	6
356	Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ). <i>European Journal of Cancer</i> , 2020, 137, 272-284.	1.3	86
357	Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 5598-5608.	3.2	13
358	Uncommon Subtypes of Malignant Melanomas: A Review Based on Clinical and Molecular Perspectives. <i>Cancers</i> , 2020, 12, 2362.	1.7	22
359	Tissue Based Biomarkers for Metastatic Clear Cell Renal Carcinoma: A Systematic Review. <i>Kidney Cancer</i> , 2020, 4, 197-210.	0.2	1
360	Treatment of Advanced Renal Cell Carcinoma: Immunotherapies Have Demonstrated Overall Survival Benefits While Targeted Therapies Have Not. <i>European Urology Open Science</i> , 2020, 22, 61-73.	0.2	11
361	Efficacy and Safety of Axitinib Therapy After Nivolumab for Patients With Metastatic Renal Cell Cancer. <i>Anticancer Research</i> , 2020, 40, 6493-6497.	0.5	5
362	Characteristics of the Tumor Microenvironment That Influence Immune Cell Functions: Hypoxia, Oxidative Stress, Metabolic Alterations. <i>Cancers</i> , 2020, 12, 3802.	1.7	65

#	ARTICLE	IF	CITATIONS
363	Feasibility and Safety of Robotic Excision of Ipsilateral Retroperitoneal Recurrence After Nephrectomy for Renal Cell Carcinoma. <i>Urology</i> , 2020, 145, 159-165.	0.5	7
364	The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 284.	3.5	67
365	Individualizing Systemic Therapies in First Line Treatment and beyond for Advanced Renal Cell Carcinoma. <i>Cancers</i> , 2020, 12, 3750.	1.7	10
366	Complete Pathologic Responses With Immunotherapy in Metastatic Renal Cell Carcinoma: Case Reports. <i>Frontiers in Oncology</i> , 2020, 10, 609235.	1.3	9
368	Immunotherapy in metastatic sarcomatoid renal cell carcinoma: A single institution experience. <i>Cancer Treatment and Research Communications</i> , 2020, 25, 100251.	0.7	5
369	Inflammatory Biomarkers to Detect Immune Checkpoint Inhibitor-Associated Cardiotoxicity in Lung Cancer Patients. <i>JACC: CardioOncology</i> , 2020, 2, 503-505.	1.7	2
370	Downstream neighbor of SON (DONSON) is associated with unfavorable survival across diverse cancers with oncogenic properties in clear cell renal cell carcinoma. <i>Translational Oncology</i> , 2020, 13, 100844.	1.7	8
371	Therapeutic strategies to remodel immunologically cold tumors. <i>Clinical and Translational Immunology</i> , 2020, 9, e1226.	1.7	23
372	Immunotherapy in sarcomatoid renal cell carcinoma: A case for optimism. <i>Cancer Treatment and Research Communications</i> , 2020, 25, 100257.	0.7	0
373	Infiltration of M2 Macrophages and Regulatory T Cells Plays a Role in Recurrence of Renal Cell Carcinoma. <i>European Urology Open Science</i> , 2020, 20, 62-71.	0.2	20
374	Bone Scintigraphy in Pembrolizumab-Induced Inflammatory Arthritis. <i>Clinical Nuclear Medicine</i> , 2020, 45, 999-1000.	0.7	2
375	<p>>Review of Adjuvant Therapies in Renal Cell Carcinoma: Evidence to Date</p>>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 12301-12316.	1.0	22
376	Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma. <i>Oncolmmunology</i> , 2020, 9, 1846901.	2.1	27
377	Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade. <i>Cancer Cell</i> , 2020, 38, 803-817.e4.	7.7	262
378	Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities. <i>Frontiers in Immunology</i> , 2020, 11, 598877.	2.2	133
379	TFE3&PD&L1 axis is pivotal for sunitinib resistance in clear cell renal cell carcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 14441-14452.	1.6	7
380	Acute interstitial nephritis, a potential predictor of response to immune checkpoint inhibitors in renal cell carcinoma. , 2020, 8, e001198.		24
381	First-Line Immune Checkpoint Inhibitor-Based Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review. <i>Kidney Cancer</i> , 2020, 4, 81-92.	0.2	1

#	ARTICLE	IF	CITATIONS
382	Validation of the Correlation Between Single Nucleotide Polymorphism rs307826 in VEGFR3 and Outcome in Metastatic Clear-Cell Renal Cell Carcinoma Patients Treated with Sunitinib. <i>Kidney Cancer</i> , 2020, 4, 139-149.	0.2	0
384	Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US. <i>JAMA Network Open</i> , 2020, 3, e2016144.	2.8	24
385	Survival-Inferred Fragility Index of Phase 3 Clinical Trials Evaluating Immune Checkpoint Inhibitors. <i>JAMA Network Open</i> , 2020, 3, e2017675.	2.8	20
386	Checkpoint Inhibitors in Gynecological Malignancies: Are we There Yet?. <i>BioDrugs</i> , 2020, 34, 749-762.	2.2	5
387	Cancer Immunotherapy Dosing: A Pharmacokinetic/Pharmacodynamic Perspective. <i>Vaccines</i> , 2020, 8, 632.	2.1	23
388	Response to nivolumab combining radiotherapy and nimotuzumab in metastatic oral squamous cell carcinoma patient with strong PD-L1 expression: a case report. <i>Annals of Translational Medicine</i> , 2020, 8, 402-402.	0.7	8
389	Efficacy of Axitinib After Nivolumab Failure in Metastatic Renal Cell Carcinoma. <i>In Vivo</i> , 2020, 34, 1541-1546.	0.6	10
390	Small moleculesâ€”Giant leaps for immuno-oncology. <i>Progress in Medicinal Chemistry</i> , 2020, 59, 1-62.	4.1	2
391	PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma. <i>Nature Communications</i> , 2020, 11, 2135.	5.8	114
392	The preliminary outcome of the combination of immunotherapy and targeted therapy after recurrence and metastasis for hereditary leiomyomatosis and renal cell cancerâ€”a case report. <i>Translational Andrology and Urology</i> , 2020, 9, 789-793.	0.6	6
393	Combination treatments with immunotherapy in brain metastases patients. <i>Future Oncology</i> , 2020, 16, 1691-1705.	1.1	2
394	Checkpoint blockade treatment sensitises relapsed/refractory nonâ€”Hodgkin lymphoma to subsequent therapy. <i>British Journal of Haematology</i> , 2020, 191, 44-51.	1.2	19
395	Advancing the Science and Management of Renal Cell Carcinoma: Bridging the Divide between Academic and Community Practices. <i>Journal of Clinical Medicine</i> , 2020, 9, 1508.	1.0	3
396	Angiogenic and immunomodulatory biomarkers in axitinib-treated patients with advanced renal cell carcinoma. <i>Future Oncology</i> , 2020, 16, 1199-1210.	1.1	4
397	Scientific based combination therapies with immunoâ€”oncology checkpoint inhibitors. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1711-1725.	1.1	6
398	Immune-related adverse events of checkpoint inhibitors. <i>Nature Reviews Disease Primers</i> , 2020, 6, 38.	18.1	684
399	Efficacy and safety of nivolumab for renal cell carcinoma in patients over 75Â”years old from multiple Japanese institutes. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1543-1550.	1.0	10
400	Immune checkpoint blockade in solid organ tumours: Choice, dose and predictors of response. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1736-1752.	1.1	10

#	ARTICLE	IF	CITATIONS
401	Renal Cell and Urothelial Carcinoma: Biomarkers for New Treatments. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e197-e206.	1.8	10
402	PD-L1 and HER2 Expression in Gastroesophageal Cancer: a Matched Case Control Study. Pathology and Oncology Research, 2020, 26, 2225-2235.	0.9	15
403	Immune Checkpoint Blockade for Prostate Cancer: Niche Role or Next Breakthrough?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e89-e106.	1.8	17
404	The Prognostic Value of Systemic Inflammatory Markers in Advanced Renal Cell Carcinoma Patients Treated With Molecular Targeted Therapies. Anticancer Research, 2020, 40, 1739-1745.	0.5	11
405	Therapeutic Targeting of Autophagy for Renal Cell Carcinoma Therapy. Cancers, 2020, 12, 1185.	1.7	31
407	Elective Cytoreductive Nephrectomy After Checkpoint Inhibitor Immunotherapy in Patients With Initially Unresectable Metastatic Clear Cell Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2020, 18, 361-366.	0.9	13
408	PD-1/PD-L1 Based Combinational Cancer Therapy: Icing on the Cake. Frontiers in Pharmacology, 2020, 11, 722.	1.6	65
409	Immune checkpoint inhibition in muscle-invasive and locally advanced bladder cancer. Current Opinion in Urology, 2020, 30, 547-556.	0.9	12
410	Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Annals of Oncology, 2020, 31, 1030-1039.	0.6	316
411	Chemotherapy Reverses Anti-PD-1 Resistance in One Patient With Advanced Non-small Lung Cell Cancer. Frontiers in Oncology, 2020, 10, 507.	1.3	6
412	Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients. European Urology, 2020, 78, 195-206.	0.9	192
413	Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study. , 2020, 8, e000538.		19
414	Tumor Endothelial Cellâ€™A Biological Tool for Translational Cancer Research. International Journal of Molecular Sciences, 2020, 21, 3238.	1.8	22
415	An evaluation of avelumab for the treatment of genitourinary tumors. Expert Opinion on Biological Therapy, 2020, 20, 971-979.	1.4	4
416	The hypoxic tumour microenvironment: A safe haven for immunosuppressive cells and a therapeutic barrier to overcome. Cancer Letters, 2020, 487, 34-44.	3.2	32
417	Real-world use of temsirolimus in Japanese patients with unresectable or metastatic renal cell carcinoma: recent consideration based on the results of a post-marketing, all-case surveillance study. Japanese Journal of Clinical Oncology, 2020, 50, 940-947.	0.6	3
418	Novel therapies for advanced urologic cancers. Current Opinion in Urology, 2020, 30, 594-601.	0.9	2
419	Safety and efficacy of CDX-014, an antibody-drug conjugate directed against T cell immunoglobulin mucin-1 in advanced renal cell carcinoma. Investigational New Drugs, 2020, 38, 1807-1814.	1.2	14

#	ARTICLE	IF	CITATIONS
420	A Systematic Review of Systemic Treatment Options for Advanced Non-Clear Cell Renal Cell Carcinoma. <i>Kidney Cancer</i> , 2020, 4, 15-27.	0.2	5
421	Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2020, 6, 1606.	3.4	79
422	Hypoxia-induced epithelial to mesenchymal transition in cancer. <i>Cancer Letters</i> , 2020, 487, 10-20.	3.2	86
423	The future of cancer immunotherapy: microenvironment-targeting combinations. <i>Cell Research</i> , 2020, 30, 507-519.	5.7	480
424	Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. <i>Nature Medicine</i> , 2020, 26, 909-918.	15.2	488
425	Safety evaluation of pembrolizumab for treating recurrent head and neck squamous cell carcinoma. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 927-934.	1.0	5
426	PD1/PD-L1 therapy in metastatic renal cell carcinoma. <i>Current Opinion in Urology</i> , 2020, 30, 534-541.	0.9	8
427	The Pan-Omics Landscape of Renal Cell Carcinoma and Its Implication on Future Clinical Practice. <i>Kidney Cancer</i> , 2020, 4, 121-129.	0.2	2
428	Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial. <i>Frontiers in Oncology</i> , 2020, 10, 664.	1.3	19
429	Anti-angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma. <i>Journal of Clinical Medicine</i> , 2020, 9, 1594.	1.0	49
430	Immune Checkpoint Inhibitors in Genitourinary Malignancies. <i>Current Oncology</i> , 2020, 27, 69-77.	0.9	13
431	Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients. <i>Oncolimmunology</i> , 2020, 9, 1773200.	2.1	10
432	The landscape of contemporary clinical trials for untreated metastatic clear cell renal cell carcinoma. <i>Cancer Treatment and Research Communications</i> , 2020, 24, 100183.	0.7	8
433	Cytoreductive Nephrectomy in the Era of Tyrosine Kinase and Immuno-Oncology Checkpoint Inhibitors. <i>Urologic Clinics of North America</i> , 2020, 47, 359-370.	0.8	10
434	<p>>Ipilimumab and Nivolumab as First-Line Treatment of Patients with Renal Cell Carcinoma: The Evidence to Date</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 4871-4881.	0.9	29
435	Epidemiology, Risk Assessment, and Biomarkers for Patients with Advanced Renal Cell Carcinoma. <i>Urologic Clinics of North America</i> , 2020, 47, 293-303.	0.8	25
436	Pazopanib as a possible option for the treatment of metastatic non-clear cell renal carcinoma patients: a systematic review. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592091530.	1.4	10
437	Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors. <i>Journal of Clinical Oncology</i> , 2020, 38, 3088-3094.	0.8	61

#	ARTICLE	IF	CITATIONS
438	Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design. <i>Future Oncology</i> , 2020, 16, 1525-1536.	1.1	50
439	Clinical outcomes of second-line treatment following prior targeted therapy in patients with metastatic renal cell carcinoma: a comparison of axitinib and nivolumab. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1678-1686.	1.0	9
440	Co-Regulation of Immune Checkpoint PD-L1 with Interferon-Gamma Signaling is Associated with a Survival Benefit in Renal Cell Cancer. <i>Targeted Oncology</i> , 2020, 15, 377-390.	1.7	15
441	Cytoreductive Nephrectomy in Metastatic Patients with Signs or Symptoms: Implications for Renal Cell Carcinoma Guidelines. <i>European Urology</i> , 2020, 78, 321-326.	0.9	25
442	Systemic therapy in metastatic renal cell carcinoma: Emerging challenges in therapeutic choice. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 152, 102971.	2.0	7
444	<p>Optimal Management of First-Line Advanced Renal Cell Carcinoma: Focus on Pembrolizumab</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 4021-4034.	1.0	5
445	Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1778-1789.	1.1	34
446	A Randomized Phase IIa Trial with Temsirolimus versus Sunitinib in Advanced Non-Clear Cell Renal Cell Carcinoma: An Intergroup Study of the CESAR Central European Society for Anticancer Drug Research-EWIV and the Interdisciplinary Working Group on Renal Cell Cancer (IAGN) of the German Cancer Society. <i>Oncology Research and Treatment</i> , 2020, 43, 333-339.	0.8	20
447	Sequencing Therapies for Metastatic Renal Cell Carcinoma. <i>Urologic Clinics of North America</i> , 2020, 47, 305-318.	0.8	14
448	Neoadjuvant Therapy for Locally Advanced Renal Cell Carcinoma. <i>Urologic Clinics of North America</i> , 2020, 47, 329-343.	0.8	10
449	The Evolving Role of Metastasectomy for Patients with Metastatic Renal Cell Carcinoma. <i>Urologic Clinics of North America</i> , 2020, 47, 379-388.	0.8	12
450	Gross Hematuria Eight Years Following Nephrectomy for Renal Cell Cancer. <i>Urology</i> , 2020, 143, 1-4.	0.5	0
451	Impact of the systemic immune-inflammation index for the prediction of prognosis and modification of the risk model in patients with metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitors. <i>Canadian Urological Association Journal</i> , 2020, 14, E582-E587.	0.3	11
452	The Cancer-Immune Set Point in Oesophageal Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 891.	1.3	15
453	Optimizing patient selection for cytoreductive nephrectomy based on outcomes in the contemporary era of systemic therapy. <i>Cancer</i> , 2020, 126, 3950-3960.	2.0	34
454	Neoadjuvant Cabozantinib in Renal-Cell Carcinoma: A Brief Review. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e688-e691.	0.9	11
455	Exploring Biological Predictive Factors of Progression After Surgery in High-Risk Renal Cell Carcinoma: Results From the French Cohort of the Randomized S-TRAC Trial Patients. <i>Frontiers in Surgery</i> , 2020, 7, 26.	0.6	2
456	Spectrum and Clinical Activity of PD-1/PD-L1 Inhibitors: Regulatory Approval and Under Development. <i>Current Oncology Reports</i> , 2020, 22, 70.	1.8	11

#	ARTICLE	IF	CITATIONS
457	Genomic profiling in renal cell carcinoma. <i>Nature Reviews Nephrology</i> , 2020, 16, 435-451.	4.1	99
458	Advanced renal cell carcinoma and COVID-19 – a personal perspective. <i>Nature Reviews Urology</i> , 2020, 17, 425-427.	1.9	10
459	Redefining the Role of Surgical Management of Metastatic Renal Cell Carcinoma. <i>Current Oncology Reports</i> , 2020, 22, 35.	1.8	3
460	Gastrointestinal and Hepatic Complications of Immunotherapy: Current Management and Future Perspectives. <i>Current Gastroenterology Reports</i> , 2020, 22, 15.	1.1	20
461	Multicentric Analytical and Inter-observer Comparability of Four Clinically Developed Programmed Death-ligand 1 Immunohistochemistry Assays in Advanced Clear-cell Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e629-e642.	0.9	8
462	Harnessing cell-free DNA: plasma circulating tumour DNA for liquid biopsy in genitourinary cancers. <i>Nature Reviews Urology</i> , 2020, 17, 271-291.	1.9	32
464	Lactate dehydrogenase: a marker of diminished antitumor immunity. <i>Oncolimmunology</i> , 2020, 9, 1731942.	2.1	107
465	Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents. <i>Journal of Clinical Medicine</i> , 2020, 9, 675.	1.0	57
466	Real-world Experience With Sunitinib Treatment in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to Risk Score. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e588-e597.	0.9	11
467	Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial. <i>European Journal of Cancer</i> , 2020, 129, 107-116.	1.3	35
468	Immuno-oncology gene expression profiling of formalin-fixed and paraffin-embedded clear cell renal cell carcinoma: Performance comparison of the NanoString nCounter technology with targeted RNA sequencing. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 406-416.	1.5	10
470	New prognostic model for synchronous metastatic renal cell carcinoma. <i>International Journal of Urology</i> , 2020, 27, 448-456.	0.5	4
471	Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592090750.	1.4	94
472	Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients. <i>Cancers</i> , 2020, 12, 808.	1.7	10
473	The glucocorticoids prednisone and dexamethasone differentially modulate T cell function in response to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1423-1436.	2.0	36
474	The Therapeutic Landscape of Renal Cell Carcinoma: From the Dark Age to the Golden Age. <i>Seminars in Nephrology</i> , 2020, 40, 28-41.	0.6	42
475	Immune Checkpoint Inhibitors in the Treatment of Renal Cell Carcinoma. <i>Seminars in Nephrology</i> , 2020, 40, 76-85.	0.6	18
476	First-line Treatment of Metastatic Renal Cell Carcinoma in the Immuno-oncology Era: Systematic Review and Network Meta-analysis. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 244-251.e4.	0.9	16

#	ARTICLE	IF	CITATIONS
477	The role of active surveillance and cytoreductive nephrectomy in metastatic renal cell carcinoma. <i>Cancer Treatment and Research Communications</i> , 2020, 23, 100169.	0.7	6
478	Systemic Therapy of Extensive Stage Small Cell Lung Cancer in the Era of Immunotherapy. <i>Current Treatment Options in Oncology</i> , 2020, 21, 64.	1.3	22
479	Targeting DNA Damage Repair Pathways in Pancreatic Adenocarcinoma. <i>Current Treatment Options in Oncology</i> , 2020, 21, 62.	1.3	5
481	Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma. <i>European Journal of Cancer</i> , 2020, 135, 203-210.	1.3	50
482	Immunomodulatory Roles of VEGF Pathway Inhibitors in Renal Cell Carcinoma. <i>Drugs</i> , 2020, 80, 1169-1181.	4.9	53
483	Efficacy and Prognostic Factors of Sunitinib as First-Line Therapy for Patients With Metastatic Renal Cell Carcinoma in an Arab Population. <i>JCO Global Oncology</i> , 2020, 6, 19-26.	0.8	8
484	Immune Checkpoint Inhibitors in the Treatment of Renal Cancer: Current State and Future Perspective. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4691.	1.8	40
485	Combination Therapy for Metastatic Renal Cell Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 477-483.	0.6	3
486	The immunotherapy revolution in genitourinary malignancies. <i>Immunotherapy</i> , 2020, 12, 819-831.	1.0	10
487	A comprehensive review of the role of immune checkpoint inhibitors in elderly patients affected by renal cell carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 153, 103036.	2.0	5
488	Comparative Efficacy of First-Line Immune-Based Combination Therapies in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis. <i>Cancers</i> , 2020, 12, 1673.	1.7	13
489	Safety, efficacy and prognostic impact of immune checkpoint inhibitors in older patients with genitourinary cancers. <i>Journal of Geriatric Oncology</i> , 2020, 11, 1061-1066.	0.5	11
490	The impact of cytoreductive nephrectomy on survival outcomes in patients treated with tyrosine kinase inhibitors for metastatic renal cell carcinoma in a real-world cohort. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 739.e9-739.e15.	0.8	11
491	Evolving Role of Urologists in the Management of Advanced Renal Cell Carcinoma. <i>Urologic Clinics of North America</i> , 2020, 47, 271-280.	0.8	2
492	Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events. <i>British Journal of Cancer</i> , 2020, 123, 898-904.	2.9	36
493	Hyperprogressive disease in patients with advanced renal cell carcinoma: a new pattern of post-treatment cancer behavior. <i>Immunologic Research</i> , 2020, 68, 204-212.	1.3	5
494	Efficacy and safety of neoadjuvant immunotherapy in resectable nonsmall cell lung cancer: A meta-analysis. <i>Lung Cancer</i> , 2020, 147, 143-153.	0.9	66
495	Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations. <i>BMC Urology</i> , 2020, 20, 84.	0.6	12

#	ARTICLE	IF	CITATIONS
496	Immunotherapy combinations for the treatment of patients with solid tumors. <i>Future Oncology</i> , 2020, 16, 1715-1736.	1.1	6
497	Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer. <i>Seminars in Cancer Biology</i> , 2022, 79, 44-57.	4.3	104
498	Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 251-266.	12.5	408
499	Nanomedicines blocking adaptive signals in cancer cells overcome tumor TKI resistance. <i>Journal of Controlled Release</i> , 2020, 321, 132-144.	4.8	9
500	Clinical efficacy and safety of anti-PD-1/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis. <i>Scientific Reports</i> , 2020, 10, 2083.	1.6	124
501	A Case Report with Severe Thrombocytopenia Induced by Axitinib. <i>Case Reports in Hematology</i> , 2020, 2020, 1-4.	0.3	2
502	Phase Ib/II Clinical Trial of Pembrolizumab With Bevacizumab for Metastatic Renal Cell Carcinoma: BTCRC-GU14-003. <i>Journal of Clinical Oncology</i> , 2020, 38, 1138-1145.	0.8	32
503	New First Line Treatment Options of Clear Cell Renal Cell Cancer Patients with PD-1 or PD-L1 Immune-Checkpoint Inhibitor-Based Combination Therapies. <i>Journal of Clinical Medicine</i> , 2020, 9, 565.	1.0	35
504	Pembrolizumabâ€axitinibâ€induced tumor lysis syndrome in a patient with metastatic renal cancer. <i>Clinical Case Reports (discontinued)</i> , 2020, 8, 704-708.	0.2	5
505	Modeling clear cell renal cell carcinoma and therapeutic implications. <i>Oncogene</i> , 2020, 39, 3413-3426.	2.6	86
506	Clinical and histological response to combination nivolumab and ipilimumab in metastatic renal cell carcinoma. <i>Baylor University Medical Center Proceedings</i> , 2020, 33, 258-260.	0.2	2
507	Pembrolizumab monotherapy in Japanese patients with advanced ovarian cancer: Subgroup analysis from the KEYNOTEâ€100. <i>Cancer Science</i> , 2020, 111, 1324-1332.	1.7	27
508	Flawed trials for cancer. <i>Annals of Oncology</i> , 2020, 31, 331-333.	0.6	5
509	Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcomeâ€Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>European Urology Oncology</i> , 2020, 3, 530-539.	2.6	29
510	Results of the ADAPT Phase 3 Study of Ropapludencel-T in Combination with Sunitinib as First-Line Therapy in Patients with Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 2327-2336.	3.2	49
511	Outcomes Associated with First-Line anti-PD-1/ PD-L1 agents vs. Sunitinib in Patients with Sarcomatoid Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2020, 12, 408.	1.7	32
512	Current State of Systemic Therapies for Advanced Renal Cell Carcinoma. <i>Current Oncology Reports</i> , 2020, 22, 26.	1.8	38
513	A new scenario in metastatic renal cell carcinoma: a SOG-GU consensus. <i>Clinical and Translational Oncology</i> , 2020, 22, 1565-1579.	1.2	1

#	ARTICLE	IF	CITATIONS
514	Neutrophil-lymphocyte ratio as a prognostic factor for survival in patients with advanced renal cell carcinoma (Turkish Oncology Group Study). <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1583-1589.	0.5	6
515	Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group. <i>Oncologist</i> , 2020, 25, 422-430.	1.9	12
516	Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 72, 307-319.	1.8	310
517	Overcoming immunotherapeutic resistance by targeting the cancer inflammation cycle. <i>Seminars in Cancer Biology</i> , 2020, 65, 38-50.	4.3	34
518	Immunotherapy-based combinations versus standard first-line treatment for metastatic clear cell renal cell carcinoma: a systematic review and meta-analysis. <i>Clinical and Translational Oncology</i> , 2020, 22, 1657-1663.	1.2	5
519	Ex-Vivo Treatment of Tumor Tissue Slices as a Predictive Preclinical Method to Evaluate Targeted Therapies for Patients with Renal Carcinoma. <i>Cancers</i> , 2020, 12, 232.	1.7	40
520	New rising entities in cancer of unknown primary: Is there a real therapeutic benefit?. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 147, 102882.	2.0	42
521	Immune checkpoint inhibitors in advanced non-small cell lung cancer: A metacentric experience from India. <i>Current Problems in Cancer</i> , 2020, 44, 100549.	1.0	4
522	A historical turning point for the treatment of advanced renal cell carcinoma: inhibition of immune checkpoint. <i>Current Medical Research and Opinion</i> , 2020, 36, 625-635.	0.9	4
523	The Future of Immunotherapy-Based Combination Therapy in Metastatic Renal Cell Carcinoma. <i>Cancers</i> , 2020, 12, 143.	1.7	36
524	Possibilities of Improving the Clinical Value of Immune Checkpoint Inhibitor Therapies in Cancer Care by Optimizing Patient Selection. <i>International Journal of Molecular Sciences</i> , 2020, 21, 556.	1.8	21
525	Systemic therapy for chromophobe renal cell carcinoma: A systematic review. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 137-149.	0.8	9
526	Clinical importance of the expression of CD4+CD8+ T cells in renal cell carcinoma. <i>International Immunology</i> , 2020, 32, 347-357.	1.8	10
527	SEOM clinical guideline for treatment of kidney cancer (2019). <i>Clinical and Translational Oncology</i> , 2020, 22, 256-269.	1.2	18
528	Anti-VEGF/VEGFR2 Monoclonal Antibodies and their Combinations with PD-1/PD-L1 Inhibitors in Clinic. <i>Current Cancer Drug Targets</i> , 2020, 20, 3-18.	0.8	43
529	Beyond the concept of cold and hot tumors for the development of novel predictive biomarkers and the rational design of immunotherapy combination. <i>International Journal of Cancer</i> , 2020, 147, 1509-1518.	2.3	44
530	Optimising first-line treatment for metastatic renal cell carcinoma. <i>Lancet, The</i> , 2020, 395, e6.	6.3	1
531	PD-1 Blockade Reinvigorates Bone Marrow CD8+ T Cells from Patients with Multiple Myeloma in the Presence of TGF- β Inhibitors. <i>Clinical Cancer Research</i> , 2020, 26, 1644-1655.	3.2	25

#	ARTICLE	IF	CITATIONS
532	Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2020, 38, 1154-1163.	0.8	276
533	Evolution in upfront treatment strategies for metastatic RCC. <i>Nature Reviews Urology</i> , 2020, 17, 73-74.	1.9	9
534	Treatment Choices for Front-line Metastatic Clear Cell Renal Cancer. <i>European Urology</i> , 2020, 77, 454-456.	0.9	6
535	Combining microenvironment normalization strategies to improve cancer immunotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 3728-3737.	3.3	163
536	Clinical and economic outcomes of treatment sequences for intermediate- to poor-risk advanced renal cell carcinoma. <i>Immunotherapy</i> , 2020, 12, 37-51.	1.0	10
538	Phase I trial of vorolanib (CM082) in combination with everolimus in patients with advanced clear-cell renal cell carcinoma. <i>EBioMedicine</i> , 2020, 55, 102755.	2.7	12
539	Clinical implications of food-drug interactions with small-molecule kinase inhibitors. <i>Lancet Oncology</i> , 2020, 21, e265-e279.	5.1	46
540	Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2020, 78, 615-623.	0.9	44
541	Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab + Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 2506-2514.	3.2	20
542	IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation. <i>Future Oncology</i> , 2020, 16, 975-989.	1.1	136
543	Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence. <i>Cancers</i> , 2020, 12, 738.	1.7	826
544	Immunotherapy in Renal Cell Carcinoma: The Future Is Now. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2532.	1.8	126
545	A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy. <i>Oncologist</i> , 2020, 25, e1280-e1285.	1.9	14
546	PD-L1 Assay Concordance in Metastatic Renal Cell Carcinoma and Metastatic Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 509-513.	0.9	1
547	Evolving treatment paradigm in metastatic non clear cell renal cell carcinoma. <i>Cancer Treatment and Research Communications</i> , 2020, 23, 100172.	0.7	11
548	Targeting angiogenesis for liver cancer: Past, present, and future. <i>Genes and Diseases</i> , 2020, 7, 328-335.	1.5	61
549	Clinicopathological implications of the expression of vascular endothelial growth factor and programmed death ligand 1 in clear-cell renal cell carcinoma. <i>Human Pathology</i> , 2020, 99, 88-97.	1.1	2
550	Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: An analysis of the National Cancer Database. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 604.e9-604.e17.	0.8	77

#	ARTICLE	IF	CITATIONS
551	Tumour grade significantly correlates with total dysfunction of tumour tissue-infiltrating lymphocytes in renal cell carcinoma. <i>Scientific Reports</i> , 2020, 10, 6220.	1.6	25
552	Atezolizumab for the treatment of renal cell carcinoma. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 679-686.	1.4	0
553	The Anticancer Efficacy of Immune Checkpoint Inhibitors According to Patients' Age: A Systematic Review and Meta-Analysis. <i>Journal of Immunotherapy</i> , 2020, 43, 95-103.	1.2	7
554	<i>LAG3</i> (<i>LAG-3</i> , <i>CD223</i>) DNA methylation correlates with <i>LAG3</i> expression by tumor and immune cells, immune cell infiltration, and overall survival in clear cell renal cell carcinoma. , 2020, 8, e000552.		70
555	Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors. <i>Cancer Immunology Research</i> , 2020, 8, 1075-1084.	1.6	47
556	Combination Strategies for Immune-Checkpoint Blockade and Response Prediction by Artificial Intelligence. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2856.	1.8	31
557	Apatinib as targeted therapy for advanced bone and soft tissue sarcoma: a dilemma of reversing multidrug resistance while suffering drug resistance itself. <i>Angiogenesis</i> , 2020, 23, 279-298.	3.7	30
558	The genetic landscapes of urological cancers and their clinical implications in the era of high-throughput genome analysis. <i>BJU International</i> , 2020, 126, 26-54.	1.3	5
559	Current Approaches to the Treatment of Advanced or Metastatic Renal Cell Carcinoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 187-196.	1.8	26
560	On the Shoulders of Giants: The Evolution of Renal Cell Carcinoma Treatment—Cytokines, Targeted Therapy, and Immunotherapy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 418-435.	1.8	16
561	Tumor Mutational Burden Determined by Panel Sequencing Predicts Survival After Immunotherapy in Patients With Advanced Gastric Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 314.	1.3	62
562	Treatment discontinuation and re-initiation of anti-PD-(L)1 agents in metastatic cancers. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2153-2160.	1.2	8
563	Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma. <i>Pathology and Oncology Research</i> , 2020, 26, 2201-2207.	0.9	4
564	Avelumab and axitinib in the treatment of renal cell carcinoma: safety and efficacy. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 343-354.	1.1	0
565	Immune Checkpoint Inhibitors for Brain Metastases: A Primer for Neurosurgeons. <i>Neurosurgery</i> , 2020, 87, E281-E288.	0.6	22
566	Challenges and opportunities in the management of metastatic renal cell carcinoma: combination therapy and the role of cytoreductive surgery. <i>Current Opinion in Oncology</i> , 2020, 32, 240-249.	1.1	15
567	Mechanism-based treatment of cancer with immune checkpoint inhibitor therapies. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1690-1702.	1.1	26
568	Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma. <i>BJU International</i> , 2020, 126, 73-82.	1.3	19

#	ARTICLE	IF	CITATIONS
569	Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma. , 2020, 8, e000144.		56
570	Pazopanib after Nivolumab-Induced Tumor Lysis Syndrome in a Patient with Metastatic Clear-Cell Renal Cell Carcinoma. Case Reports in Oncology, 2020, 13, 249-254.	0.3	3
571	Targeting PD-1 or PD-L1 in Metastatic Kidney Cancer: Combination Therapy in the First-Line Setting. Clinical Cancer Research, 2020, 26, 2087-2095.	3.2	35
572	Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy. Journal of Hematology and Oncology, 2020, 13, 29.	6.9	146
573	Landscape and Future Perspectives of Immunotherapy in Neuroendocrine Neoplasia. Cancers, 2020, 12, 832.	1.7	27
574	Coalescing lessons from oxygen sensing, tumor metabolism, and epigenetics to target VHL loss in kidney cancer. Seminars in Cancer Biology, 2020, 67, 34-42.	4.3	12
575	High level of EZH2 expression is linked to high density of CD8-positive T-lymphocytes and an aggressive phenotype in renal cell carcinoma. World Journal of Urology, 2021, 39, 481-490.	1.2	11
576	Real-world efficacy and safety of pembrolizumab in patients with non-small cell lung cancer: a retrospective observational study. Tumori, 2021, 107, 32-38.	0.6	4
577	The unique immune microenvironment of liver metastases: Challenges and opportunities. Seminars in Cancer Biology, 2021, 71, 143-156.	4.3	35
578	Patientsâ€™ Perspective on Digital Technologies in Advanced Genitourinary Cancers. Clinical Genitourinary Cancer, 2021, 19, 76-82.e6.	0.9	12
579	Glucocorticoids and immune checkpoint inhibitors in glioblastoma. Journal of Neuro-Oncology, 2021, 151, 13-20.	1.4	15
580	Blocking IL1 Beta Promotes Tumor Regression and Remodeling of the Myeloid Compartment in a Renal Cell Carcinoma Model: Multidimensional Analyses. Clinical Cancer Research, 2021, 27, 608-621.	3.2	73
581	Is there a role for novel TKI/ICI combinations in metastatic renal cell carcinoma? Definitely maybe. Annals of Oncology, 2021, 32, 12-14.	0.6	7
582	Systemic therapy for metastatic renal cell carcinoma in the first-line setting: a systematic review and network meta-analysis. Cancer Immunology, Immunotherapy, 2021, 70, 265-273.	2.0	44
583	The tumour microenvironment and metabolism in renal cell carcinoma targeted or immune therapy. Journal of Cellular Physiology, 2021, 236, 1616-1627.	2.0	85
584	Complete response of hereditary leiomyomatosis and renal cell cancer (HLRCC)-associated renal cell carcinoma to nivolumab and ipilimumab combination immunotherapy by: a case report. Familial Cancer, 2021, 20, 75-80.	0.9	17
585	From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm. Trends in Cancer, 2021, 7, 15-28.	3.8	61
586	TiNivo: safety and efficacy of tivozanib-nivolumab combination therapy in patients with metastatic renal cell carcinoma. Annals of Oncology, 2021, 32, 97-102.	0.6	42

#	ARTICLE	IF	CITATIONS
587	Multicenter Phase II Trial of Axitinib Monotherapy for Gemcitabine-Based Chemotherapy Refractory Advanced Biliary Tract Cancer (AX-BC Study). <i>Oncologist</i> , 2021, 26, 97-e201.	1.9	2
588	Prognostic impact of systemic therapy change in metastatic renal cell carcinoma treated with cytoreductive nephrectomy. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 296-304.	0.6	4
589	Comparison of nivolumab plus ipilimumab with tyrosine kinase inhibitors as first-line therapies for metastatic renal-cell carcinoma: a multicenter retrospective study. <i>International Journal of Clinical Oncology</i> , 2021, 26, 154-162.	1.0	11
590	Pembrolizumab plus axitinib combination and the paradigm change in the treatment of advanced renal cell carcinoma. <i>Future Oncology</i> , 2021, 17, 241-254.	1.1	4
591	Synergism between anti-angiogenic and immune checkpoint inhibitor drugs: A hypothesis. <i>Medical Hypotheses</i> , 2021, 146, 110399.	0.8	5
592	Modest efficacy of nivolumab plus ipilimumab in patients with papillary renal cell carcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 646-653.	0.6	22
593	KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. <i>Cancer Immunology Research</i> , 2021, 9, 156-169.	1.6	56
594	An Illustrative Case of Combination Cabozantinib/Nivolumab for Progressive Metastatic Renal Cell Carcinoma (mRCC). <i>Oncologist</i> , 2021, 26, e508-e511.	1.9	4
595	Exploring the knowledge gap of immune checkpoint inhibitors in chronic renal failure: A systematic review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103169.	2.0	14
596	Recent eUpdate to the ESMO Clinical Practice Guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer. <i>Annals of Oncology</i> , 2021, 32, 422-423.	0.6	84
597	Enhancing anti-tumour efficacy with immunotherapy combinations. <i>Lancet, The</i> , 2021, 397, 1010-1022.	6.3	196
598	Creation of a primary tumor tissue expression biomarker-augmented prognostic model for patients with metastatic renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 135.e1-135.e8.	0.8	2
599	Multicenter Phase I/II Study of Nivolumab Combined with Paclitaxel Plus Ramucirumab as Second-line Treatment in Patients with Advanced Gastric Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 1029-1036.	3.2	46
600	Hypofractionated stereotactic re-irradiation with pembrolizumab and bevacizumab in patients with recurrent high-grade gliomas: results from a phase I study. <i>Neuro-Oncology</i> , 2021, 23, 677-686.	0.6	60
601	Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma. <i>Clinical Cancer Research</i> , 2021, 27, 1048-1057.	3.2	129
602	A novel prognostic model based on immunogenomics for clear cell renal cell carcinoma. <i>International Immunopharmacology</i> , 2021, 90, 107119.	1.7	2
603	Predictive role of $\hat{\Gamma}^3$ -glutamyltransferase in patients receiving nivolumab therapy for metastatic renal cell carcinoma. <i>International Journal of Clinical Oncology</i> , 2021, 26, 552-561.	1.0	7
604	Summary from the Kidney Cancer Association's Inaugural Think Thank: Coalition for a Cure. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 167-175.	0.9	4

#	ARTICLE	IF	CITATIONS
605	Molecular Profiling of Exceptional Responders to Cancer Therapy. <i>Oncologist</i> , 2021, 26, 186-195.	1.9	15
606	Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies. <i>Cancer</i> , 2021, 127, 840-849.	2.0	51
607	The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2021, 79, 783-792.	0.9	46
608	Efficacy of nivolumab versus molecularly targeted therapy as second-line therapy for metastatic renal cell carcinoma: Real-world data from two Japanese institutions. <i>International Journal of Urology</i> , 2021, 28, 99-106.	0.5	4
609	Combination of Immunotherapy and Antiangiogenic Therapy in Cancer—a Rational Approach. <i>Journal of Thoracic Oncology</i> , 2021, 16, 178-182.	0.5	8
610	Systemic Therapies for the Management of Non-clear Cell Renal Cell Carcinoma: What Works, What Doesn't, and What the Future Holds. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 103-116.	0.9	31
611	The need for new algorithms of treatment sequencing in clear-cell metastatic renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 401-412.	1.1	8
612	Safety and efficacy of pembrolizumab plus lenvatinib versus pembrolizumab and lenvatinib monotherapies in cancers: A systematic review. <i>International Immunopharmacology</i> , 2021, 91, 107281.	1.7	32
613	Predicative value of IFITM2 in renal clear cell carcinoma: IFITM2 is associated with lymphatic metastasis and poor clinical outcome. <i>Biochemical and Biophysical Research Communications</i> , 2021, 534, 157-164.	1.0	11
614	Current status of PD-1/PD-L1 blockade immunotherapy in breast cancer. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 321-332.	0.6	22
615	Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy. <i>Clinical Cancer Research</i> , 2021, 27, 1296-1304.	3.2	79
616	Assessing improvements in metastatic renal cell carcinoma systemic treatments from the pre-cytokine to the immune checkpoint inhibitor eras: a retrospective analysis of real-world data. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 793-801.	0.6	7
617	A network meta-analysis of efficacy and safety of first-line and second-line therapies for the management of metastatic renal cell carcinoma. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, 46, 35-49.	0.7	18
618	Absorption of the orally active multikinase inhibitor axitinib as a therapeutic index to guide dose titration in metastatic renal cell carcinoma. <i>Investigational New Drugs</i> , 2021, 39, 595-604.	1.2	6
619	Prognostic impact of metastasectomy in renal cell carcinoma in the postcytokine therapy era. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 77.e17-77.e25.	0.8	16
620	Systemic Analysis and Review of Nivolumab-ipilimumab Combination as a Rescue Strategy for Renal Cell Carcinoma After Treatment With Anti-PD-1/PD-L1 Therapy. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 95-102.	0.9	9
621	TIM3 expression on tumor cells predicts response to anti-PD-1 therapy for renal cancer. <i>Translational Oncology</i> , 2021, 14, 100918.	1.7	11
622	Cost-Effectiveness of Pembrolizumab plus Axitinib Versus Sunitinib as First-Line Therapy in Advanced Renal Cell Carcinoma in the U.S.. <i>Oncologist</i> , 2021, 26, e290-e297.	1.9	15

#	ARTICLE	IF	CITATIONS
623	Immune evasion in renal cell carcinoma: biology, clinical translation, future directions. <i>Kidney International</i> , 2021, 99, 75-85.	2.6	22
624	Clinical Pharmacology and Interplay of Immune Checkpoint Agents: A Yin-Yang Balance. <i>Annual Review of Pharmacology and Toxicology</i> , 2021, 61, 85-112.	4.2	50
625	Avelumab: search for combinations of immune checkpoint inhibition with chemotherapy. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 311-322.	1.4	10
626	Intratumoral Immunotherapy: From Trial Design to Clinical Practice. <i>Clinical Cancer Research</i> , 2021, 27, 665-679.	3.2	69
627	Pazopanib as Second-line Antiangiogenic Treatment in Metastatic Renal Cell Carcinoma After Tyrosine Kinase Inhibitor (TKI) Failure: A Phase 2 Trial Exploring Immune-related Biomarkers for Testing in the Post-immunotherapy/TKI Era. <i>European Urology Oncology</i> , 2021, 4, 502-505.	2.6	5
628	Aberrant Epidermal Growth Factor Receptor RNA Splice Products Are Among the Most Frequent Somatic Alterations in Clear Cell Renal Cell Carcinoma and Are Associated with a Poor Response to Immunotherapy. <i>European Urology Focus</i> , 2021, 7, 373-380.	1.6	4
629	Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors. <i>European Urology Oncology</i> , 2021, 4, 102-111.	2.6	26
630	Lenvatinib and pembrolizumab in patients with advanced uterine cancer. <i>Opuholi Zenskoj Reproktivnoy Sistem</i> , 2021, 16, 72-80.	0.1	1
632	Genetic analysis of primary renal cell carcinoma to determine treatment approaches. <i>Expert Review of Precision Medicine and Drug Development</i> , 2021, 6, 107-115.	0.4	1
633	Update on First-Line Combination Treatment Approaches in Metastatic Clear-Cell Renal Cell Carcinoma. <i>Current Treatment Options in Oncology</i> , 2021, 22, 15.	1.3	13
634	Neuropilin 1 and Neuropilin 2 gene invalidation or pharmacological inhibition reveals their relevance for the treatment of metastatic renal cell carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 33.	3.5	11
635	Real-world effectiveness of eribulin in heavily pretreated patients with metastatic breast cancer in China: a multicenter retrospective study. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110302.	1.4	6
636	Response to systemic therapy in locally advanced and metastatic renal cell carcinoma: can it be predicted?. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 629-639.	1.1	0
637	Cardiotoxic effects of angiogenesis inhibitors. <i>Clinical Science</i> , 2021, 135, 71-100.	1.8	46
638	Factors Modifying the Associations of Single or Combination Programmed Cell Death 1 and Programmed Cell Death Ligand 1 Inhibitor Therapies With Survival Outcomes in Patients With Metastatic Clear Cell Renal Cell Carcinoma. <i>JAMA Network Open</i> , 2021, 4, e2034201.	2.8	4
639	Profiling of Serum Extracellular Vesicles Reveals <i>miRNA-4525</i> as a Potential Biomarker for Advanced Renal Cell Carcinoma. <i>Cancer Genomics and Proteomics</i> , 2021, 18, 253-259.	1.0	13
640	Cytoreductive stereotactic body radiotherapy (SBRT) and combination SBRT with immune checkpoint inhibitors (ICIs) in metastatic renal cell carcinoma. <i>Canadian Urological Association Journal</i> , 2021, 15, 281-286.	0.3	7
641	The implementation of lenvatinib/everolimus or lenvatinib/pembrolizumab combinations in the treatment of metastatic renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 365-372.	1.1	5

#	ARTICLE	IF	CITATIONS
642	Increased expression of adenosine 2A receptors in metastatic renal cell carcinoma is associated with poorer response to anti-vascular endothelial growth factor agents and anti-PD-1/Anti-CTLA4 antibodies and shorter survival. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2009-2021.	2.0	27
643	ACE2 abrogates tumor resistance to VEGFR inhibitors suggesting angiotensin-(1-7) as a therapy for clear cell renal cell carcinoma. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	29
644	New approaches to first-line treatment of advanced renal cell carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110347.	1.4	25
645	Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer. <i>Cancers</i> , 2021, 13, 334.	1.7	44
646	Update on the most promising biomarkers of response to immune checkpoint inhibitors in clear cell renal cell carcinoma. <i>World Journal of Urology</i> , 2021, 39, 1377-1385.	1.2	15
647	Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 in renal cell carcinoma: Lessons from CheckMate 9ER and IMmotion 151. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 266-267.	0.5	6
648	Unleashing the power of immunotherapy and targeted therapy combinations: Advancing cancer care or discovering unknown toxicities?. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 930-938.	0.5	6
649	External validation of the albumin, C-reactive protein and lactate dehydrogenase model in patients with metastatic renal cell carcinoma receiving second-line axitinib therapy in a Japanese multi-center cohort. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 810-818.	0.6	0
650	Tumor flare of brain metastases upon dose interruption of sunitinib in a patient with metastatic renal cell carcinoma. <i>Cancer Treatment and Research Communications</i> , 2021, 27, 100367.	0.7	2
651	Phase II Trial Investigating Definitive Radiation Therapy in Lieu of Systemic Therapy for Oligometastatic Renal Cell Carcinoma. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
652	A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy. <i>Investigational New Drugs</i> , 2021, 39, 1019-1027.	1.2	22
653	Pembrolizumab plus axitinib and nivolumab plus ipilimumab as first-line treatments of advanced intermediate- or poor-risk renal-cell carcinoma: a number needed to treat analysis from the Brazilian private perspective. <i>Journal of Medical Economics</i> , 2021, 24, 291-298.	1.0	4
654	Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy. , 2021, 9, e001642.		28
655	Tumor Microenvironment Features as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors (ICI) in Metastatic Clear Cell Renal Cell Carcinoma (mccRCC). <i>Cancers</i> , 2021, 13, 231.	1.7	42
656	Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE): A Single-arm, Open-label, Phase II Trial. <i>Clinical Cancer Research</i> , 2021, 27, 2139-2147.	3.2	77
657	Efficacy and safety of anti-PD-1/PD-L1 combinations versus standard of care in cancer: a systematic review and meta-analysis.. <i>Oncolmmunology</i> , 2021, 10, 1878599.	2.1	11
658	Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival. <i>JAMA Network Open</i> , 2021, 4, e2021869.	2.8	104
659	Development of a novel gene signature to predict prognosis and response to PD-1 blockade in clear cell renal cell carcinoma. <i>Oncolmmunology</i> , 2021, 10, 1933332.	2.1	26

#	ARTICLE	IF	CITATIONS
660	Immunotherapy in colorectal cancer. <i>Advances in Cancer Research</i> , 2021, 151, 137-196.	1.9	18
661	Comorbidity and frailty assessment in renal cell carcinoma patients. <i>World Journal of Urology</i> , 2021, 39, 2831-2841.	1.2	7
662	Intratumoral CXCL13 ⁺ CD8 ⁺ T cell infiltration determines poor clinical outcomes and immunoevasive contexture in patients with clear cell renal cell carcinoma. , 2021, 9, e001823.		87
663	Real Impact of Novel Immunotherapy Drugs in Cancer. The Experience of 10 Last Years. <i>Toxins</i> , 2021, 13, 149.	1.5	6
664	Progress Update in Pediatric Renal Tumors. <i>Current Oncology Reports</i> , 2021, 23, 33.	1.8	14
665	First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts. <i>ESMO Open</i> , 2021, 6, 100030.	2.0	35
666	Natural history of untreated kidney cancer. <i>World Journal of Urology</i> , 2021, 39, 2825-2829.	1.2	5
667	Characteristics and outcome of pediatric renal cell carcinoma patients registered in the International Society of Pediatric Oncology (<scp>SIOP</scp>) 93â€01, 2001 and <scp>UKâ€IMPORT</scp> database: A report of the <scp>SIOPâ€Renal</scp> Tumor Study Group. <i>International Journal of Cancer</i> , 2021, 148, 2724-2735.	2.3	26
668	Anti-tumor efficacy of human anti-â€met CARâ€T cells against papillary renal cell carcinoma in an orthotopic model. <i>Cancer Science</i> , 2021, 112, 1417-1428.	1.7	21
669	Dissecting Outcomes: Should Cytoreductive Nephrectomy Be Performed for Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid Dedifferentiation?. <i>Frontiers in Oncology</i> , 2020, 10, 627025.	1.3	6
670	Survival After Combining Stereotactic Body Radiation Therapy and Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 607595.	1.3	5
671	Efficacy and safety of subsequent molecular targeted therapy after immuno-checkpoint therapy, retrospective study of Japanese patients with metastatic renal cell carcinoma (AFTER I-O study). <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 966-975.	0.6	12
672	m ⁶ A modification patterns and tumor immune landscape in clear cell renal carcinoma. , 2021, 9, e001646.		42
673	Modulation of intratumoural myeloid cells, the hallmark of the anti-tumour efficacy induced by a triple combination: tumour-associated peptide, TLR-3 ligand and Î±-PD-1. <i>British Journal of Cancer</i> , 2021, 124, 1275-1285.	2.9	5
674	Plk1, upregulated by HIF-2, mediates metastasis and drug resistance of clear cell renal cell carcinoma. <i>Communications Biology</i> , 2021, 4, 166.	2.0	19
675	A challenging frontier â€“ the genomics and therapeutics of nonclear cell renal cell carcinoma. <i>Current Opinion in Oncology</i> , 2021, 33, 212-220.	1.1	6
676	Safety and Efficacy of Robotic Radiosurgery for Visceral and Lymph Node Metastases of Renal Cell Carcinoma: A Retrospective, Single Center Analysis. <i>Cancers</i> , 2021, 13, 680.	1.7	2
677	Sunitinib Exerts In Vitro Immunomodulatory Activity on Sarcomas via Dendritic Cells and Synergizes With PD-1 Blockade. <i>Frontiers in Immunology</i> , 2021, 12, 577766.	2.2	16

#	ARTICLE	IF	CITATIONS
678	PD-L1 as a biomarker of response to immune-checkpoint inhibitors. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 345-362.	12.5	646
679	Association between Immune Related Adverse Events and Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. <i>Cancers</i> , 2021, 13, 860.	1.7	37
681	Dual immune checkpoint inhibition in metastatic renal cell carcinoma. <i>ESMO Open</i> , 2021, 6, 100035.	2.0	2
682	Combination of immune checkpoint inhibitors and tyrosine kinase inhibitors for the treatment of renal cell carcinoma. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 1215-1226.	1.4	10
684	Symptomatic methemoglobinemia in a patient with metastatic clear cell renal cell carcinoma treated with pembrolizumab and axitinib combination therapy: a case report. <i>Journal of Medical Case Reports</i> , 2021, 15, 72.	0.4	1
685	Clear-cell renal cell carcinoma - A comprehensive review of agents used in the contemporary management of advanced/metastatic disease. <i>Oncology Reviews</i> , 2021, 15, 530.	0.8	9
686	Immune checkpoint blockade in renal cell carcinoma. <i>Journal of Surgical Oncology</i> , 2021, 123, 739-750.	0.8	13
687	Real-world experience with pembrolizumab in patients with advanced soft tissue sarcoma. <i>Annals of Translational Medicine</i> , 2021, 9, 339-339.	0.7	12
688	Clinical utility of head computed tomography scan during systemic therapy for metastatic renal cell carcinoma. <i>International Journal of Urology</i> , 2021, 28, 450-456.	0.5	4
689	Sex-specific hormone changes during immunotherapy and its influence on survival in metastatic renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2805-2817.	2.0	13
690	Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 72.	7.1	191
691	IgL5 is correlated with tumor-infiltrating immune cells in clear cell renal cell carcinoma. <i>FEBS Open Bio</i> , 2021, 11, 898-910.	1.0	11
692	Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades. <i>Molecular Cancer</i> , 2021, 20, 27.	7.9	54
694	Current Advance of Immune Evasion Mechanisms and Emerging Immunotherapies in Renal Cell Carcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 639636.	2.2	33
695	Challenging anticoagulation cases: Cancer-associated venous thromboembolism and chemotherapy-induced thrombocytopenia – A case-based review of clinical management. <i>Thrombosis Research</i> , 2021, 199, 38-42.	0.8	6
696	Next Steps: Sequencing Therapies in Metastatic Kidney Cancer in the Contemporary Era. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, 187-197.	1.8	11
697	Perioperative therapy in renal cancer in the era of immune checkpoint inhibitor therapy. <i>Current Opinion in Urology</i> , 2021, 31, 262-269.	0.9	16
698	Phase IB study of sorafenib and evofosfamide in patients with advanced hepatocellular and renal cell carcinomas (NCCTG N1135, Alliance). <i>Investigational New Drugs</i> , 2021, 39, 1072-1080.	1.2	4

#	ARTICLE	IF	CITATIONS
699	Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2021, 384, 829-841.	13.9	961
700	A case of multiple metastatic sarcomatoid renal cell carcinoma with complete response to nivolumab. <i>Cancer Reports</i> , 2021, 4, e1356.	0.6	2
701	Checkpoint blockade toxicities: Insights into autoimmunity and treatment. <i>Seminars in Immunology</i> , 2021, 52, 101473.	2.7	11
702	What is next in second- and later-line treatment of metastatic renal cell carcinoma? review of the recent literature. <i>Current Opinion in Urology</i> , 2021, 31, 276-284.	0.9	7
703	Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-“Clear Cell Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 1029-1039.	0.8	145
704	Renal Cell Carcinoma and Kidney Transplantation: A Narrative Review. <i>Transplantation</i> , 2022, 106, e52-e63.	0.5	25
705	Pazopanib in patients with metastatic renal cell carcinoma: a single-center, real-world, retrospective Chinese study. <i>Translational Andrology and Urology</i> , 2021, 10, 1321-1331.	0.6	1
706	Finding predictive factors for immunotherapy in metastatic renal-cell carcinoma: What are we looking for?. <i>Cancer Treatment Reviews</i> , 2021, 94, 102157.	3.4	16
707	Transcriptional Profiling Reveals Kidney Neutrophil Heterogeneity in Both Healthy People and ccRCC Patients. <i>Journal of Immunology Research</i> , 2021, 2021, 1-17.	0.9	13
708	Direct and Indirect Modulation of T Cells by VEGF-A Counteracted by Anti-Angiogenic Treatment. <i>Frontiers in Immunology</i> , 2021, 12, 616837.	2.2	72
709	The evolving paradigm of biomarker actionability: Histology-agnosticism as a spectrum, rather than a binary quality. <i>Cancer Treatment Reviews</i> , 2021, 94, 102169.	3.4	14
710	Clinical Features and Multiplatform Molecular Analysis Assist in Understanding Patient Response to Anti-PD-1/PD-L1 in Renal Cell Carcinoma. <i>Cancers</i> , 2021, 13, 1475.	1.7	10
711	The Evolving Immunotherapy Landscape and the Epidemiology, Diagnosis, and Management of “Cardiotoxicity. <i>JACC: CardioOncology</i> , 2021, 3, 35-47.	1.7	80
712	Site-specific Response to Nivolumab in Renal Cell Carcinoma. <i>Anticancer Research</i> , 2021, 41, 1539-1545.	0.5	14
713	Biomarker-Oriented Therapy in Bladder and Renal Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2832.	1.8	18
714	Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials. <i>European Urology Focus</i> , 2022, 8, 514-521.	1.6	64
715	Management of advanced kidney cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2021. <i>Canadian Urological Association Journal</i> , 2020, 15, 84-97.	0.3	11
716	Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC). <i>Cancer</i> , 2021, 127, 2204-2212.	2.0	32

#	ARTICLE	IF	CITATIONS
717	Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial. <i>European Journal of Cancer</i> , 2021, 145, 1-10.	1.3	17
718	Impact of BMI on Survival Outcomes of Immunotherapy in Solid Tumors: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2628.	1.8	21
719	Immunotherapy in uveal melanoma: novel strategies and opportunities for personalized treatment. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 555-569.	1.9	14
720	Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma. <i>European Urology</i> , 2021, 79, 339-342.	0.9	98
721	Drug-Related Pneumonitis in Cancer Treatment during the COVID-19 Era. <i>Cancers</i> , 2021, 13, 1052.	1.7	5
722	Paradigms on Immunotherapy Combinations with Chemotherapy. <i>Cancer Discovery</i> , 2021, 11, 1353-1367.	7.7	197
723	Real-World Experience of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis). <i>Kidney Cancer</i> , 2021, 5, 21-29.	0.2	3
725	PD-L1 Expression and Treatment Implications in Metastatic Clear Cell Renal Cell Carcinoma: A Systematic Review. <i>Kidney Cancer</i> , 2021, 5, 31-46.	0.2	2
726	Individualizing renal cell carcinoma treatment through biomarkers discovery in the era of immune checkpoint inhibitors: where do we stand?. <i>Current Opinion in Urology</i> , 2021, 31, 236-241.	0.9	4
727	Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes. <i>Cancer Medicine</i> , 2021, 10, 2341-2349.	1.3	15
728	Roles of the Dynamic Tumor Immune Microenvironment in the Individualized Treatment of Advanced Clear Cell Renal Cell Carcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 653358.	2.2	19
729	Systemic inflammation is a determinant of outcomes of CD40 agonist-based therapy in pancreatic cancer patients. <i>JCI Insight</i> , 2021, 6, .	2.3	14
730	Strategies to overcome relapse of immunotherapy-related hepatitis: dose reduction is not the key. <i>Acta Clinica Belgica</i> , 2021, , 1-6.	0.5	1
731	Outcomes of patients with intermediate-risk or poor-risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: The MD Anderson Cancer Center experience. <i>International Journal of Cancer</i> , 2021, 149, 387-393.	2.3	6
732	Control of renal cell carcinoma brain metastases with cabozantinib following progression on immune checkpoint inhibitor therapy. <i>Current Problems in Cancer Case Reports</i> , 2021, 3, 100060.	0.1	0
733	Comparative efficacy and safety of immunotherapy in the first-line treatment of metastatic renal cell carcinoma: a systematic review and network meta-analysis. <i>Annals of Palliative Medicine</i> , 2021, 10, 2805-2814.	0.5	5
734	Current status of antigen-specific T-cell immunotherapy for advanced renal-cell carcinoma. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 1882-1896.	1.4	10
735	A phase I/II study of stereotactic radiotherapy and pembrolizumab for oligometastatic renal tumours (RAPPORT): Clinical trial protocol. <i>Contemporary Clinical Trials Communications</i> , 2021, 21, 100703.	0.5	6

#	ARTICLE	IF	CITATIONS
736	Renal cell carcinoma pathology in 2021: â€œnew need for renal cancer immune profilingâ€™. Current Opinion in Urology, 2021, 31, 228-235.	0.9	5
737	Dual immune check point blockade or immune check point-tyrosine kinase inhibitor combination: as a first-line treatment in metastatic renal cell carcinoma?. Current Opinion in Urology, 2021, 31, 270-275.	0.9	5
738	Beyond immune checkpoint blockade: emerging immunological strategies. Nature Reviews Drug Discovery, 2021, 20, 899-919.	21.5	208
739	Where to Start and What to Do Next: The Sequencing of Treatments in Metastatic Esophagogastric Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, 170-185.	1.8	1
740	Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy. Supportive Care in Cancer, 2021, 29, 5417-5423.	1.0	15
741	Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma. Journal of Clinical Oncology, 2021, 39, 1020-1028.	0.8	83
742	Balancing efficacy and quality of life measurements among metastatic renal cell carcinoma (RCC) studies. Oncoscience, 2021, 8, 40-45.	0.9	1
743	Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydrataseâ€œDeficient Renal Cell Carcinoma. Clinical Cancer Research, 2021, 27, 2910-2919.	3.2	45
744	Functional Assessment of Four Novel Immune-Related Biomarkers in the Pathogenesis of Clear Cell Renal Cell Carcinoma. Frontiers in Cell and Developmental Biology, 2021, 9, 621618.	1.8	7
745	First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. European Urology Oncology, 2021, 4, 755-765.	2.6	100
747	Abnormal Crosstalk between Endothelial Cells and Podocytes Mediates Tyrosine Kinase Inhibitor (TKI)-Induced Nephrotoxicity. Cells, 2021, 10, 869.	1.8	12
748	Pembrolizumab plus axitinib for the treatment of advanced renal cell carcinoma. Expert Review of Anticancer Therapy, 2021, 21, 693-703.	1.1	3
749	Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. New England Journal of Medicine, 2021, 384, 1289-1300.	13.9	956
750	Soluble BTN2A1 Is a Potential Prognosis Biomarker in Pre-Treated Advanced Renal Cell Carcinoma. Frontiers in Immunology, 2021, 12, 670827.	2.2	10
751	Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies. Oncologist, 2021, 26, 476-482.	1.9	19
752	Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC. Journal of Thoracic Oncology, 2021, 16, 643-652.	0.5	123
753	Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases. Immunotherapy, 2021, 13, 419-432.	1.0	9
754	Axitinib Induces and Aggravates Hypertension Regardless of Prior Treatment With Tyrosine Kinase Inhibitors. Circulation Reports, 2021, 3, 234-240.	0.4	5

#	ARTICLE	IF	CITATIONS
755	Efficacy and Safety of Checkpoint Inhibitor Treatment in Patients with Advanced Renal or Urothelial Cell Carcinoma and Concomitant Chronic Kidney Disease: A Retrospective Cohort Study. <i>Cancers</i> , 2021, 13, 1623.	1.7	4
756	Development of a Novel Risk Score to Select the Optimal Candidate for Cytoreductive Nephrectomy Among Patients with Metastatic Renal Cell Carcinoma. Results from a Multi-institutional Registry (REMARCC). <i>European Urology Oncology</i> , 2021, 4, 256-263.	2.6	24
757	Anti-angiogenic agents “overcoming tumour endothelial cell anergy and improving immunotherapy outcomes. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 527-540.	12.5	162
758	Development of Immunotherapy Combination Strategies in Cancer. <i>Cancer Discovery</i> , 2021, 11, 1368-1397.	7.7	130
759	Advances in Targeting Cutaneous Melanoma. <i>Cancers</i> , 2021, 13, 2090.	1.7	19
761	Immunology and Immunotherapeutic Approaches for Advanced Renal Cell Carcinoma: A Comprehensive Review. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4452.	1.8	13
762	Do we need skin toxicity? Association of immune checkpoint inhibitor and tyrosine kinase inhibitor-related cutaneous adverse events with outcomes in metastatic renal cell carcinoma. <i>International Journal of Dermatology</i> , 2021, 60, 1242-1247.	0.5	2
763	Efficacy and Safety of Nivolumab and Ipilimumab for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study. <i>Current Oncology</i> , 2021, 28, 1402-1411.	0.9	11
764	Systemic therapy and COVID19: Immunotherapy and chemotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 213-220.	0.8	5
765	Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities. <i>Cancers</i> , 2021, 13, 1781.	1.7	17
766	A Step Ahead in Metastatic Renal Cell Carcinoma. <i>New England Journal of Medicine</i> , 2021, 384, 1360-1361.	13.9	5
767	Metastatic Renal Cell Carcinoma Management: From Molecular Mechanism to Clinical Practice. <i>Frontiers in Oncology</i> , 2021, 11, 657639.	1.3	18
768	Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy. <i>Journal of Controlled Release</i> , 2021, 332, 109-126.	4.8	33
769	The Next Decade of Immune Checkpoint Therapy. <i>Cancer Discovery</i> , 2021, 11, 838-857.	7.7	363
770	Endocrine toxicities of immune checkpoint inhibitors. <i>Nature Reviews Endocrinology</i> , 2021, 17, 389-399.	4.3	162
771	Nephrotoxicity of Anti-Angiogenic Therapies. <i>Diagnostics</i> , 2021, 11, 640.	1.3	16
772	Registration trials in countries without access to US standards of care “pitfalls of interpretation. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 395-396.	12.5	1
773	Tumor mutational burden and immune infiltrates in renal cell carcinoma and matched brain metastases. <i>ESMO Open</i> , 2021, 6, 100057.	2.0	13

#	ARTICLE	IF	CITATIONS
774	Therapeutic Targeting of the Tumor Microenvironment. <i>Cancer Discovery</i> , 2021, 11, 933-959.	7.7	646
775	Development of a highly pulmonary metastatic orthotopic renal cell carcinoma murine model. <i>Biology Open</i> , 2021, 10, .	0.6	6
776	Resistance mechanisms to checkpoint inhibitors. <i>Current Opinion in Immunology</i> , 2021, 69, 47-55.	2.4	19
777	Real-World Outcomes Among US Veterans Health Administration Patients Newly Diagnosed with Metastatic Renal Cell Carcinoma and Treated with First-Line Monotherapy. <i>Advances in Therapy</i> , 2021, 38, 2644-2661.	1.3	1
778	Development and validation of the prognostic value of the immune-related genes in clear cell renal cell carcinoma. <i>Translational Andrology and Urology</i> , 2021, 10, 1607-1619.	0.6	10
779	Tumor cell PD-L1 expression is a strong predictor of unfavorable prognosis in immune checkpoint therapy-naïve clear cell renal cell cancer. <i>International Urology and Nephrology</i> , 2021, 53, 2493-2503.	0.6	11
780	Cytoreductive nephrectomy in the era of targeted- And immuno- therapy for metastatic renal cell carcinoma: An elusive issue? A systematic review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 160, 103293.	2.0	7
781	Addressing resistance to immune checkpoint inhibitor therapy: An urgent unmet need. <i>Future Oncology</i> , 2021, 17, 1401-1439.	1.1	17
782	A Living, Interactive Systematic Review and Network Meta-analysis of First-line Treatment of Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2021, 80, 712-723.	0.9	43
783	The DEAD/DEAH Box Helicase, DDX11, Is Essential for the Survival of Advanced Clear Cell Renal Cell Carcinoma and Is a Determinant of PARP Inhibitor Sensitivity. <i>Cancers</i> , 2021, 13, 2574.	1.7	7
784	Adverse events of systemic immune-based combination therapies in the first-line treatment of patients with metastatic renal cell carcinoma: systematic review and network meta-analysis. <i>Current Opinion in Urology</i> , 2021, 31, 332-339.	0.9	9
785	Investigating the Impact of Immune-Related Adverse Events, Glucocorticoid Use and Immunotherapy Interruption on Long-Term Survival Outcomes. <i>Cancers</i> , 2021, 13, 2365.	1.7	11
786	Real-world Clinical Effectiveness of Lenvatinib/Everolimus in a Heavily Pretreated Advanced/Metastatic Renal Cell Carcinoma Population in the US Community Oncology Setting. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 531-539.	0.9	2
787	Serum alanine aminotransferase as an early marker of outcomes in patients receiving anti-PD-1 or anti-CTLA-4 antibody. <i>Scientific Reports</i> , 2021, 11, 10264.	1.6	0
788	Combination Strategies to Augment Immune Check Point Inhibitors Efficacy - Implications for Translational Research. <i>Frontiers in Oncology</i> , 2021, 11, 559161.	1.3	34
789	Real-World Survival Outcomes Associated With First-Line Immunotherapy, Targeted Therapy, and Combination Therapy for Metastatic Clear Cell Renal Cell Carcinoma. <i>JAMA Network Open</i> , 2021, 4, e2111329.	2.8	21
790	Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma. <i>Cancer Cell</i> , 2021, 39, 649-661.e5.	7.7	263
791	Control of Tumor Progression by Angiocrine Factors. <i>Cancers</i> , 2021, 13, 2610.	1.7	19

#	ARTICLE	IF	CITATIONS
792	Pazopanib together with 6â€“8 cycles of sintilimab followed by single use of pazopanib in the second-line treatment of advanced renal cell carcinoma. <i>Translational Andrology and Urology</i> , 2021, 10, 2078-2083.	0.6	3
793	Advanced Renal-Cell Carcinoma Pseudoprogression After Combined Immunotherapy: Case Report and Literature Review. <i>Frontiers in Oncology</i> , 2021, 11, 640447.	1.3	2
794	Targeting the Proteasome in Advanced Renal Cell Carcinoma: Complexity and Limitations of Patient-Individualized Preclinical Drug Discovery. <i>Biomedicines</i> , 2021, 9, 627.	1.4	5
795	Clinical Insights Into Novel Immune Checkpoint Inhibitors. <i>Frontiers in Pharmacology</i> , 2021, 12, 681320.	1.6	76
796	Cytoreductive Nephrectomy Following Immunotherapy-Base Treatment in Metastatic Renal Cell Carcinoma: A Case Series and Review of Current Literature. <i>Current Oncology</i> , 2021, 28, 1921-1926.	0.9	6
797	CD137 as an Attractive T Cell Co-Stimulatory Target in the TNFRSF for Immuno-Oncology Drug Development. <i>Cancers</i> , 2021, 13, 2288.	1.7	32
798	Thrombospondin-2 and LDH Are Putative Predictive Biomarkers for Treatment with Everolimus in Second-Line Metastatic Clear Cell Renal Cell Carcinoma (MARC-2 Study). <i>Cancers</i> , 2021, 13, 2594.	1.7	2
799	Heart Failure With Targeted Cancer Therapies. <i>Circulation Research</i> , 2021, 128, 1576-1593.	2.0	33
800	High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab. <i>Molecular Cancer Research</i> , 2021, 19, 1510-1521.	1.5	20
801	Sarcomatoid Renal Cell Carcinoma: An Immune Checkpointâ€“responsive Subset?. <i>European Urology</i> , 2021, 79, 663-664.	0.9	0
802	Durable Response to Immunotherapy With Antiangiogenic Drug in Large-Cell Lungâ€“Carcinoma With Multiple Fulminant Postoperative Metastases: A Case Report. <i>Frontiers in Oncology</i> , 2021, 11, 633446.	1.3	4
803	Expanding the Role of Checkpoint Inhibitors in Immune Cold Tumors. <i>Advances in Oncology</i> , 2021, 1, 85-95.	0.1	0
804	Adjuvant Tyrosine Kinase Inhibitors in Renal Cell Carcinoma: A Concluded Living Systematic Review and Meta-Analysis. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 588-599.	1.0	4
805	Anti-Vascular Endothelial Growth Factor C Antibodies Efficiently Inhibit the Growth of Experimental Clear Cell Renal Cell Carcinomas. <i>Cells</i> , 2021, 10, 1222.	1.8	10
806	The Immunotherapy Landscape in Adrenocortical Cancer. <i>Cancers</i> , 2021, 13, 2660.	1.7	8
807	Treatment of advanced urogenital cancers with immune checkpoint inhibitors. <i>Journal of the Korean Medical Association</i> , 2021, 64, 349-357.	0.1	0
808	Childhood Cancer: Occurrence, Treatment and Risk of Second Primary Malignancies. <i>Cancers</i> , 2021, 13, 2607.	1.7	26
809	Circulating PD-L1 levels change during bevacizumab-based treatment in recurrent glioma. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3643-3650.	2.0	10

#	ARTICLE	IF	CITATIONS
810	Active Surveillance in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 521-530.	0.9	8
811	Adoption of multiple primary endpoints in phase III trials of systemic treatments in patients with advanced solid tumours. A systematic review. <i>European Journal of Cancer</i> , 2021, 149, 49-60.	1.3	1
812	PD-L1 induces macrophage polarization toward the M2 phenotype via Erk/Akt/mTOR. <i>Experimental Cell Research</i> , 2021, 402, 112575.	1.2	27
813	An update on immunotherapy in uro-oncology. <i>Expert Review of Precision Medicine and Drug Development</i> , 2021, 6, 229-233.	0.4	2
814	Neutralization of PD-L2 is Essential for Overcoming Immune Checkpoint Blockade Resistance in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4435-4448.	3.2	35
815	Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy. <i>Cancer Cell</i> , 2021, 39, 662-677.e6.	7.7	179
816	Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 201.	7.1	607
817	PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5123.	1.8	61
818	Gene Expression Signature Correlates with Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Everolimus Alone or with a Vascular Disrupting Agent. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1454-1461.	1.9	6
819	Surgery for renal cell carcinoma extending to the right atrium in Japanese institutions: Focusing on cardiopulmonary bypass with or without deep hypothermic circulatory arrest. <i>International Journal of Urology</i> , 2021, 28, 1001-1007.	0.5	0
820	Practical Considerations and Recommendations for Master Protocol Framework: Basket, Umbrella and Platform Trials. <i>Therapeutic Innovation and Regulatory Science</i> , 2021, 55, 1145-1154.	0.8	31
822	Real-world symptoms, disease burden, resource use and quality of life in US patients with advanced renal cell cancer. <i>Future Oncology</i> , 2021, 17, 2169-2182.	1.1	3
823	Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 186.	3.5	77
824	Combining VEGF receptor inhibitors and angiotensin-(1 ⁷) to target renal cell carcinoma. <i>Molecular and Cellular Oncology</i> , 2021, 8, 1918529.	0.3	2
825	PBRM1 Mutations as a Predictive Biomarker for Immunotherapy in Metastatic Renal Cell Carcinoma: A Systematic Review. <i>Kidney Cancer</i> , 2021, 5, 79-92.	0.2	2
826	Racial Differences in Clinical Outcomes for Metastatic Renal Cell Carcinoma Patients Treated With Immune-Checkpoint Blockade. <i>Frontiers in Oncology</i> , 2021, 11, 701345.	1.3	4
827	Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges. <i>Cancer Communications</i> , 2021, 41, 830-850.	3.7	42
828	Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: a meta-analysis. <i>Immunotherapy</i> , 2021, 13, 783-793.	1.0	3

#	ARTICLE	IF	CITATIONS
830	Ang2 inhibitors and Tie2 activators: potential therapeutics in perioperative treatment of early stage cancer. <i>EMBO Molecular Medicine</i> , 2021, 13, e08253.	3.3	18
831	The Efficacy of Surgical Metastasectomy for Solitary Metastasis of Renal Cell Carcinoma. <i>Urologia Internationalis</i> , 2022, 106, 397-403.	0.6	3
832	The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 641428.	1.3	32
833	Prognostic Role of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma: A Large, Multicenter, Prospective Trial. <i>Oncologist</i> , 2021, 26, 740-750.	1.9	19
834	Biomarkers in renal cell carcinoma: Are we there yet?. <i>Asian Journal of Urology</i> , 2021, 8, 362-375.	0.5	15
835	Determinants of treatment for first-line immune-based combinations in metastatic renal cell carcinoma: a critical overview of recent evidence. <i>Immunotherapy</i> , 2021, 13, 685-692.	1.0	7
836	In the Age of Immunotherapy, How Can We Translate the CARMENA Results into Practice?. <i>European Urology Oncology</i> , 2021, 4, 515-516.	2.6	0
837	Real-world outcomes in patients with metastatic renal cell carcinoma according to risk factors: the STAR-TOR registry. <i>Future Oncology</i> , 2021, 17, 2325-2338.	1.1	3
838	Two cases of delayed onset of immune-related adverse events after discontinuation of nivolumab in patients with metastatic renal cell cancer. <i>IJU Case Reports</i> , 2021, 4, 326-329.	0.1	2
839	The nivolumab/cabozantinib combination and the future of doublets in advanced renal cell cancer treatment. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 1553-1554.	0.5	0
840	Making Patient-Specific Treatment Decisions Using Prognostic Variables and Utilities of Clinical Outcomes. <i>Cancers</i> , 2021, 13, 2741.	1.7	23
841	Immune Checkpoint Inhibitors in Metastatic Clear-cell Renal Cell Carcinoma: Is PD-L1 Expression Useful?. <i>European Urology</i> , 2021, 79, 793-795.	0.9	10
842	The effect of adding immune checkpoint inhibitors on the risk of pneumonitis for solid tumours: a meta-analysis of phase III randomised controlled trials. <i>European Journal of Cancer</i> , 2021, 150, 168-178.	1.3	11
844	Response to Combination of Pembrolizumab and Axitinib in Hereditary Leyomiomatosis and Renal Cell Cancer (HLRCC). <i>Current Oncology</i> , 2021, 28, 2346-2350.	0.9	3
845	Validation of the updated renal graded prognostic assessment (GPA) for patients with renal cancer brain metastases treated with gamma knife radiosurgery. <i>Journal of Neuro-Oncology</i> , 2021, 153, 527-536.	1.4	3
846	Biomarkers of therapeutic response with immune checkpoint inhibitors. <i>Annals of Translational Medicine</i> , 2021, 9, 1040-1040.	0.7	3
847	Breaking Barriers: Addressing Issues of Inequality in Trial Enrollment and Clinical Outcomes for Patients With Kidney and Bladder Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, e174-e181.	1.8	4
848	Immune Checkpoint Inhibition in Advanced Bladder and Kidney Cancer: Responses and Further Management. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, e182-e189.	1.8	7

#	ARTICLE	IF	CITATIONS
849	Breast Cancer Metastasis in a Renal Carcinoma Pulmonary Metastasis: A Rare Example of Tumor-to-Tumor Metastasis. <i>Case Reports in Oncological Medicine</i> , 2021, 2021, 1-6.	0.2	2
850	Detection of von Hippel-Lindau gene mutation in circulating cell-free DNA for clear cell renal cell carcinoma. <i>Cancer Science</i> , 2021, 112, 3363-3374.	1.7	10
851	Multidiscipline Immunotherapy-Based Rational Combinations for Robust and Durable Efficacy in Brain Metastases from Renal Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6290.	1.8	4
853	Comparative Risk of Renal Adverse Events in Patients Receiving Immune Checkpoint Inhibitors: A Bayesian Network Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 662731.	1.3	10
854	Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2022, 22, 45-51.	0.7	6
855	Metachronous Renal Cell Carcinoma: A Rare Presentation of Adrenal Crisis. <i>Cureus</i> , 2021, 13, e15965.	0.2	0
856	Non-clear cell renal carcinomas: Review of new molecular insights and recent clinical data. <i>Cancer Treatment Reviews</i> , 2021, 97, 102191.	3.4	17
858	Pembrolizumab for the treatment of renal cell carcinoma. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 1157-1164.	1.4	2
859	Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC) – an International mRCC Database Consortium (IMDC) analysis. <i>Journal of Geriatric Oncology</i> , 2021, 12, 820-826.	0.5	10
860	Circulating Levels of the Interferon- γ -Regulated Chemokines CXCL10/CXCL11, IL-6 and HGF Predict Outcome in Metastatic Renal Cell Carcinoma Patients Treated with Antiangiogenic Therapy. <i>Cancers</i> , 2021, 13, 2849.	1.7	10
861	T-cell responses and combined immunotherapy against human carbonic anhydrase 9-expressing mouse renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 339-352.	2.0	2
862	Sunitinib and Axitinib increase secretion and glycolytic activity of small extracellular vesicles in renal cell carcinoma. <i>Cancer Gene Therapy</i> , 2022, 29, 683-696.	2.2	4
863	The association between antibiotic use and survival in renal cell carcinoma patients treated with immunotherapy: a multi-center study. <i>Current Problems in Cancer</i> , 2021, 45, 100760.	1.0	14
864	Prognosis of Japanese metastatic renal cell carcinoma patients in the targeted therapy era. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1947-1954.	1.0	4
865	Integrated transcriptional-phenotypic analysis captures systemic immunomodulation following antiangiogenic therapy in renal cell carcinoma patients. <i>Clinical and Translational Medicine</i> , 2021, 11, e434.	1.7	3
866	Quality of life assessment in renal cell carcinoma – Phase II and III clinical trials published between 2010 and 2020: a systematic review. <i>Future Oncology</i> , 2021, 17, 2671-2681.	1.1	17
867	Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitors. , 2021, 9, e002835.		11
868	Changes in prescribing habits for the treatment of metastatic renal clear cell carcinoma (<sc>mRCC</sc>) in Australia. <i>Internal Medicine Journal</i> , 2021, 51, 1173-1177.	0.5	0

#	ARTICLE	IF	CITATIONS
869	Lenvatinib plus pembrolizumab in patients with either treatment-naïve or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study. <i>Lancet Oncology</i> , The, 2021, 22, 946-958.	5.1	100
870	Risk of Infection with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. <i>Targeted Oncology</i> , 2021, 16, 553-568.	1.7	13
871	Prognostic value of programmed death-ligand 1 status in Japanese patients with renal cell carcinoma. <i>International Journal of Clinical Oncology</i> , 2021, 26, 2073-2084.	1.0	4
872	Screening a novel signature and predicting the immune landscape of metastatic osteosarcoma in children via immune-related lncRNAs. <i>Translational Pediatrics</i> , 2021, 10, 1851-1866.	0.5	7
873	Antiangiogenic therapy reverses the immunosuppressive breast cancer microenvironment. <i>Biomarker Research</i> , 2021, 9, 59.	2.8	32
874	A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 1-10.	0.9	4
875	Von Hippel-Lindau tumor suppressor pathways & corresponding therapeutics in kidney cancer. <i>Journal of Genetics and Genomics</i> , 2021, 48, 552-559.	1.7	8
876	Multiplexed single-cell pathology reveals the association of CD8 T-cell heterogeneity with prognostic outcomes in renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3001-3013.	2.0	17
877	Immunotherapy in Older Adults With Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 2115-2127.	0.8	33
878	Renal cell carcinoma therapy: Current and new drug candidates. <i>Drug Discovery Today</i> , 2022, 27, 304-314.	3.2	29
879	The Emerging Role of Poly (ADP-Ribose) Polymerase Inhibitors as Effective Therapeutic Agents in Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 681441.	1.3	13
880	Differential Dermatologic Adverse Events Associated With Checkpoint Inhibitor Monotherapy and Combination Therapy: A Meta-Analysis of Randomized Control Trials. <i>Frontiers in Pharmacology</i> , 2021, 12, 640099.	1.6	3
881	Role of Radioembolization in the Management of Liver-Dominant Metastatic Renal Cell Carcinoma: A Single-Center, Retrospective Study. <i>CardioVascular and Interventional Radiology</i> , 2021, 44, 1755-1762.	0.9	4
882	Prognostic value of DCE-CT-derived blood volume and flow compared to core biopsy microvessel density in patients with metastatic renal cell carcinoma. <i>European Radiology Experimental</i> , 2021, 5, 32.	1.7	2
883	The therapeutic implications of immunosuppressive tumor aerobic glycolysis. <i>Cellular and Molecular Immunology</i> , 2022, 19, 46-58.	4.8	39
884	Outcomes of axitinib versus sunitinib as first-line therapy to patients with metastatic renal cell carcinoma in the immune-oncology era. <i>Cancer Medicine</i> , 2021, 10, 5839-5846.	1.3	10
885	Tumor Growth Rate Decline despite Progressive Disease May Predict Improved Nivolumab Treatment Outcome in mRCC: When RECIST Is Not Enough. <i>Cancers</i> , 2021, 13, 3492.	1.7	3
886	Recent Advances in Glioma Therapy: Combining Vascular Normalization and Immune Checkpoint Blockade. <i>Cancers</i> , 2021, 13, 3686.	1.7	16

#	ARTICLE	IF	CITATIONS
887	FOXA1 overexpression suppresses interferon signaling and immune response in cancer. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	48
888	Comparisons of Underlying Mechanisms, Clinical Efficacy and Safety Between Anti-PD-1 and Anti-PD-L1 Immunotherapy: The State-of-the-Art Review and Future Perspectives. <i>Frontiers in Pharmacology</i> , 2021, 12, 714483.	1.6	9
889	B2B: Kidney Cancer Summary. <i>Société Internationale D'urologie Journal</i> , 2021, 2, S19-S28.	0.2	0
890	Deciphering Intratumoral Molecular Heterogeneity in Clear Cell Renal Cell Carcinoma with a Radiogenomics Platform. <i>Clinical Cancer Research</i> , 2021, 27, 4794-4806.	3.2	17
891	Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors. , 2021, 9, e002851.		12
892	Lenvatinib plus Pembrolizumab for Renal Cell Carcinoma. <i>New England Journal of Medicine</i> , 2021, 385, 287-287.	13.9	14
893	How low can you go? PD-L1 expression as a biomarker in trials of cancer immunotherapy. <i>Annals of Oncology</i> , 2021, 32, 833-836.	0.6	21
894	Response to systemic therapy in fumarate hydratase-deficient renal cell carcinoma. <i>European Journal of Cancer</i> , 2021, 151, 106-114.	1.3	18
895	Current Imaging Evaluation of Tumor Response to Advanced Medical Treatment in Metastatic Renal-Cell Carcinoma: Clinical Implications. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 6930.	1.3	4
896	Immune-Related Endocrine Dysfunctions in Combined Modalities of Treatment: Real-World Data. <i>Cancers</i> , 2021, 13, 3797.	1.7	2
897	Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials. <i>European Journal of Cancer</i> , 2021, 151, 115-125.	1.3	22
898	Traumatic Fractures Should Trigger Osteoporosis Assessment in Postmenopausal Women. , 2021, 28, .		0
899	SNP-mediated lncRNA-ENTPD3-AS1 upregulation suppresses renal cell carcinoma via miR-155/HIF-1 α signaling. <i>Cell Death and Disease</i> , 2021, 12, 672.	2.7	29
900	Precision Bayesian phase I dose-finding based on utilities tailored to prognostic subgroups. <i>Statistics in Medicine</i> , 2021, 40, 5199-5217.	0.8	15
901	Renal cell carcinoma (RCC): fatter is better? A review on the role of obesity in RCC. <i>Endocrine-Related Cancer</i> , 2021, 28, R207-R216.	1.6	14
902	Challenges and advances for the treatment of renal cancer patients with brain metastases: From immunological background to upcoming clinical evidence on immune-checkpoint inhibitors. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 163, 103390.	2.0	10
903	Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health. <i>Oncologist</i> , 2021, 26, e1786-e1799.	1.9	52
905	Tislelizumab combined with apatinib in the treatment of advanced renal clear cell carcinoma: a case report. <i>Anti-Cancer Drugs</i> , 2022, 33, e834-e839.	0.7	2

#	ARTICLE	IF	CITATIONS
906	Re: Nivolumab plus Cabozantinib Versus Sunitinib for Advanced Renal-cell Carcinoma. <i>European Urology</i> , 2021, 80, 256-257.	0.9	0
907	Clinical implications of isolated troponinemia following immune checkpoint inhibitor therapy. <i>ESMO Open</i> , 2021, 6, 100216.	2.0	17
908	What is the role of real-world data in metastatic renal cell cancer?. <i>Future Oncology</i> , 2021, 17, 3905-3909.	1.1	1
909	Outcome of immune checkpoint inhibitors in metastatic renal cell carcinoma across different treatment lines. <i>ESMO Open</i> , 2021, 6, 100122.	2.0	6
910	Clinical observation of the efficacy of PD-1/PD-L1 inhibitors in the treatment of patients with advanced solid tumors. <i>Immunity, Inflammation and Disease</i> , 2021, 9, 1584-1595.	1.3	4
911	The Promise of Adjuvant Immunotherapy in Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2021, 385, 756-758.	13.9	13
912	A Contemporary Review of Immune Checkpoint Inhibitors in Advanced Clear Cell Renal Cell Carcinoma. <i>Vaccines</i> , 2021, 9, 919.	2.1	9
913	Evaluation of Technology-Enabled Monitoring of Patient-Reported Outcomes to Detect and Treat Toxic Effects Linked to Immune Checkpoint Inhibitors. <i>JAMA Network Open</i> , 2021, 4, e2122998.	2.8	13
914	Myocarditis occurrence with cancer immunotherapy across indications in clinical trial and post-marketing data. <i>Scientific Reports</i> , 2021, 11, 17324.	1.6	24
915	Efficacy of PD-1/PD-L1 inhibitors in ovarian cancer: a single-arm meta-analysis. <i>Journal of Ovarian Research</i> , 2021, 14, 112.	1.3	24
916	Altered proTGF β ₁ /cleaved TGF β ₁ ratios offer new therapeutic strategies in renal carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 256.	3.5	1
917	Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study. <i>Npj Breast Cancer</i> , 2021, 7, 110.	2.3	20
918	Clinical outcomes of second-line treatment following first-line VEGFR-TKI failure in patients with metastatic renal cell carcinoma: a comparison of axitinib alone and axitinib plus anti-PD-1 antibody. <i>Cancer Communications</i> , 2021, 41, 1071-1074.	3.7	4
919	Pathology and systemic therapy of non-clear cell renal cell carcinoma: an overview. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1273-1286.	1.1	7
920	Clinical Effectiveness of Second-line Sunitinib Following Immuno-oncology Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-world Study. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 354-361.	0.9	5
921	Prognostic Impact of Trial-Eligibility Criteria in Patients with Metastatic Renal Cell Carcinoma. <i>Urologia Internationalis</i> , 2022, 106, 368-375.	0.6	6
922	Immune-related dermatitis during combined treatment with pembrolizumab and axitinib in a patient with metastatic renal cell carcinoma with stasis dermatitis. <i>IJU Case Reports</i> , 2021, 4, 386-390.	0.1	0
923	Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade. <i>Clinical Cancer Research</i> , 2021, 27, 6749-6760.	3.2	39

#	ARTICLE	IF	CITATIONS
924	First-Line Immuno-Oncology Combinations for Metastatic Clear Cell Renal Cell Carcinoma (mRCC): A Systematic Review of Phase III Clinical Trials. <i>Kidney Cancer</i> , 2021, 5, 207-217.	0.2	3
925	PD-1/PD-L1 inhibitors-based treatment for advanced renal cell carcinoma: Mechanisms affecting efficacy and combination therapies. <i>Cancer Medicine</i> , 2021, 10, 6384-6401.	1.3	10
926	A Systematic Review and Meta-analysis of Dual Therapy in Patients With Advanced Renal Cell Carcinoma of Favourable Risk. <i>Urology</i> , 2021, 157, 8-14.	0.5	3
927	Predictive radiomics signature for treatment response to nivolumab in patients with advanced renal cell carcinoma. <i>Canadian Urological Association Journal</i> , 2021, 16, .	0.3	2
928	CTLA4 promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma. , 2021, 9, e002949.		22
929	Camrelizumab plus Famitinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: Data from an Open-label, Multicenter Phase II Basket Study. <i>Clinical Cancer Research</i> , 2021, 27, 5838-5846.	3.2	14
930	Cancer-associated fibroblasts in renal cell carcinoma: implication in prognosis and resistance to anti-angiogenic therapy. <i>BJU International</i> , 2022, 129, 80-92.	1.3	25
931	Does sunitinib still have a place in the current recommendations for the systemic treatment of advanced renal cell carcinoma?. <i>Meditsinskiy Sovet</i> , 2021, , 89-94.	0.1	2
932	Roles of CCL2-CCR2 Axis in the Tumor Microenvironment. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8530.	1.8	50
933	Integrated mRNA and miRNA Transcriptomic Analyses Reveals Divergent Mechanisms of Sunitinib Resistance in Clear Cell Renal Cell Carcinoma (ccRCC). <i>Cancers</i> , 2021, 13, 4401.	1.7	8
934	Biological Hallmarks and New Therapeutic Approaches for the Treatment of PDAC. <i>Life</i> , 2021, 11, 843.	1.1	5
935	Eosinophil counts as a relevant prognostic marker for response to nivolumab in the management of renal cell carcinoma: a retrospective study. <i>Cancer Medicine</i> , 2021, 10, 6705-6713.	1.3	13
936	Cost-effectiveness analysis of a lung cancer screening programme in Spain. <i>European Journal of Cancer Prevention</i> , 2022, 31, 235-244.	0.6	5
937	Immune Checkpoint Inhibitor in First-Line Treatment of Metastatic Renal Cell Carcinoma: A Review of Current Evidence and Future Directions. <i>Frontiers in Oncology</i> , 2021, 11, 707214.	1.3	26
938	Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study. <i>Targeted Oncology</i> , 2021, 16, 625-632.	1.7	6
939	Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2021, 385, 683-694.	13.9	394
940	Cabozantinib and nivolumab as first-line treatment in advanced renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1183-1192.	1.1	0
941	Current status and future perspectives of immunotherapy against urothelial and kidney cancer. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1481-1492.	0.6	7

#	ARTICLE	IF	CITATIONS
942	First-Line Immunotherapy Combinations in Advanced Renal Cell Carcinoma: A Rapid Review and Meta-Analysis. <i>Kidney Cancer</i> , 2021, 5, 153-163.	0.2	1
943	A Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Versus Pembrolizumab Plus Axitinib and Versus Avelumab Plus Axitinib in First-Line Treatment of Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 370-370.e7.	0.9	8
944	Median time to progression with TKI-based therapy after failure of immuno-oncology therapy in metastatic kidney cancer: A systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2021, 155, 245-255.	1.3	2
945	Primary Renal Tumour Response in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma: Results from the GETUG-AFU 26 NIVOREN Trial. <i>European Urology</i> , 2021, 80, 325-329.	0.9	16
946	Profiling the inhibitory receptors LAG-3, TIM-3, and TIGIT in renal cell carcinoma reveals malignancy. <i>Nature Communications</i> , 2021, 12, 5547.	5.8	31
947	Sotorasib: Is Maximum Tolerated Dose Really the Issue at Hand?. <i>Journal of Clinical Oncology</i> , 2021, 39, 3427-3429.	0.8	3
948	Immune checkpoint inhibitors and cardiotoxicity: possible mechanisms, manifestations, diagnosis and management. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1211-1228.	1.1	1
950	Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer. <i>Nature Communications</i> , 2021, 12, 5668.	5.8	91
951	Use of Second-line Immunotherapy in Control Arms of Randomized Clinical Trials in Kidney Cancer. <i>JAMA Network Open</i> , 2021, 4, e2124728.	2.8	4
952	Treatment Options for De Novo Metastatic Clear-cell Renal Cell Carcinoma: Current Recommendations and Future Insights. <i>European Urology Oncology</i> , 2022, 5, 125-133.	2.6	10
953	Atezolizumab: an investigational agent for the treatment of biliary tract cancer. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 1007-1015.	1.9	2
954	2021 ASCO genitourinary cancers symposium: a focus on renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1203-1206.	1.1	2
956	Safety and Efficacy of Tivozanib in First-Line mRCC: A Multicenter Compassionate-Use Study (Meet-Uro) Tj ETQq0 0,0,rgBT /Overlock 10	0.9	3
957	An open-label single-arm phase II study of regorafenib for the treatment of angiosarcoma. <i>European Journal of Cancer</i> , 2021, 154, 201-208.	1.3	14
958	Complete response and renal cell carcinoma in the immunotherapy era: The paradox of good news. <i>Cancer Treatment Reviews</i> , 2021, 99, 102239.	3.4	13
959	Clinical Review on the Management of Metastatic Renal Cell Carcinoma. <i>JCO Oncology Practice</i> , 2022, 18, 187-196.	1.4	62
960	Sex and Gender Differences in Kidney Cancer: Clinical and Experimental Evidence. <i>Cancers</i> , 2021, 13, 4588.	1.7	24
961	Prospective observational study on Pazopanib in patients treated for advanced or metastatic renal cell carcinoma in countries in Asia Pacific, North Africa, and Middle East regions: PARACHUTE study. <i>BMC Cancer</i> , 2021, 21, 1021.	1.1	7

#	ARTICLE	IF	CITATIONS
962	Stereotactic Ablative Radiation Therapy for Oligoprogressive Renal Cell Carcinoma. <i>Advances in Radiation Oncology</i> , 2021, 6, 100692.	0.6	18
963	Tumor-infiltrating CD8+ T cells recognize a heterogeneously expressed functional neoantigen in clear cell renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 905-918.	2.0	8
964	RAMPART: A model for a regulatory-ready academic-led phase III trial in the adjuvant renal cell carcinoma setting. <i>Contemporary Clinical Trials</i> , 2021, 108, 106481.	0.8	2
965	Loss of Von Hippel-Lindau (VHL) Tumor Suppressor Gene Function: VHL-HIF Pathway and Advances in Treatments for Metastatic Renal Cell Carcinoma (RCC). <i>International Journal of Molecular Sciences</i> , 2021, 22, 9795.	1.8	32
966	A 25 year perspective on the evolution and advances in an understanding of the biology, evaluation and treatment of kidney cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 548-560.	0.8	13
967	Development of an Interferon Gamma Response-Related Signature for Prediction of Survival in Clear Cell Renal Cell Carcinoma. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 4969-4985.	1.6	7
968	Tumor diameter response in patients with metastatic clear cell renal cell carcinoma is associated with overall survival. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 837.e9-837.e17.	0.8	3
969	Re: Keiichiro Mori, Mohammad Abufaraj, Hadi Mostafaei, et al. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. <i>Eur Urol</i> 2021;79:783-92. <i>European Urology</i> , 2021, 80, e143-e144.	0.9	0
970	Precision Oncology in Metastatic Uterine Cancer; Croatian First-Year Experience of the Comprehensive Genomic Profiling in Everyday Clinical Practice. <i>Pathology and Oncology Research</i> , 2021, 27, 1609963.	0.9	2
971	Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis. <i>Lancet Oncology</i> , 2021, 22, 1265-1274.	5.1	102
972	Activity of Systemic Treatments After Cabozantinib Failure in Advanced Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 80-87.	0.9	7
973	The effectiveness of systemic therapies after surgery for metastatic renal cell carcinoma to the spine: a propensity analysis controlling for sarcopenia, frailty, and nutrition. <i>Journal of Neurosurgery: Spine</i> , 2021, 35, 356-365.	0.9	6
974	Unexpected Favorable Outcome to PD-1 Antibody Plus Lenvatinib in a Patient With Recurrent Intestinal Follicular Dendritic Cell Sarcoma: A Case Report and Literature Review. <i>Frontiers in Immunology</i> , 2021, 12, 653319.	2.2	7
975	Nivolumab Reduces PD1 Expression and Alters Density and Proliferation of Tumor Infiltrating Immune Cells in a Tissue Slice Culture Model of Renal Cell Carcinoma. <i>Cancers</i> , 2021, 13, 4511.	1.7	5
976	Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 3725-3736.	0.8	69
977	Normalizing Tumor Vasculature to Reduce Hypoxia, Enhance Perfusion, and Optimize Therapy Uptake. <i>Cancers</i> , 2021, 13, 4444.	1.7	42
978	RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse. <i>Contemporary Clinical Trials</i> , 2021, 108, 106482.	0.8	33
979	Hypopituitarism in patients with metastatic renal cell carcinoma treated with ipilimumab and nivolumab combination therapy. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1744-1750.	0.6	2

#	ARTICLE	IF	CITATIONS
980	Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2021, 99, 102242.	3.4	13
981	ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma. <i>Annals of Oncology</i> , 2021, 32, 1511-1519.	0.6	113
982	Combination strategies to maximize the benefits of cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2021, 14, 156.	6.9	202
983	Efficacy and safety of atezolizumab, in combination with etoposide and carboplatin regimen, in the first-line treatment of extensive-stage small-cell lung cancer: a single-center experience. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1093-1101.	2.0	23
984	The Role of Immunotherapy in the Treatment of Advanced Cervical Cancer: Current Status and Future Perspectives. <i>Journal of Clinical Medicine</i> , 2021, 10, 4523.	1.0	12
985	Effects of early vs delayed progression on clinical and economic outcomes in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors as first-line therapy: results from the IMPACT RCC claims data analysis. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 1171-1181.	0.5	1
986	ImmunoOncology-tyrosine kinase inhibitors combination, sometimes less is more. <i>International Immunopharmacology</i> , 2021, 98, 107673.	1.7	2
987	Checkpoint inhibitors in metastatic papillary renal cell carcinoma. <i>Cancer Treatment Reviews</i> , 2021, 99, 102228.	3.4	14
988	PD-L1 Expression and Clinicopathological Factors in Renal Cell Carcinoma: A Comparison of Antibody Clone 73-10 With Clone 28-8. <i>Anticancer Research</i> , 2021, 41, 4577-4586.	0.5	4
989	Prediction of early progression of metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitor. <i>Current Urology</i> , 2021, 15, 187-192.	0.4	3
990	Development of patient-derived tumor organoids and a drug testing model for renal cell carcinoma. <i>Oncology Reports</i> , 2021, 46, .	1.2	14
991	Real-world efficacy and safety of axitinib in combination with anti-programmed cell death-1 antibody for advanced mucosal melanoma. <i>European Journal of Cancer</i> , 2021, 156, 83-92.	1.3	7
992	Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study. <i>European Urology</i> , 2022, 81, 274-282.	0.9	55
993	A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and Pembrolizumab Combination Therapy in Patients with Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 434-446.	0.9	16
994	An update on immunotherapy with PD-1 and PD-L1 blockade. <i>Yeungnam University Journal of Medicine</i> , 2021, 38, 308-317.	0.7	1
996	Metastatic Renal Cell Carcinoma to the Spine: Outcomes and Morbidity: Single-Center Experience. <i>World Neurosurgery</i> , 2021, 154, e398-e405.	0.7	4
997	Treatment-free survival after discontinuation of immune checkpoint inhibitors in metastatic renal cell carcinoma: a systematic review and meta-analysis. , 2021, 9, e003473.		8
998	Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study. , 2021, 9, e003476.		20

#	ARTICLE	IF	CITATIONS
999	Immunotherapy for metastatic renal cell carcinoma: A brief history, current trends, and future directions. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 664-677.	0.8	7
1000	Prognostic impact of immune-related adverse events in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 735.e9-735.e16.	0.8	15
1001	The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naïve Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care. <i>European Urology</i> , 2021, 80, 393-397.	0.9	103
1002	Treatment strategy for myocarditis in patients using immune checkpoint inhibitors or combined anti-vascular endothelial growth factor therapy by clinical severity. <i>European Journal of Cancer</i> , 2021, 157, 10-20.	1.3	4
1003	Ocular side effects of checkpoint inhibitors. <i>Survey of Ophthalmology</i> , 2021, 66, 951-959.	1.7	16
1004	Combinatorial therapy in tumor microenvironment: Where do we stand?. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188585.	3.3	48
1005	Acute renal failure in patient with renal cell carcinoma after combination immune checkpoint inhibitor therapy. <i>Current Problems in Cancer Case Reports</i> , 2021, 4, 100082.	0.1	0
1006	The role of immunotherapy in advanced renal cell carcinoma. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2021, 47, 1228-1242.	0.7	10
1007	The effects of anticancer therapies on bone metastases in breast cancer. , 2022, , 987-1002.		0
1008	Delivery strategies to overcome tumor immunotherapy resistance. , 2022, , 529-547.		0
1009	Promising Biomarkers in Renal Cell Carcinoma. <i>Société Internationale D'urologie Journal</i> , 2021, 2, 43-52.	0.2	3
1010	Ferritin as a diagnostic, differential diagnostic, and prognostic marker for immune-related adverse events. <i>Cancer Biology and Medicine</i> , 2021, 18, 0-0.	1.4	2
1011	Emerging immune checkpoint inhibitors for the treatment of hepatocellular carcinoma. <i>Expert Opinion on Emerging Drugs</i> , 2021, 26, 39-52.	1.0	9
1012	Targeting metastatic cancer. <i>Nature Medicine</i> , 2021, 27, 34-44.	15.2	447
1013	Antitumour immunity regulated by aberrant ERBB family signalling. <i>Nature Reviews Cancer</i> , 2021, 21, 181-197.	12.8	141
1014	Localized pleural metastasis without other organ metastases after nephrectomy for renal cell carcinoma. <i>Respiratory Medicine Case Reports</i> , 2021, 33, 101388.	0.2	4
1015	Prognostic Value of Plasma hPG80 (Circulating Progastrin) in Metastatic Renal Cell Carcinoma. <i>Cancers</i> , 2021, 13, 375.	1.7	9
1016	Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Cancer Medicine</i> , 2021, 10, 1212-1221.	1.3	22

#	ARTICLE	IF	CITATIONS
1017	Efficacy and safety of immunological checkpoint inhibitors combined with anti-angiogenic drugs in first-line treatment of metastatic renal cell carcinoma: a systematic review and meta-analysis. <i>Translational Andrology and Urology</i> , 2021, 10, 300-309.	0.6	4
1018	The efficacy and safety of the combination of axitinib and pembrolizumab+activated autologous DC+CIK cell immunotherapy for patients with advanced renal cell carcinoma: a phase 2 study. <i>Clinical and Translational Immunology</i> , 2021, 10, e1257.	1.7	4
1019	Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism?. <i>Therapeutic Advances in Urology</i> , 2021, 13, 175628722110297.	0.9	2
1020	Testosterone for Managing Treatment-related Fatigue in Patients With Metastatic Renal Cell Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 137-142.	0.6	3
1021	IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110365.	1.4	24
1022	Beyond conventional immune-checkpoint inhibition – novel immunotherapies for renal cell carcinoma. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 199-214.	12.5	179
1023	Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?. <i>Diagnostics</i> , 2021, 11, 138.	1.3	13
1024	Clinical Outcomes of Metastatic Renal Carcinoma Following Disease Progression to Programmed Death (PD)-1 or PD-L1 Inhibitors (IO). <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 121-125.	0.6	12
1025	T cells expanded from renal cell carcinoma display tumor-specific CD137 expression but lack significant IFN- γ , TNF- α or IL-2 production. <i>Oncolimmunology</i> , 2021, 10, 1860482.	2.1	16
1026	Current Landscape of Immunotherapy in Genitourinary Malignancies. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1244, 107-147.	0.8	3
1027	Identification of low-dose multidrug combinations for sunitinib-naïve and pre-treated renal cell carcinoma. <i>British Journal of Cancer</i> , 2020, 123, 556-567.	2.9	16
1028	Checkpoint inhibitor immunotherapy in kidney cancer. <i>Nature Reviews Urology</i> , 2020, 17, 137-150.	1.9	162
1032	CD28 costimulation drives tumor-infiltrating T cell glycolysis to promote inflammation. <i>JCI Insight</i> , 2020, 5, .	2.3	52
1033	Tivozanib in renal cell carcinoma: a new approach to previously treated disease. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092381.	1.4	10
1034	Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2020, 38, 1081.	0.8	101
1035	Toxicity Management of Front-Line Pembrolizumab Combined With Axitinib in Clear Cell Metastatic Renal Cell Carcinoma: A Case Study Approach. <i>JCO Oncology Practice</i> , 2020, 16, 15s-19s.	1.4	8
1036	Evolving Paradigms in the Management and Outcomes of Sarcomatoid Renal Cell Carcinoma in the Era of Immune Checkpoint Inhibitors. <i>World Journal of Oncology</i> , 2020, 11, 183-187.	0.6	4
1037	Impact of the COVID-19 Pandemic on the Urologist's clinical practice in Brazil: a management guideline proposal for low- and middle-income countries during the crisis period. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2020, 46, 501-510.	0.7	59

#	ARTICLE	IF	CITATIONS
1038	Cabozantinib: from studies to clinical practice. <i>Onkourologiya</i> , 2019, 15, 28-41.	0.1	6
1039	Efficacy and safety of lenvatinib in combination with everolimus in metastatic renal cell carcinoma resistant to antiangiogenic targeted therapy: Russian multicenter observational study ROSLERCM. <i>Onkourologiya</i> , 2019, 15, 56-69.	0.1	2
1040	Renal cell carcinoma: what's new in 2019. <i>Onkourologiya</i> , 2020, 15, 120-125.	0.1	3
1041	To Be or Not to Be: Nodal Disease and the Role of Lymphadenectomy in the Treatment of Renal Cell Carcinoma. <i>Medical Research Archives</i> , 2020, 8, .	0.1	4
1042	Overexpression of steroid sulfotransferase genes is associated with worsened prognosis and with immune exclusion in clear cell-renal cell carcinoma. <i>Aging</i> , 2019, 11, 9209-9219.	1.4	2
1043	Identification of international metastatic renal cell carcinoma database consortium (IMDC) intermediate-risk subgroups in patients with metastatic clear-cell renal cell carcinoma. <i>Oncotarget</i> , 2020, 11, 4582-4592.	0.8	14
1044	A review of mechanisms of resistance to immune checkpoint inhibitors and potential strategies for therapy. , 2020, 3, 252-275.		18
1045	https://cdrjournal.com/article/view/3531 . , 2020, 3, 454-471.		4
1046	The PD-1/PD-L1 pathway in advanced prostate cancer—have we milked this cow?. <i>Annals of Translational Medicine</i> , 2019, 7, 346-346.	0.7	7
1047	Systemic therapy for metastatic renal cell carcinoma—is timing everything?. <i>Annals of Translational Medicine</i> , 2019, 7, S185-S185.	0.7	2
1048	Immunotherapy and Radiation Therapy in Renal Cell Carcinoma. <i>Current Drug Targets</i> , 2020, 21, 1463-1475.	1.0	10
1049	PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: The Role of PD-L1 Assay. <i>Current Drug Targets</i> , 2020, 21, 1664-1671.	1.0	12
1050	Combinations using checkpoint blockade to overcome resistance. <i>Ecancermedicalsecience</i> , 2020, 14, 1148.	0.6	11
1051	Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade. <i>Frontiers in Immunology</i> , 2020, 11, 339.	2.2	77
1052	Novel Nuclear Medicine Imaging Applications in Immuno-Oncology. <i>Cancers</i> , 2020, 12, 1303.	1.7	6
1053	Immune Checkpoint Inhibitors in Uro-Oncology: Urgent Call for Biomarkers. <i>Cancers</i> , 2020, 12, 2768.	1.7	2
1054	New Treatments in Renal Cancer: The AhR Ligands. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3551.	1.8	14
1055	ABL001, a Bispecific Antibody Targeting VEGF and DLL4, with Chemotherapy, Synergistically Inhibits Tumor Progression in Xenograft Models. <i>International Journal of Molecular Sciences</i> , 2021, 22, 241.	1.8	26

#	ARTICLE	IF	CITATIONS
1056	Immunotherapy and Targeted Therapy for Hepatocellular Carcinoma: A Literature Review and Treatment Perspectives. <i>Pharmaceuticals</i> , 2021, 14, 28.	1.7	17
1057	Different immunological effects of the molecular targeted agents sunitinib, everolimus and temsirolimus in patients with renal cell carcinoma. <i>International Journal of Oncology</i> , 2020, 56, 999-1013.	1.4	5
1058	Guillain-Barré syndrome induced by pembrolizumab and sunitinib: A case report. <i>Molecular and Clinical Oncology</i> , 2020, 13, 38-42.	0.4	8
1059	Cancer Immunotherapy: An Impossible Dream for the Common Man?. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2020, 41, 312-316.	0.1	1
1060	Combination drug regimens for metastatic clear cell renal cell carcinoma. <i>World Journal of Clinical Oncology</i> , 2020, 11, 541-562.	0.9	19
1061	NCCN Guidelines Insights: Kidney Cancer, Version 2.2020. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1278-1285.	2.3	185
1062	NCCN Guidelines Updates: Management of Metastatic Kidney Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 587-589.	2.3	22
1063	NCCN Guidelines Insights: Kidney Cancer, Version 1.2021. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1160-1170.	2.3	163
1064	Prognosis of Incidental Brain Metastases in Patients With Advanced Renal Cell Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 432-438.	2.3	19
1065	Immune-Related Adverse Events (irAEs): Implications for Immune Checkpoint Inhibitor Therapy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1287-1290.	2.3	5
1066	ISPRF: a machine learning model to predict the immune subtype of kidney cancer samples by four genes. <i>Translational Andrology and Urology</i> , 2021, 10, 3773-3786.	0.6	6
1067	The Advancement in Diagnosis and Therapy of Liver Injury Induced by Immune Checkpoint Inhibitors. <i>Advances in Clinical Medicine</i> , 2021, 11, 4628-4634.	0.0	0
1068	Renal Cancer. <i>UNIPA Springer Series</i> , 2021, , 755-774.	0.1	1
1069	Characterizing the tumor microenvironment in rare renal cancer histological types. <i>Journal of Pathology: Clinical Research</i> , 2022, 8, 88-98.	1.3	8
1070	Evolving Patterns of Metastasis in Renal Cell Carcinoma. <i>Journal of Kidney Cancer and VHL</i> , 2021, 8, 13-19.	0.2	1
1071	Cytoreductive Nephrectomy in the Management of Metastatic Renal Cell Carcinoma: Is There Still a Debate?. <i>Current Urology Reports</i> , 2021, 22, 54.	1.0	6
1072	Efficacy and safety of immune checkpoint inhibitors in elderly patients with metastatic renal cell carcinoma. <i>International Urology and Nephrology</i> , 2022, 54, 47-54.	0.6	3
1073	Immunotherapies in Genitourinary Oncology: Where Are We Now? Where Are We Going?. <i>Cancers</i> , 2021, 13, 5065.	1.7	13

#	ARTICLE	IF	CITATIONS
1074	Metabolomic Profiling in Renal Cell Carcinoma Patients: News and Views. <i>Cancers</i> , 2021, 13, 5229.	1.7	7
1075	Association between prior nephrectomy and efficacy of immune checkpoint inhibitor therapy in metastatic renal cell carcinoma - A systematic review and meta-analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 64.e17-64.e24.	0.8	3
1076	Landscape of prognostic signatures and immunogenomics of the AXL/GAS6 axis in renal cell carcinoma. <i>British Journal of Cancer</i> , 2021, 125, 1533-1543.	2.9	13
1077	Balancing the Risk-Benefit Ratio of Immune Checkpoint Inhibitor and Anti-VEGF Combination Therapy in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 739263.	1.3	8
1078	Complete Response of Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC)-Associated Renal Cell Carcinoma to Pembrolizumab Immunotherapy: A Case Report. <i>Frontiers in Oncology</i> , 2021, 11, 735077.	1.3	5
1079	Predictive impact of early changes in serum C-reactive protein levels in nivolumab plus ipilimumab therapy for metastatic renal cell carcinoma. <i>Clinical Genitourinary Cancer</i> , 2021, , .	0.9	6
1080	Endoscopic Ultrasound-Guided Radiofrequency Ablation as an Future Alternative to Pancreatectomy for Pancreatic Metastases from Renal Cell Carcinoma: A Prospective Study. <i>Cancers</i> , 2021, 13, 5267.	1.7	10
1081	Efficacy of nivolumab plus ipilimumab as first-line therapy for primary tumors in patients with renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 13.e19-13.e27.	0.8	4
1082	Experimental and computational modeling for signature and biomarker discovery of renal cell carcinoma progression. <i>Molecular Cancer</i> , 2021, 20, 136.	7.9	17
1083	Axitinib Reverses Resistance to Anti-Programmed Cell Death-1 Therapy in a Patient With Renal Cell Carcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 728750.	2.2	4
1084	Cost-Effectiveness Analysis of Durvalumab Plus Chemotherapy in the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 1141-1147.	2.3	23
1085	Clinical factors associated with long-term benefit in patients with metastatic renal cell carcinoma treated with axitinib: Real-world AXILONG study. <i>Clinical Genitourinary Cancer</i> , 2021, , .	0.9	2
1086	â€œÎ³T Cell-IL17A-Neutrophilâ€•Axis Drives Immunosuppression and Confers Breast Cancer Resistance to High-Dose Anti-VEGFR2 Therapy. <i>Frontiers in Immunology</i> , 2021, 12, 699478.	2.2	8
1087	Metastasectomy in kidney cancer: current indications and treatment approaches. <i>Current Opinion in Supportive and Palliative Care</i> , 2021, 15, 266-275.	0.5	4
1088	Immune checkpoint inhibitors for cancer and venous thromboembolic events. <i>European Journal of Cancer</i> , 2021, 158, 99-110.	1.3	35
1089	The impact of hypoxia on immune state in cancer. <i>Life Sciences</i> , 2021, 286, 120057.	2.0	46
1090	Uroonkologie beim Älteren Patienten. <i>Springer Reference Medizin</i> , 2019, , 1-10.	0.0	0
1091	Real-world clinical outcomes of pazopanib immediately following immunotherapy discontinuation for the treatment of advanced renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 573-573.	0.8	1

#	ARTICLE	IF	CITATIONS
1093	Revisiting the role of lymph node dissection in renal cell carcinoma. <i>Annals of Translational Medicine</i> , 2019, 7, S91-S91.	0.7	0
1094	Role of stereotactic body radiation therapy for the management of renal cell carcinoma: tailoring treatment in the era of the "embarrassment of riches". <i>Annals of Translational Medicine</i> , 2019, 7, S106-S106.	0.7	0
1095	Biomarkers in metastatic renal cell carcinoma in the era of immune checkpoint inhibitors. <i>Annals of Translational Medicine</i> , 2019, 7, S203-S203.	0.7	1
1096	The way towards tailored treatment for metastatic renal cancer patients in the omics era: are we getting a "transcriptomic compass"? <i>Annals of Translational Medicine</i> , 2019, 7, S190-S190.	0.7	1
1097	Which Way Should be Chosen for Treatment of Metastatic Renal Cell Carcinoma?. <i>Novel Approaches in Cancer Study</i> , 2019, 3, .	0.2	0
1098	Impact of Systemic Anticancer Therapy on Fertility. , 2020, , 67-80.		0
1099	The role of immunotherapy in the management of patients with renal cell carcinoma and brain metastases. <i>Annals of Translational Medicine</i> , 2019, 7, S313-S313.	0.7	3
1100	The tango of immunotherapy and targeted therapy in metastatic renal cell carcinoma. <i>Translational Cancer Research</i> , 2019, 8, E1-E6.	0.4	3
1102	Klassifikation und medikamentöse Therapie des Nierenzellkarzinoms. , 2020, , 163-187.		0
1103	Tumors: Urologic Cancer. , 2020, , 1-11.		0
1105	Precision medicine in medical oncology: hope, disappointment and reality. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 1427-1431.	1.4	4
1106	Pembrolizumab: The Nut Cracker. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2020, 41, 393-396.	0.1	0
1108	Latest progress in molecular biology and treatment in genitourinary tumours. <i>Clinical and Translational Oncology</i> , 2020, 22, 2175-2195.	1.2	2
1109	Resistance to Pembrolizumab and Axitinib in Renal Cell Carcinoma: Clinical and Genomic Evaluation. <i>Journal of Kidney Cancer and VHL</i> , 2020, 7, 7-11.	0.2	4
1110	The Recent Advances of Anti-PD-1/PD-L1 Immunotherapy. , 2020, , .		0
1111	Clinical efficacy, predictive biomarkers and response patterns of immunotherapy combinations for patients with cancer. <i>Future Oncology</i> , 2020, 16, 1659-1664.	1.1	2
1112	Tumor Genotype Is Shaping Immunophenotype and Responses to Immune Checkpoint Inhibitors in Solid Tumors. <i>Journal of Immunotherapy and Precision Oncology</i> , 2020, 3, 121-127.	0.6	1
1113	Biomarkers for Immune Checkpoint Inhibitors. , 2021, , 449-463.		0

#	ARTICLE	IF	CITATIONS
1115	What morphology can teach us about renal cell carcinoma clonal evolution. <i>Kidney Cancer Journal: Official Journal of the Kidney Cancer Association</i> , 2020, 18, 68-76.	0.1	12
1116	The role of vascular endothelial growth factor inhibitors in the treatment of epithelial ovarian cancer. <i>British Journal of Cancer</i> , 2021, , .	2.9	3
1117	Overall survival improvement in patients with metastatic clear-cell renal cell carcinoma between 2000 and 2020: a retrospective cohort study. <i>Acta OncolÃ³gica</i> , 2022, 61, 22-29.	0.8	17
1118	Durable Remission with Immunotherapy in a Patient with Sarcomatoid Renal Cell Carcinoma. <i>Journal of Kidney Cancer and VHL</i> , 2021, 8, 38-42.	0.2	0
1119	Sarcomatoid Renal Cell Carcinoma: The Present and Future of Treatment Paradigms. <i>Kidney Cancer</i> , 2021, 5, 167-179.	0.2	1
1120	Immune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and Biomarkers. <i>Cancers</i> , 2021, 13, 5415.	1.7	13
1121	Angiogenesis Pathway in Kidney Renal Clear Cell Carcinoma and Its Prognostic Value for Cancer Risk Prediction. <i>Frontiers in Medicine</i> , 2021, 8, 731214.	1.2	4
1122	Immunotherapy-based combinations in the first-line treatment of metastatic renal cell carcinoma with sarcomatoid features: a systematic review and network meta-analysis. <i>Current Opinion in Urology</i> , 2022, 32, 61-68.	0.9	7
1123	Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1732-1739.	5.1	84
1124	ESMO guidelines on Renal Cell Carcinoma: the paradox of the fine line that separates scientific robustness from cost-efficiency analysis. <i>Annals of Oncology</i> , 2021, 32, 1466-1467.	0.6	1
1125	Outcomes of Cytoreductive Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Real World Data from Canadian Centers. <i>European Urology Focus</i> , 2022, 8, 1703-1710.	1.6	5
1126	Immune checkpoint inhibition for the treatment of cancers: An update and critical review of ongoing clinical trials. <i>Clinical Immunology</i> , 2021, 232, 108873.	1.4	19
1127	Ten years-experience of sunitinib in the treatment of advanced pan-NETs: an update on safety profile. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 303-310.	1.0	1
1128	The Tumor Microenvironment of Bladder Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1296, 275-290.	0.8	18
1130	CheckMate 214 trial: Immune checkpoint regulators for advanced renal cell carcinoma. <i>Indian Journal of Urology</i> , 2020, 36, 231.	0.2	4
1131	Applications of Antibodies in Therapy, Diagnosis, and Science. <i>Learning Materials in Biosciences</i> , 2021, , 129-159.	0.2	0
1132	Thyroid gland metastasis from renal cell carcinoma: a case series and literature review. <i>ANZ Journal of Surgery</i> , 2021, 91, 708-715.	0.3	7
1133	Emerging Therapies for Advanced Clear Cell Renal Cell Carcinoma. <i>Journal of Kidney Cancer and VHL</i> , 2020, 7, 17-26.	0.2	7

#	ARTICLE	IF	CITATIONS
1135	Remarkable response to combined immunochemotherapy in patients with metastatic triple-negative breast cancer. <i>Immunotherapy</i> , 2020, 12, 1293-1302.	1.0	0
1136	C�ancer renal avanzado, perfiles para los nuevos tratamientos. <i>Medicina Clinica Practica</i> , 2022, 5, 100277.	0.2	0
1137	Modern Multidisciplinary Care in Spine Tumors. , 2020, , 59-66.		0
1138	Current advances in kidney cancer immunotherapy. <i>Onkourologiya</i> , 2020, 15, 30-38.	0.1	3
1139	Current and emerging therapies for first line treatment of metastatic clear cell renal cell carcinoma. , 2021, 7, .		16
1140	Is there a preferred first-line therapy for metastatic renal cell carcinoma? A network meta-analysis. <i>Therapeutic Advances in Urology</i> , 2021, 13, 175628722110531.	0.9	11
1141	State of the Art for Metastatic Histologies. , 2020, , 211-233.		0
1142	Axitinib plus Immuncheckpoint-Inhibitor: evidenz- und expertenbasierte Konsensusempfehlungen f�ur die Behandlungsoptimierung und das Management von therapieassoziierten Nebenwirkungen. <i>Karger Kompass Onkologie</i> , 2020, 7, 180-189.	0.0	0
1143	Neue Arzneimittel 2019. , 2020, , 43-150.		2
1144	Immune checkpoint inhibitor � antiangiogenic drugs combination in treatment-na�ve metastatic clear cell renal cell carcinoma: Why should immunotherapy have all the fun!. <i>International Journal of Molecular and Immuno Oncology</i> , 0, 5, 1-7.	0.0	0
1145	Metastasiertes Nierenzellkarzinom: Ist das Alter therapierelevant?. <i>Karger Kompass Onkologie</i> , 2020, 7, 190-191.	0.0	0
1146	Cancer Immunotherapy Confers a Global Benefit. , 2020, , 1-48.		0
1147	Improved prognosis for elderly patients with metastatic renal cell carcinoma in the era of targeted therapy. <i>Molecular and Clinical Oncology</i> , 2020, 12, 557-564.	0.4	2
1148	News in the treatment of metastatic renal cancer. <i>Onkologie (Czech Republic)</i> , 2020, 14, 26-31.	0.0	0
1149	Tumor-Specific and Tumor-Agnostic Molecular Signatures Associated With Response to Immune Checkpoint Inhibitors. <i>JCO Precision Oncology</i> , 2021, 5, 1625-1638.	1.5	10
1150	Uptake and Survival Outcomes Following Immune Checkpoint Inhibitor Therapy Among Trial-Ineligible Patients With Advanced Solid Cancers. <i>JAMA Oncology</i> , 2021, 7, 1843.	3.4	26
1151	First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma: What Are the Most Appropriate Combination Therapies?. <i>Cancers</i> , 2021, 13, 5548.	1.7	11
1152	Persistent Response to a Combination Treatment Featuring a Targeted Agent and an Immune Checkpoint Inhibitor in a Patient With Collecting Duct Renal Carcinoma: A Case Report and Literature Review. <i>Frontiers in Oncology</i> , 2021, 11, 764352.	1.3	4

#	ARTICLE	IF	CITATIONS
1153	Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21). Expert Review of Anticancer Therapy, 2022, 22, 115-121.	1.1	5
1155	Risk Factors, Incidence, and Prognosis of Thromboembolism in Cancer Patients Treated With Immune Checkpoint Inhibitors. Frontiers in Pharmacology, 2021, 12, 747075.	1.6	3
1156	Stereotactic body radiotherapy in combination with non-frontline PD-1 inhibitors and targeted agents in metastatic renal cell carcinoma. Radiation Oncology, 2021, 16, 211.	1.2	8
1157	Lipid metabolism reprogramming in renal cell carcinoma. Cancer and Metastasis Reviews, 2022, 41, 17-31.	2.7	37
1158	Molecular Pathology of Lung Cancer. Cold Spring Harbor Perspectives in Medicine, 2022, 12, a037812.	2.9	8
1159	Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma. Nature Communications, 2021, 12, 6375.	5.8	22
1160	Combination therapy with immune checkpoint inhibitors in advanced renal cell carcinoma: A meta-analysis of randomized controlled trials. Clinical Immunology, 2021, 232, 108876.	1.4	4
1161	Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma. Biomarker Research, 2021, 9, 80.	2.8	16
1162	HIF2 α promotes tumour growth in clear cell renal cell carcinoma by increasing the expression of NUDT1 to reduce oxidative stress. Clinical and Translational Medicine, 2021, 11, e592.	1.7	6
1163	Multidisciplinary Management of Advanced Kidney Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 977-981.	2.3	0
1167	An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: the "Pamerit"™ study. Japanese Journal of Clinical Oncology, 2021, 51, 484-491.	0.6	1
1168	Combination of pembrolizumab and axitinib: a new gold standard in the first-line therapy for metastatic clear-cell renal-cell carcinoma?. Onkourologiya, 2020, 16, 29-37.	0.1	0
1169	Combination of nivolumab and ipilimumab in the treatment of disseminated renal cell carcinoma. Realities and prospects. Onkourologiya, 2020, 16, 38-52.	0.1	0
1170	A case series of advanced renal cell carcinoma patients treated with neoadjuvant cabozantinib prior to cytoreductive nephrectomy within the phase 2 CABOPRE trial. Oncotarget, 2020, 11, 4457-4462.	0.8	5
1171	Patients with metastatic renal cell carcinoma treated with cabozantinib in the Czech Republic: analysis of four cancer centers. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2022, 166, 97-104.	0.2	2
1172	Combining Immunotherapy with Multikinase Inhibitors: A Cautious New Promise. Indian Journal of Medical and Paediatric Oncology, 2020, 41, 901-905.	0.1	0
1173	Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitor Therapy. Anesthesia and Analgesia, 2021, 132, 374-383.	1.1	8
1174	Next Generation Sequencing in Renal Cell Carcinoma: Towards Precision Medicine. Kidney Cancer Journal: Official Journal of the Kidney Cancer Association, 2019, 17, 94-104.	0.1	0

#	ARTICLE	IF	CITATIONS
1175	The Role of Immunotherapy in Urologic Cancers. <i>Missouri Medicine</i> , 2020, 117, 127-132.	0.3	1
1176	Assessment for prognostic value of differentially expressed genes in immune microenvironment of clear cell renal cell carcinoma. <i>American Journal of Translational Research (discontinued)</i> , 2020, 12, 5416-5432.	0.0	4
1177	Assessment of hazard immune-related genes and tumor immune infiltrations in renal cell carcinoma. <i>American Journal of Translational Research (discontinued)</i> , 2020, 12, 7096-7113.	0.0	2
1178	The current role of cytoreductive nephrectomy for metastatic renal cell carcinoma. <i>Indian Journal of Urology</i> , 2021, 37, 13-19.	0.2	1
1179	What morphology can teach us about renal cell carcinoma clonal evolution. <i>Kidney Cancer Journal: Official Journal of the Kidney Cancer Association</i> , 2020, 18, 68-76.	0.1	5
1181	Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study. <i>Frontiers in Oncology</i> , 2021, 11, 683502.	1.3	2
1182	Nierenzellkarzinom. , 2022, , 304-307.		0
1183	Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial. <i>Clinical Cancer Research</i> , 2021, 27, 6687-6695.	3.2	25
1184	Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker for Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 746976.	1.3	21
1185	Addition of Salvage Immunotherapy to Targeted Therapy in Patients with Metastatic Renal Cell Carcinoma. <i>Current Oncology</i> , 2021, 28, 5019-5024.	0.9	0
1186	Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial. , 2021, 9, e003318.		7
1188	Cabozantinib plus immunotherapy combinations in metastatic renal cell and urothelial carcinoma. <i>Future Oncology</i> , 2022, 18, 21-33.	1.1	5
1189	Hypoxia as a driver of resistance to immunotherapy. <i>Drug Resistance Updates</i> , 2021, 59, 100787.	6.5	94
1190	Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920. <i>Cancer</i> , 2022, 128, 966-974.	2.0	24
1191	Updates on Immunotherapy and Immune Landscape in Renal Clear Cell Carcinoma. <i>Cancers</i> , 2021, 13, 5856.	1.7	39
1192	Antiangiogenic Therapy in Clear Cell Renal Carcinoma (CCRC): Pharmacological Basis and Clinical Results. <i>Cancers</i> , 2021, 13, 5896.	1.7	15
1193	Development and Validation of a Predictive Model to Evaluate the Risk of Bone Metastasis in Kidney Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 731905.	1.3	14
1194	Venous thromboembolism events in patients with advanced cancer on immune checkpoint inhibitors. <i>Immunotherapy</i> , 2022, 14, 23-30.	1.0	5

#	ARTICLE	IF	CITATIONS
1195	Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges. <i>Frontiers in Oncology</i> , 2021, 11, 771335.	1.3	15
1196	Kinase Inhibitorsâ€™ Effects on Innate Immunity in Solid Cancers. <i>Cancers</i> , 2021, 13, 5695.	1.7	5
1197	Impact of Value Frameworks on the Magnitude of Clinical Benefit: Evaluating a Decade of Randomized Trials for Systemic Therapy in Solid Malignancies. <i>Current Oncology</i> , 2021, 28, 4894-4928.	0.9	0
1199	Combination of Osimertinib and Pembrolizumab Successfully Overcome Dual Resistances in a Patient with Advanced Adenocarcinoma of the Lung, a Case Report. <i>Current Problems in Cancer Case Reports</i> , 2021, , 100132.	0.1	0
1200	Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 study. <i>International Journal of Clinical Oncology</i> , 2022, 27, 154-164.	1.0	16
1201	Identification of a Novel Stem Cell Subtype for Clear Cell Renal Cell Carcinoma Based on Stem Cell Gene Profiling. <i>Frontiers in Oncology</i> , 2021, 11, 758989.	1.3	2
1202	Utility of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune Inflammation Index as Prognostic, Predictive Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab and Ipilimumab. <i>Journal of Clinical Medicine</i> , 2021, 10, 5325.	1.0	25
1203	Risk Stratification and Treatment Algorithm of Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Medicine</i> , 2021, 10, 5339.	1.0	5
1204	Experience of using 1st line combination immunotherapy in patients with metastatic renal cell carcinoma. <i>Onkourologiya</i> , 2021, 17, 47-63.	0.1	1
1205	Combination Therapy in Renal Cell Carcinoma: the Best Choice for Every Patient?. <i>Current Oncology Reports</i> , 2021, 23, 147.	1.8	15
1206	Treatment Selection in First-line Metastatic Renal Cell Carcinomaâ€”The Contemporary Treatment Paradigm in the Age of Combination Therapy. <i>JAMA Oncology</i> , 2022, 8, 292.	3.4	35
1207	Supportive therapy and complementary medicine in renal cell carcinoma. <i>World Journal of Urology</i> , 2021, , 1.	1.2	0
1208	From Bench to Bedside: How the Tumor Microenvironment Is Impacting the Future of Immunotherapy for Renal Cell Carcinoma. <i>Cells</i> , 2021, 10, 3231.	1.8	18
1209	Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment. <i>Pharmacological Research</i> , 2022, 175, 105997.	3.1	43
1210	Assessment of prognostic factors in previously treated Japanese patients with metastatic renal cell carcinoma who received nivolumab: An observational multiâ€™institute study. <i>Molecular and Clinical Oncology</i> , 2021, 16, 17.	0.4	2
1211	Impact of Patient Age on Clinical Efficacy and Toxicity of Checkpoint Inhibitor Therapy. <i>Frontiers in Immunology</i> , 2021, 12, 786046.	2.2	17
1212	Moving beyond conventional stratified analysis to assess the treatment effect in a comparative oncology study. , 2021, 9, e003323.		0
1213	Inhibition of FGFR Reactivates IFNÎ³ Signaling in Tumor Cells to Enhance the Combined Antitumor Activity of Lenvatinib with Anti-PD-1 Antibodies. <i>Cancer Research</i> , 2022, 82, 292-306.	0.4	58

#	ARTICLE	IF	CITATIONS
1214	First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series. <i>World Journal of Clinical Oncology</i> , 2021, 12, 1037-1046.	0.9	2
1215	Cancer Immunotherapy: Current and Future Perspectives on a Therapeutic Revolution. <i>Journal of Clinical Medicine</i> , 2021, 10, 5246.	1.0	2
1216	Stereotactic Radiosurgery Results for Brain Metastasis Patients with Renal Cancer: A Validity Study of Renal Graded Prognostic Assessment and Proposal of a New Grading Index (JLGK2101 Study). <i>Clinical and Translational Radiation Oncology</i> , 2021, 32, 69-75.	0.9	1
1217	Molecular Mechanisms of Resistance to Immunotherapy and Antiangiogenic Treatments in Clear Cell Renal Cell Carcinoma. <i>Cancers</i> , 2021, 13, 5981.	1.7	31
1218	Immune Checkpoint Inhibitor Therapy for Bone Metastases: Specific Microenvironment and Current Situation. <i>Journal of Immunology Research</i> , 2021, 2021, 1-18.	0.9	21
1220	Gene signatures with therapeutic value: emerging perspective for personalized immunotherapy in renal cancer. <i>Immunotherapy</i> , 2021, 13, 1535-1547.	1.0	1
1221	Tumor metastasis: Mechanistic insights and therapeutic interventions. <i>MedComm</i> , 2021, 2, 587-617.	3.1	42
1222	Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma. <i>ESMO Open</i> , 2021, 6, 100304.	2.0	14
1223	Rational Combination with an Immunotherapy Backbone in Genitourinary Cancers. <i>Urological Science</i> , 2020, 31, 4-7.	0.2	4
1224	Current and Future Aspect of Immunotherapy for Advanced Renal Cell Carcinoma. <i>Urological Science</i> , 2020, 31, 8-14.	0.2	2
1226	Landscape of Immunotherapy in Genitourinary Malignancies. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 143-192.	0.8	2
1227	Resistance to Immunotherapy: Mechanisms and Means for Overcoming. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 45-80.	0.8	2
1228	A Systematic Analysis of Post-Protocol Therapy in First Line Checkpoint Inhibitor Trials. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1229	Câ€reactive protein flareâ€response predicts longâ€term efficacy to firstâ€line antiâ€PDâ€1â€based combination therapy in metastatic renal cell carcinoma. <i>Clinical and Translational Immunology</i> , 2021, 10, e1358.	1.7	15
1230	HHLA2 Immune Checkpoint Is a Novel Prognostic Predictor in Hepatocellular Carcinoma. <i>American Journal of Clinical Pathology</i> , 2022, 158, 62-69.	0.4	4
1232	A Linear Discriminant Analysis Model Based on the Changes of 7 Proteins in Plasma Predicts Response to Anlotinib Therapy in Advanced Non-Small Cell Lung Cancer Patients. <i>Frontiers in Oncology</i> , 2021, 11, 756902.	1.3	0
1233	Combination therapies in clinical trials for renal cell carcinoma: how could they impact future treatments?. <i>Expert Opinion on Investigational Drugs</i> , 2021, , 1-9.	1.9	4
1234	First-Line Treatments for Metastatic Clear Cell Renal Cell Carcinoma: An Ever-Enlarging Landscape. <i>Oncologist</i> , 2022, 27, 125-134.	1.9	9

#	ARTICLE	IF	CITATIONS
1235	Immunotherapy for prostate cancer: Requirements for a successful regime transfer. Investigative and Clinical Urology, 2022, 63, 3.	1.0	8
1236	Cytoreductive Nephrectomy in 2021: Obsolete. European Urology Open Science, 2022, 36, 44-46.	0.2	8
1237	The efficacy and safety of immune checkpoint inhibitors combined with antiangiogenic drugs in renal cell carcinomas: a systematic review and meta-analysis. Translational Cancer Research, 2020, 9, 6780-6791.	0.4	2
1238	Tumors: Urologic Cancer. , 2021, , 5291-5301.		0
1239	Novel emerging biomarkers to immunotherapy in kidney cancer. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110593.	1.4	12
1240	A New Direction of Tumor Therapyâ€”Immune Checkpoint Inhibitor Combined with Anti Angiogenesis Therapy. Advances in Clinical Medicine, 2021, 11, 5666-5672.	0.0	0
1241	Anlotinib in Combination with TQB2450 in Patients with Platinum-Resistant or Platinum-Refractory Ovarian Cancer (ACTION): A Multicenter, Single-Arm, Open-Label, Phase 1b Trial. SSRN Electronic Journal, 0, , .	0.4	1
1242	Fortgeschrittenes Nierenzellkarzinom: Neuerungen beim Einsatz zielgerichteter Therapien. , 0, , .		0
1243	Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study. Frontiers in Oncology, 2021, 11, 683502.	1.3	21
1244	Case Series of Steroid-Resistant Immune Checkpoint Inhibitor Associated Myocarditis: A Comparative Analysis of Corticosteroid and Tofacitinib Treatment. Frontiers in Pharmacology, 2021, 12, 770631.	1.6	23
1245	Experience of successful use of axitinib in therapy of metastatic renal cell carcinoma after immunotargeted therapy. Meditsinskiy Sovet, 2021, , 146-149.	0.1	0
1246	Phase Ib/II trial of Ibrutinib and Nivolumab in Patients with Advanced Refractory Renal Cell Carcinoma1. Kidney Cancer, 2021, 5, 181-187.	0.2	1
1247	Stereotactic Ablative Radiotherapy as a Tool in Renal Cell Carcinoma for Building RAPPORT with Systemic Therapy. European Urology, 2022, 81, 373-374.	0.9	0
1249	Immune checkpoint-targeted antibodies: a room for dose and schedule optimization?. Journal of Hematology and Oncology, 2022, 15, 6.	6.9	17
1250	Interrogating the interplay of angiogenesis and immunity in metastatic colorectal cancer. World Journal of Methodology, 2022, 12, 43-53.	1.1	7
1251	Fighting in a wasteland: deleterious metabolites and antitumor immunity. Journal of Clinical Investigation, 2022, 132, .	3.9	21
1252	Pembrolizumab: first adjuvant immunotherapy in renal cell carcinoma?. Future Oncology, 2022, 18, 519-522.	1.1	0
1253	Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study. Expert Opinion on Drug Metabolism and Toxicology, 2021, 17, 1455-1466.	1.5	7

#	ARTICLE	IF	CITATIONS
1254	Improvement of Medical Treatment in Japanese Patients With Metastatic Renal Cell Carcinoma. <i>Cancer Diagnosis & Prognosis</i> , 2022, 2, 25-30.	0.3	0
1255	High Complete Response Rate in Patients With Metastatic Renal Cell Carcinoma Receiving Autologous Cytokine-Induced Killer Cell Therapy Plus Anti-Programmed Death-1 Agent: A Single-Center Study. <i>Frontiers in Immunology</i> , 2021, 12, 779248.	2.2	3
1256	Outcomes of sorafenib treatment of advanced renal cell carcinoma according to International Metastatic Renal Cell Carcinoma Data Consortium risk criteria: analysis of Japanese real-world data from postmarketing all-patient surveillance of sorafenib. <i>Future Oncology</i> , 2022, , .	1.1	1
1257	Combination of Anti-Angiogenics and Checkpoint Inhibitors for Renal Cell Carcinoma: Is the Whole Greater Than the Sum of Its Parts?. <i>Cancers</i> , 2022, 14, 644.	1.7	11
1259	Adverse Events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer Patients in Clinical Trials: A Collaborative Systematic Review and Meta-analysis. <i>European Urology</i> , 2022, 81, 414-425.	0.9	40
1260	SBRT in Localized Renal Carcinoma: A Review of the Literature. <i>Anticancer Research</i> , 2022, 42, 667-674.	0.5	8
1261	Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 71-90.	2.3	248
1263	KEYNOTE-564: Adjuvant immunotherapy for renal cell carcinoma. <i>Indian Journal of Urology</i> , 2022, 38, 75.	0.2	6
1264	Systemic Injection of Oncolytic Vaccinia Virus Suppresses Primary Tumor Growth and Lung Metastasis in Metastatic Renal Cell Carcinoma by Remodeling Tumor Microenvironment. <i>Biomedicines</i> , 2022, 10, 173.	1.4	6
1265	Immunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2022, 23, 820.	1.8	15
1266	Immunotherapy: A new standard in the treatment of metastatic clear cell renal cell carcinoma. <i>World Journal of Clinical Oncology</i> , 2022, 13, 28-38.	0.9	10
1267	Outcomes of Radiation Therapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System. <i>Advances in Radiation Oncology</i> , 2022, 7, 100899.	0.6	1
1268	Independent Drug Action in Combination Therapy: Implications for Precision Oncology. <i>Cancer Discovery</i> , 2022, 12, 606-624.	7.7	93
1269	The Frontline Immunotherapy-Based Treatment of Advanced Clear Cell Renal Cell Carcinoma: Current Evidence and Clinical Perspective. <i>Biomedicines</i> , 2022, 10, 251.	1.4	13
1270	Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies. , 2022, 10, e003024.		15
1271	Histone Acetylation Regulator-Mediated Acetylation Patterns Define Tumor Malignant Pathways and Tumor Microenvironment in Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , 2022, 13, 761046.	2.2	19
1272	Imaging and tracing the pattern of adult ovarian angiogenesis implies a strategy against female reproductive aging. <i>Science Advances</i> , 2022, 8, eabi8683.	4.7	15
1273	IL-1A is associated with postoperative survival and immune contexture in clear cell renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, , .	0.8	3

#	ARTICLE	IF	CITATIONS
1274	Predictable Clinical Benefits without Evidence of Synergy in Trials of Combination Therapies with Immune-Checkpoint Inhibitors. <i>Clinical Cancer Research</i> , 2022, 28, 368-377.	3.2	40
1275	Immunotherapy and Gene Therapy: New Challenges in the Diagnosis and Management of Drug-Induced Liver Injury. <i>Frontiers in Pharmacology</i> , 2021, 12, 786174.	1.6	8
1276	Update on the treatment of metastatic renal cell carcinoma. <i>World Journal of Clinical Oncology</i> , 2022, 13, 1-8.	0.9	10
1277	Reviewing Treatment Options for Advanced Renal Cell Carcinoma: Is There Still a Place for Tyrosine Kinase Inhibitor (TKI) Monotherapy?. <i>Advances in Therapy</i> , 2022, 39, 1107-1125.	1.3	10
1278	A Cost-effectiveness Analysis Comparing Pembrolizumab-Axitinib, Nivolumab-Ipilimumab, and Sunitinib for Treatment of Advanced Renal Cell Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2022, 45, 66-73.	0.6	6
1279	Antiangiogenic drugs: Chemosensitizers for combination cancer therapy. , 2022, , 29-66.		1
1281	A novel FBW7/NFAT1 axis regulates cancer immunity in sunitinib-resistant renal cancer by inducing PD-L1 expression. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 38.	3.5	17
1282	Comparative Efficacy of Combination Therapy of Ipilimumab Plus Nivolumab for Non-clear Cell Renal Cell Carcinoma. <i>Anticancer Research</i> , 2022, 42, 973-979.	0.5	5
1283	Tumors resurrect an embryonic vascular program to escape immunity. <i>Science Immunology</i> , 2022, 7, eabm6388.	5.6	27
1284	Phase II Trial of Stereotactic Ablative Radiation for Oligoprogressive Metastatic Kidney Cancer. <i>European Urology Oncology</i> , 2022, 5, 216-224.	2.6	26
1285	Antiangiogenic drugs as chemosensitizer in renal cell cancer. , 2022, , 79-84.		0
1286	Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 245-253.	3.7	34
1287	Image-Guided Robotic Radiosurgery for the Treatment of Lung Metastases of Renal Cell Carcinoma—A Retrospective, Single Center Analysis. <i>Cancers</i> , 2022, 14, 356.	1.7	1
1289	A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2022, 18, 1185-1198.	1.1	10
1290	Recent Advances in First-Line Management of Metastatic Renal Cell Carcinoma. <i>Indian Journal of Medical and Paediatric Oncology</i> , 0, , .	0.1	0
1291	Second-line treatment with axitinib plus toripalimab in metastatic renal cell carcinoma: a retrospective multicenter study. <i>Future Oncology</i> , 2022, 18, 1461-1471.	1.1	2
1292	Chronic Use of Proton Pump Inhibitors Is Associated With an Increased Risk of Immune Checkpoint Inhibitor Colitis in Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 260-269.	0.9	8
1293	Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: A review. <i>Cancer Treatment Reviews</i> , 2022, 103, 102333.	3.4	21

#	ARTICLE	IF	CITATIONS
1294	Immune checkpoint inhibitors rechallenge in urological tumors: An extensive review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 170, 103579.	2.0	10
1295	The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 170, 103596.	2.0	76
1296	Global management of brain metastasis from renal cell carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 171, 103600.	2.0	2
1297	Efficacy and Safety of First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. <i>European Urology Open Science</i> , 2022, 37, 14-26.	0.2	48
1298	OUP accepted manuscript. <i>Oncologist</i> , 2022, , .	1.9	2
1299	Outcomes following cytoreductive nephrectomy without immediate postoperative systemic therapy for patients with synchronous metastatic renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 166.e1-166.e8.	0.8	5
1300	Salvage nivolumab and ipilimumab after prior anti-PD-1/ PD-L1 therapy in metastatic renal cell carcinoma: A meta-analysis. <i>Cancer Medicine</i> , 2022, , .	1.3	5
1301	Predictors of Survival in Patients Undergoing Surgery for Renal Cell Carcinoma and Inferior Vena Cava Tumor Thrombus. <i>Clinical Genitourinary Cancer</i> , 2022, , .	0.9	3
1302	Disrupting cancer angiogenesis and immune checkpoint networks for improved tumor immunity. <i>Seminars in Cancer Biology</i> , 2022, 86, 981-996.	4.3	15
1303	Surgical management of renal cancer metastasis in the humerus: novel use of a trabecular metal spacer. <i>BMJ Case Reports</i> , 2022, 15, e244313.	0.2	0
1304	Soluble PD-L1 as an early marker of progressive disease on nivolumab. , 2022, 10, e003527.		35
1305	Integrative Analysis of m6A RNA Methylation Regulators and the Tumor Immune Microenvironment in Non-Small-Cell Lung Cancer. <i>Disease Markers</i> , 2022, 2022, 1-34.	0.6	5
1306	Systematic Review of Treatment of Metastatic Non-Clear Cell Renal Cell Carcinoma. <i>Kidney Cancer</i> , 2022, 6, 53-68.	0.2	2
1307	Predictors of Survival in Favorable Risk Patients with Metastatic Renal Cell Carcinoma Treated with a Single-Agent First-Line Therapy. <i>Urologia Internationalis</i> , 2022, , 1-5.	0.6	1
1308	Coordinated Pembrolizumab and High Dose IL-2 (5-in-a-Row Schedule) for Therapy of Metastatic Clear Cell Renal Cancer. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 252-259.	0.9	4
1309	As a prognostic biomarker of clear cell renal cell carcinoma RUFY4 predicts immunotherapy responsiveness in a PDL1-related manner. <i>Cancer Cell International</i> , 2022, 22, 66.	1.8	2
1310	Association of differential expression of immunoregulatory molecules and presence of targetable mutations may inform rational design of clinical trials. <i>ESMO Open</i> , 2022, 7, 100396.	2.0	9
1311	Real-World Experience with Nivolumab in Metastatic Renal Cell Carcinoma Patients Who Have Progressed on Prior Therapies: A Single-Center Study from India. <i>South Asian Journal of Cancer</i> , 0, , .	0.2	0

#	ARTICLE	IF	CITATIONS
1312	Risk of toxicity with immunotherapyâ€“tyrosine kinase inhibitors for metastatic renal cell carcinoma: a meta-analysis of randomized controlled trials. <i>Future Oncology</i> , 2022, 18, 625-634.	1.1	4
1313	Retrospective analysis of clinical trial safety data for pembrolizumab reveals the effect of co-occurring infections on immune-related adverse events. <i>PLoS ONE</i> , 2022, 17, e0263402.	1.1	7
1314	Severe tyrosine-kinase inhibitor induced liver injury in metastatic renal cell carcinoma patients: two case reports assessed for causality using the updated RUCAM and review of the literature. <i>BMC Gastroenterology</i> , 2022, 22, 49.	0.8	9
1315	Modulation of the tumour microenvironment in hepatocellular carcinoma by tyrosine kinase inhibitors: from modulation to combination therapy targeting the microenvironment. <i>Cancer Cell International</i> , 2022, 22, 73.	1.8	21
1316	FCER1G positively relates to macrophage infiltration in clear cell renal cell carcinoma and contributes to unfavorable prognosis by regulating tumor immunity. <i>BMC Cancer</i> , 2022, 22, 140.	1.1	16
1317	Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinomaâ€”The RAPPOR Trial. <i>European Urology</i> , 2022, 81, 364-372.	0.9	70
1318	Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy. <i>Immune Network</i> , 2022, 22, e2.	1.6	53
1319	Lenvatinib: With more power comes more toxicity. <i>Cancer Research Statistics and Treatment</i> , 2022, 5, 177.	0.1	0
1322	Nierenzellkarzinom. , 2022, , 130-134.		0
1323	Monoclonal Antibodies to CTLA-4 with Focus on Ipilimumab. <i>Experientia Supplementum (2012)</i> , 2022, 113, 295-350.	0.5	3
1324	Immune Checkpoint Inhibitor Combination Therapy for Renal Cell Carcinomas With Concomitant Inferior Vena Cava Thrombi. <i>In Vivo</i> , 2022, 36, 1030-1034.	0.6	11
1325	Comprehensive Immune Landscape and Molecular Characteristics of Clinical Responses to Chemotherapy, Antiangiogenic Agents and PD-1 Inhibitors in Advanced Nasopharyngeal Cancer. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1326	Overview of clinical management for older patients with renal cell carcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2022, 52, 665-681.	0.6	2
1328	Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors. <i>European Urology Focus</i> , 2022, 8, 1696-1702.	1.6	17
1329	First-line Immune Checkpoint Inhibitor Combinations in Metastatic Renal Cell Carcinoma: Where Are We Going, Where Have We Been?. <i>Drugs</i> , 2022, 82, 439-453.	4.9	3
1330	Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 285-295.	0.9	5
1331	A Rare Case of Hepatic Vanishing Bile Duct Syndrome Occurring after Combination Therapy with Nivolumab and Cabozantinib in a Patient with Renal Carcinoma. <i>Diagnostics</i> , 2022, 12, 539.	1.3	2
1332	Conformational, Reactivity Analysis, Wavefunction-Based Properties, Molecular Docking and Simulations of a Benzamide Derivative with Potential Antitumor Activity-DFT and MD Simulations. <i>Polycyclic Aromatic Compounds</i> , 2023, 43, 2015-2031.	1.4	3

#	ARTICLE	IF	CITATIONS
1333	Case Study: A Japanese patient with metastatic renal cell carcinoma who achieved long-term treatment-free survival with pembrolizumab and axitinib in the KEYNOTE-426 phase III trial of pembrolizumab and axitinib versus sunitinib. <i>IJU Case Reports</i> , 2022, 5, 149-152.	0.1	1
1334	Cabozantinib plus Nivolumab: A Review in Advanced Renal Cell Carcinoma. <i>Targeted Oncology</i> , 2022, 17, 193-201.	1.7	2
1335	Recent pharmacological approaches for the treatment of renal cell carcinoma. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 187-195.	1.3	1
1336	Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma. <i>JCO Precision Oncology</i> , 2022, 6, e2100448.	1.5	5
1337	REchallenge of NIVOLUMAB (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study. <i>Journal of Oncology</i> , 2022, 2022, 1-12.	0.6	7
1338	Anti-PD-1 Monoclonal Antibody Combined With Anti-VEGF Agent Is Safe and Effective in Patients With Recurrent/Metastatic Head and Neck Squamous Cancer as Second-Line or Beyond Treatment. <i>Frontiers in Oncology</i> , 2022, 12, 781348.	1.3	6
1339	Pharmacometabolomics Applied to Personalized Medicine in Urological Cancers. <i>Pharmaceuticals</i> , 2022, 15, 295.	1.7	7
1340	Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. <i>Nature Medicine</i> , 2022, 28, 704-712.	15.2	181
1341	Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer. <i>JAMA Network Open</i> , 2022, 5, e2149040.	2.8	48
1342	VEGF Receptor Inhibitor-Induced Hypertension: Emerging Mechanisms and Clinical Implications. <i>Current Oncology Reports</i> , 2022, 24, 463-474.	1.8	28
1343	The roaring 2020s: a new decade of systemic therapy for renal cell carcinoma. <i>Current Opinion in Oncology</i> , 2022, 34, 234-242.	1.1	16
1344	Molecular biomarkers of prognosis in advanced renal cell carcinoma patients treated with Pazopanib plus interferon alpha (INF-2A) in a phase II study by the Spanish Oncology Genitourinary Group. <i>Clinical Genitourinary Cancer</i> , 2022, , .	0.9	0
1345	Incidence, predictors and 6-month overall outcome of acute kidney injury in Chinese patients receiving PD-1 inhibitors. <i>Future Oncology</i> , 2022, 18, 1951-1962.	1.1	9
1346	Challenges of the Immunotherapy: Perspectives and Limitations of the Immune Checkpoint Inhibitor Treatment. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2847.	1.8	19
1347	Unique characteristics of tertiary lymphoid structures in kidney clear cell carcinoma: prognostic outcome and comparison with bladder cancer. , 2022, 10, e003883.		13
1348	Evaluating management of progressive disease for control arm patients in trials of first line PD-1 or PD-L1 inhibitor-based treatment for metastatic solid tumours. <i>European Journal of Cancer</i> , 2022, 164, 95-104.	1.3	0
1349	Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma. <i>Cancer Medicine</i> , 2022, 11, 3106-3114.	1.3	10
1350	Axitinib Trough Concentration and its Influence on the Efficacy and Toxicity of Second-line Renal Cell Carcinoma Treatment. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 390.e1-390.e8.	0.9	3

#	ARTICLE	IF	CITATIONS
1351	Serial changes in liquid biopsy-derived variant allele frequency predict immune checkpoint inhibitor responsiveness in the pan-cancer setting. <i>Oncolmmunology</i> , 2022, 11, 2052410.	2.1	11
1352	The Effects of Axitinib plus Tislelizumab in the Treatment of Advanced Renal Cell Carcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-5.	0.6	0
1353	Identifying the Potential Role and Prognostic Value of the Platelet-Derived Growth Factor Pathway in Kidney Renal Clear Cell Carcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-20.	0.6	0
1354	Therapeutic potential of CDK4/6 inhibitors in renal cell carcinoma. <i>Nature Reviews Urology</i> , 2022, 19, 305-320.	1.9	9
1355	Preclinical Development and Evaluation of Allogeneic CAR T Cells Targeting CD70 for the Treatment of Renal Cell Carcinoma. <i>Cancer Research</i> , 2022, 82, 2610-2624.	0.4	24
1356	Angiogenesis Inhibitors and Immunomodulation in Renal Cell Cancers: The Past, Present, and Future. <i>Cancers</i> , 2022, 14, 1406.	1.7	13
1357	Reshaping Treatment Paradigms for Advanced Renal Cell Cancer Patients and Improving Patient Management. <i>Current Treatment Options in Oncology</i> , 2022, 23, 609-629.	1.3	1
1358	Camrelizumab Plus Apatinib in Treatment-Naive Patients With Advanced Nonsquamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100312.	0.6	7
1359	Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma. , 2022, 10, e004316.		45
1360	Systemic Therapy in Patients With Metastatic Xp11.2 Translocation Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 354-362.	0.9	4
1361	Surgical and focal treatment for metastatic renal cell carcinoma: A literature review. <i>International Journal of Urology</i> , 2022, 29, 494-501.	0.5	8
1362	Translational advances in pancreatic ductal adenocarcinoma therapy. <i>Nature Cancer</i> , 2022, 3, 272-286.	5.7	90
1363	Targeting circDGKD Intercepts TKIâ€™s Effects on Up-Regulation of Estrogen Receptor Î² and Vasculogenic Mimicry in Renal Cell Carcinoma. <i>Cancers</i> , 2022, 14, 1639.	1.7	5
1364	Approaches to First-Line Therapy for Metastatic Clear Cell Renal Cell Carcinoma. <i>Current Oncology Reports</i> , 2022, 24, 695-702.	1.8	9
1365	Treatment Equity in the Immunotherapy Era: Options for Patients with Both Autoimmune Disease and GU Cancers. <i>Life</i> , 2022, 12, 360.	1.1	1
1367	Temporal trends of adverse events and costs of nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinoma. <i>Future Oncology</i> , 2022, 18, 1219-1234.	1.1	3
1368	Benefit of Metastasectomy in Renal Cell Carcinoma: A Propensity Score Analysis. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 344-353.	0.9	6
1369	Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors. , 2022, 10, e003569.		10

#	ARTICLE	IF	CITATIONS
1370	Effect of active anticancer therapy on serologic response to SARS-CoV-2 BNT162b2 vaccine in patients with urothelial and renal cell carcinoma. <i>International Journal of Urology</i> , 2022, , .	0.5	4
1372	â€œPROBEâ€ing the Role of Cytoreductive Nephrectomy in Advanced Renal Cancer. <i>Kidney Cancer</i> , 2022, 6, 3-9.	0.2	7
1373	Cardio-Oncology Drug Interactions: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2022, 145, CIR0000000000001056.	1.6	40
1374	Extended Disease Control with Unconventional Cabozantinib Dose Increase in Metastatic Renal Cell Carcinoma. <i>Kidney Cancer</i> , 2022, 6, 69-79.	0.2	2
1375	Risk factors of proteinuria and potentially protective effect of renin-angiotensin system inhibitors in patients with renal cell carcinoma receiving axitinib. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 833-838.	1.1	4
1376	A Network Meta-Analysis of the Differences in Effectiveness and Safety between Nivolumab and Targeted Drug Therapy in Metastatic Renal Cell Carcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-8.	0.6	0
1377	Prognostic model of upfront cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors and/or targeted agents. <i>International Urology and Nephrology</i> , 2022, 54, 1225-1232.	0.6	8
1378	Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 1929-1938.	0.8	33
1379	Evaluation of autoantibodies as predictors of treatment response and immune-related adverse events during the treatment with immune checkpoint inhibitors: A prospective longitudinal pan-cancer study. <i>Cancer Medicine</i> , 2022, 11, 3074-3083.	1.3	16
1380	Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial. <i>Molecular Cancer</i> , 2022, 21, 84.	7.9	34
1381	Advanced Bile Duct Cancers: A Focused Review on Current and Emerging Systemic Treatments. <i>Cancers</i> , 2022, 14, 1800.	1.7	7
1382	Evaluation of Patient-Reported Outcomes (PROs) Protocol Content and Reporting for Clinical Trials that Lead to the approval of frontline Immune Checkpoint Blockade Combination for Patients with Advanced Renal Cell Carcinoma - The Patients' Voice or a Missed Opportunity. <i>Clinical Genitourinary Cancer</i> , 2022, 20, e158-e165.	0.9	5
1383	Successful apatinib treatment for advanced clear cell renal carcinoma as a first-line palliative treatment: A case report. <i>World Journal of Clinical Cases</i> , 2022, 10, 3593-3600.	0.3	1
1384	Renal cell carcinoma presentation highlights from the ESMO Congress 2021. <i>Memo - Magazine of European Medical Oncology</i> , 0, , 1.	0.3	1
1385	Recent Advances in Medical Therapy for Urological Cancers. <i>Frontiers in Oncology</i> , 2022, 12, 746922.	1.3	8
1386	Nivolumab, nivolumab+ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 612-624.	5.1	66
1387	First-line immune checkpoint inhibitors in advanced or metastatic renal cell carcinoma with sarcomatoid features. <i>Cancer Treatment Reviews</i> , 2022, 105, 102374.	3.4	7
1388	Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. <i>Cancer</i> , 2022, 128, 2085-2097.	2.0	103

#	ARTICLE	IF	CITATIONS
1389	Models of Renal Cell Carcinoma Used to Investigate Molecular Mechanisms and Develop New Therapeutics. <i>Frontiers in Oncology</i> , 2022, 12, 871252.	1.3	8
1390	Personalizing First-Line Management of Metastatic Renal Cell Carcinoma: Leveraging Current and Novel Therapeutic Options. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, , 1-9.	2.3	8
1391	Efficacy of second-line ICIs combined with TKIs among patients with metastatic renal cell carcinoma: a real-world study. <i>Immunotherapy</i> , 2022, 14, 309-320.	1.0	0
1392	Results from the INMUNOSUN-SOGUG trial: a prospective phase II study of sunitinib as a second-line therapy in patients with metastatic renal cell carcinoma after immune checkpoint-based combination therapy. <i>ESMO Open</i> , 2022, 7, 100463.	2.0	5
1393	Dermatological adverse events associated with immune checkpoint inhibitor-based combinations of anticancer therapies: a systematic review. <i>Immunotherapy</i> , 2022, 14, 489-503.	1.0	1
1394	Setting a new standard for long-term survival in metastatic kidney cancer. <i>Cancer</i> , 2022, 128, 2058-2060.	2.0	0
1395	The Chromosomes and the Kidney. <i>Physician Assistant Clinics</i> , 2022, 7, 367-375.	0.1	0
1396	New first-line immunotherapy-based combinations for metastatic renal cell carcinoma: A systematic review and network meta-analysis. <i>Cancer Treatment Reviews</i> , 2022, 106, 102377.	3.4	20
1397	Radiological patterns of tumour progression in patients treated with a combination of immune checkpoint blockers and antiangiogenic drugs. <i>European Journal of Cancer</i> , 2022, 167, 42-53.	1.3	2
1398	The effect of immune checkpoint inhibitor combination therapies in metastatic renal cell carcinoma patients with and without previous cytoreductive nephrectomy: A systematic review and meta-analysis. <i>International Immunopharmacology</i> , 2022, 108, 108720.	1.7	13
1399	Nephrotoxicity From Molecularly Targeted Chemotherapeutic Agents. <i>Advances in Chronic Kidney Disease</i> , 2021, 28, 415-428.e1.	0.6	4
1400	Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13311.	1.8	54
1401	Immunotherapy and Metastatic Renal Cell Carcinoma: A Review of New Treatment Approaches. <i>Life</i> , 2022, 12, 24.	1.1	12
1402	CD248+ Cancer-Associated Fibroblasts: A Novel Prognostic and Therapeutic Target for Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 773063.	1.3	9
1403	In silico modeling of combination systemic therapy for advanced renal cell carcinoma. , 2021, 9, e004059.		5
1404	What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy?. <i>Frontiers in Immunology</i> , 2021, 12, 773168.	2.2	18
1405	CD146 as a Prognostic-Related Biomarker in ccRCC Correlating With Immune Infiltrates. <i>Frontiers in Oncology</i> , 2021, 11, 744107.	1.3	11
1406	Phase Ib Study of Atezolizumab Plus Interferon- γ with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid Tumors. <i>Current Oncology</i> , 2021, 28, 5466-5479.	0.9	2

#	ARTICLE	IF	CITATIONS
1407	New targeted therapies in kidney cancer. Memo - Magazine of European Medical Oncology, 2022, 15, 133-136.	0.3	2
1408	From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit. Clinical Cancer Research, 2022, 28, 831-839.	3.2	12
1409	CD8+ T Cell-Based Molecular Classification With Heterogeneous Immunogenomic Landscapes and Clinical Significance of Clear Cell Renal Cell Carcinoma. Frontiers in Immunology, 2021, 12, 745945.	2.2	11
1410	Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma. Targeted Oncology, 2022, 17, 61-68.	1.7	61
1411	CANDIED: A Pan-Canadian Cohort of Immune Checkpoint Inhibitor-Induced Insulin-Dependent Diabetes Mellitus. Cancers, 2022, 14, 89.	1.7	5
1412	A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system. Expert Opinion on Drug Safety, 2022, 21, 563-572.	1.0	27
1413	Combination therapy patents: a new front in evergreening. Nature Biotechnology, 2021, 39, 1504-1510.	9.4	8
1414	Case Report: Early 68Ga-PSMA-PET Metabolic Assessment and Response to Systemic Treatment for First-Line Metastatic Clear Cell Renal Cell Carcinoma; About Two Clinical Cases. Frontiers in Oncology, 2021, 11, 782166.	1.3	3
1415	Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFN γ + Bevacizumab: Results from CALGB 90206 (Alliance). Clinical Cancer Research, 2022, 28, 2771-2778.	3.2	8
1416	A Glimpse in the Future of Malignant Mesothelioma Treatment. Frontiers in Pharmacology, 2021, 12, 809337.	1.6	2
1417	Decrease of Pro-Angiogenic Monocytes Predicts Clinical Response to Anti-Angiogenic Treatment in Patients with Metastatic Renal Cell Carcinoma. Cells, 2022, 11, 17.	1.8	7
1418	FGL1 as a Novel Mediator and Biomarker of Malignant Progression in Clear Cell Renal Cell Carcinoma. Frontiers in Oncology, 2021, 11, 756843.	1.3	8
1419	Aktuelles zur medikamentösen Therapie des rezidivierten/metastasierten Nierenzellkarzinoms (mNCC). Onkologische Welt, 2021, 12, 361-367.	0.0	0
1420	Metastatic Clear Renal-Cell Carcinoma Mimicking Anaplastic Thyroid Cancer: A Case Report. Ear, Nose and Throat Journal, 2021, , 014556132110655.	0.4	0
1421	Incidence and Distinct Features of Immune Checkpoint Inhibitor-Related Myositis From Idiopathic Inflammatory Myositis: A Single-Center Experience With Systematic Literature Review and Meta-Analysis. Frontiers in Immunology, 2021, 12, 803410.	2.2	25
1423	Differential effects of cyclo-oxygenase 1 and 2 inhibition on angiogenesis inhibitor-induced hypertension and kidney damage. Clinical Science, 2022, 136, 675-694.	1.8	6
1424	A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy. Science Translational Medicine, 2022, 14, eabm6420.	5.8	29
1425	Cabozantinib as First-line Treatment in Patients With Metastatic Collecting Duct Renal Cell Carcinoma. JAMA Oncology, 2022, 8, 910.	3.4	20

#	ARTICLE	IF	CITATIONS
1426	The Landscape of Immunotherapy Resistance in NSCLC. <i>Frontiers in Oncology</i> , 2022, 12, 817548.	1.3	27
1427	Research Trends and Most Influential Clinical Studies on Anti-PD1/PDL1 Immunotherapy for Cancers: A Bibliometric Analysis. <i>Frontiers in Immunology</i> , 2022, 13, 862084.	2.2	18
1428	Novel immune-related signature based on immune cells for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma. <i>Journal of Clinical Laboratory Analysis</i> , 2022, , e24409.	0.9	1
1429	Front-Line Therapy for Metastatic Renal Cell Carcinoma: A Perspective on the Current Algorithm and Future Directions. <i>Cancers</i> , 2022, 14, 2049.	1.7	7
1430	Impacts and mechanisms of metabolic reprogramming of tumor microenvironment for immunotherapy in gastric cancer. <i>Cell Death and Disease</i> , 2022, 13, 378.	2.7	37
1431	Targeting the gut and tumor microbiota in cancer. <i>Nature Medicine</i> , 2022, 28, 690-703.	15.2	159
1432	Pathologic complete response with pembrolizumab plus axitinib in metastatic renal cell carcinoma. <i>International Cancer Conference Journal</i> , 2022, 11, 205-209.	0.2	2
1433	Association of Immune Checkpoint Inhibitors With Neurologic Adverse Events. <i>JAMA Network Open</i> , 2022, 5, e227722.	2.8	25
1434	Bepegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study. , 2022, 10, e004419.		8
1435	Use of Immunotherapy in Clinical Management of Genitourinary Cancers â€” a Review. <i>Cancer Treatment and Research Communications</i> , 2022, 31, 100564.	0.7	3
1436	Immunotherapy and Checkpoint Inhibitors in Urologic Cancer. <i>Urologic Clinics of North America</i> , 2022, 49, 323-334.	0.8	0
1437	Hyperprogression, a challenge of PD-1/PD-L1 inhibitors treatments: potential mechanisms and coping strategies. <i>Biomedicine and Pharmacotherapy</i> , 2022, 150, 112949.	2.5	6
1452	Opposing Roles of Vascular Endothelial Growth Factor C in Metastatic Dissemination and Resistance to Radio/Chemotherapy: Discussion of Mechanisms and Therapeutic Strategies. <i>Methods in Molecular Biology</i> , 2022, 2475, 1-23.	0.4	2
1453	Changes in Real-World Outcomes in Patients with Metastatic Renal Cell Carcinoma from the Molecular-Targeted Therapy Era to the Immune Checkpoint Inhibitor Era. <i>Targeted Oncology</i> , 2022, 17, 307-319.	1.7	4
1454	Anti-angiogenesis revisited: reshaping the treatment landscape of advanced non-small cell lung cancer. <i>Archives of Pharmacal Research</i> , 2022, 45, 263-279.	2.7	11
1455	Hematological prognosticators in metastatic renal cell cancer treated with immune checkpoint inhibitors: a meta-analysis. <i>Immunotherapy</i> , 2022, 14, 709-725.	1.0	10
1457	The current role of cytoreductive nephrectomy for metastatic renal cell carcinoma. <i>Indian Journal of Urology</i> , 2021, 37, 13.	0.2	4
1458	Axitinib in management of renal cell carcinoma: Indian perspective. <i>Oncology Journal of India</i> , 2022, 6, 14.	0.1	2

#	ARTICLE	IF	CITATIONS
1459	Immunotherapy in Genitourinary Malignancy: Evolution in Revolution or Revolution in Evolution. <i>Cancer Treatment and Research</i> , 2022, 183, 201-223.	0.2	0
1460	A Systematic Review of Immune Checkpoint Inhibitors in Non-Clear-Cell Renal Cancer. <i>Kidney Cancer</i> , 2022, 6, 115-127.	0.2	2
1461	Rapidly evolving first-line therapy using checkpoint inhibitors in metastatic renal cell cancer. <i>Future Medicinal Chemistry</i> , 2022, , .	1.1	0
1462	Practice-changing publications: Kidney cancer. <i>Canadian Urological Association Journal</i> , 2021, 16, E237-9.	0.3	0
1463	Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study. <i>Lancet Oncology</i> , The, 2022, 23, 768-780.	5.1	23
1464	Feasibility of immunotherapy in cancer patients with persistent or past hepatitis B or C virus infection. <i>JGH Open</i> , 2022, 6, 309-316.	0.7	6
1465	Neoadjuvant Systemic Therapy in Localized and Locally Advanced Renal Cell Carcinoma. <i>Frontiers in Urology</i> , 2022, 2, .	0.2	1
1466	Updates in the Management of Renal Cell Carcinoma. <i>Journal of the Advanced Practitioner in Oncology</i> , 2022, 13, 315-319.	0.2	0
1467	Antibody-drug conjugates: beyond current approvals and potential future strategies. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , 252-277.	0.5	11
1468	Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study. <i>Journal of Personalized Medicine</i> , 2022, 12, 727.	1.1	3
1469	Molecular Subtypes Based on Genomic and Transcriptomic Features Correlate with the Responsiveness to Immune Checkpoint Inhibitors in Metastatic Clear Cell Renal Cell Carcinoma. <i>Cancers</i> , 2022, 14, 2354.	1.7	4
1470	A Phase II, Single-arm Trial of Sunitinib and Erlotinib in Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 415-422.	0.9	1
1471	Developments in personalized therapy for metastatic renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 647-655.	1.1	6
1472	Redistribution of <sc>CD8</sc>+ T cell subsets in metastatic renal cell carcinoma patients treated with <sc>antiâ€PD</sc> therapy. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2022, 101, 597-605.	1.1	2
1473	Checkpoint inhibition: the current treatment of renal cell carcinoma. <i>Revista Mexicana De Urologia</i> , 2022, 82, 1-13.	0.0	0
1474	Prospective phase II study of sunitinib rechallenge in metastatic renal cell carcinoma: The â€œretryâ€• study from the Italian Group of Onco-Nephrology (G.I.O.N.). <i>Journal of Onco-Nephrology</i> , 2022, 6, 107-114.	0.3	1
1475	Kidney Cancer Models for Pre-Clinical Drug Discovery: Challenges and Opportunities. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	2
1476	Systemic therapy in metastatic renal cell carcinoma (mRCC): an evidence-based recommendation of the German interdisciplinary RCC guidelines group. <i>World Journal of Urology</i> , 2022, 40, 2381-2386.	1.2	3

#	ARTICLE	IF	CITATIONS
1477	Complementary roles of surgery and systemic treatment in clear cell renal cell carcinoma. <i>Nature Reviews Urology</i> , 2022, 19, 391-418.	1.9	20
1478	Management of Pheochromocytomas and Paragangliomas: A Case-Based Review of Clinical Aspects and Perspectives. <i>Journal of Clinical Medicine</i> , 2022, 11, 2591.	1.0	4
1479	Localized PD-1 Blockade in a Mouse Model of Renal Cell Carcinoma. <i>Frontiers in Drug Delivery</i> , 2022, 2, .	0.4	0
1480	Quantifying absolute benefit for adjuvant treatment options in renal cell carcinoma: A living interactive systematic review and network meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 175, 103706.	2.0	3
1481	Serum parameters as prognostic biomarkers in a real world cancer patient population treated with anti PD-1/PD-L1 therapy. <i>Annals of Medicine</i> , 2022, 54, 1339-1349.	1.5	8
1482	The efficacy of immune checkpoint inhibitors in rare tumors: A systematic review of published clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 174, 103700.	2.0	6
1483	The multi-molecular mechanisms of tumor-targeted drug resistance in precision medicine. <i>Biomedicine and Pharmacotherapy</i> , 2022, 150, 113064.	2.5	14
1484	lIxadencel, a Cell-based Immune Primer, plus Sunitinib Versus Sunitinib Alone in Metastatic Renal Cell Carcinoma: A Randomized Phase 2 Study. <i>European Urology Open Science</i> , 2022, 40, 38-45.	0.2	5
1485	Avelumab in unresectable/metastatic, progressive, grade 2-3 neuroendocrine neoplasms (NENs): Combined results from NET-001 and NET-002 trials. <i>European Journal of Cancer</i> , 2022, 169, 74-81.	1.3	15
1486	The roles of TGF- β 2 and VEGF pathways in the suppression of antitumor immunity in melanoma and other solid tumors. , 2022, 240, 108211.		21
1488	Incidence of fatigue associated with immune checkpoint inhibitors in patients with cancer: a meta-analysis. <i>ESMO Open</i> , 2022, 7, 100474.	2.0	3
1489	Mechanism and Management of Checkpoint Inhibitor-Related Toxicities in Genitourinary Cancers. <i>Cancers</i> , 2022, 14, 2460.	1.7	2
1490	Rescuing Cancer Immunity by Plasma Exchange in Metastatic Melanoma (ReCIPE-M1): protocol for a single-institution, open-label safety trial of plasma exchange to clear sPD-L1 for immunotherapy. <i>BMJ Open</i> , 2022, 12, e050112.	0.8	6
1491	Development of a Phagocytosis-Dependent Gene Signature to Predict Prognosis and Response to Checkpoint Inhibition in Clear-Cell Renal Cell Carcinoma. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	9
1492	A Novel Classification and Scoring Method Based on Immune-Related Transcription Factor Regulation Patterns in Gastric Cancer. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	1
1493	Clear Cell Renal Cell Carcinoma with Immunotherapy Effect Mimicking Xanthogranulomatous Pyelonephritis. <i>International Journal of Surgical Pathology</i> , 2022, , 106689692211018.	0.4	0
1494	Clustered 8-Oxo-Guanine Mutations and Oncogenic Gene Fusions in Microsatellite-Unstable Colorectal Cancer. <i>JCO Precision Oncology</i> , 2022, 6, e2100477.	1.5	2
1495	Real-world data on the efficacy and safety of pazopanib in IMDC favorable- and intermediate-risk metastatic renal cell carcinoma: a multicenter retrospective cohort study of Chinese patients. <i>Translational Andrology and Urology</i> , 2022, 11, 694-709.	0.6	2

#	ARTICLE	IF	CITATIONS
1496	Reduced CDH16 expression is linked to poor prognosis in clear cell renal cell carcinoma 16. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, , .	0.8	1
1497	Re: Phase II Trial of Cabozantinib Plus Nivolumab in Patients with Non-clear-cell Renal Cell Carcinoma and Genomic Correlates. <i>European Urology</i> , 2022, 82, 331-332.	0.9	1
1498	Real-World Therapy Management and Outcomes of First-Line Axitinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma in the United States. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	6
1499	Clinically approved combination immunotherapy: Current status, limitations, and future perspective. <i>Current Research in Immunology</i> , 2022, 3, 118-127.	1.2	20
1500	Integration of Palliative and Supportive Care Into the Management of Genitourinary Malignancies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, , 341-350.	1.8	2
1501	Efficacy of Cabozantinib for Papillary Compared With Clear-cell Renal Cell Carcinoma Following Immune Checkpoint Inhibitor Treatment. <i>Anticancer Research</i> , 2022, 42, 3151-3158.	0.5	4
1502	Baseline circulating unswitched memory B cells and B-cell related soluble factors are associated with overall survival in patients with clear cell renal cell carcinoma treated with nivolumab within the NIVOREN GETUG-AFU 26 study. , 2022, 10, e004885.		13
1503	Immune-Associated Gene Signatures Serve as a Promising Biomarker of Immunotherapeutic Prognosis for Renal Clear Cell Carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10
1505	Longitudinal Molecular Profiling of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 3633-3641.	0.8	12
1506	Comprehensive assessments of immuno-oncology drug-based combination therapies as first-line treatment for advanced renal cell carcinoma. <i>International Journal of Urology</i> , 2022, 29, 816-822.	0.5	1
1507	Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy. <i>Oncolimmunology</i> , 2022, 11, .	2.1	9
1508	Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy Lung-MAP S1800A. <i>Journal of Clinical Oncology</i> , 2022, 40, 2295-2307.	0.8	84
1509	Pembrolizumab in advanced renal cell carcinoma: a meta-analysis providing level 1a evidence. <i>Current Problems in Cancer</i> , 2022, , 100875.	1.0	2
1510	An Evaluation of Cabozantinib for the Treatment of Renal Cell Carcinoma: Focus on Patient Selection and Perspectives. <i>Therapeutics and Clinical Risk Management</i> , 0, Volume 18, 619-632.	0.9	5
1511	Lung-MAP: A Collaborative Roadmap to Improve Cancer Outcomes. <i>Journal of Clinical Oncology</i> , 2022, 40, 2285-2287.	0.8	1
1512	Individualizing the Oncological Treatment of Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma by Using Gene Sequencing and Patient-Reported Outcomes: Protocol for the INDIGO Study. <i>JMIR Research Protocols</i> , 2022, 11, e36632.	0.5	1
1515	Durable benefit and change in TCR clonality with nivolumab in a Lynch syndrome-associated glioma. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211008.	1.4	1
1516	Update on Treatment of Renal Cell Carcinoma. <i>Journal of the Nihon University Medical Association</i> , 2022, 81, 77-81.	0.0	0

#	ARTICLE	IF	CITATIONS
1517	Emergence of new strategies in metastatic kidney cancer. <i>Bulletin Du Cancer</i> , 2022, 109, 2S1-2S3.	0.6	0
1518	Future treatment options in metastatic clear cell renal cell carcinoma. <i>Bulletin Du Cancer</i> , 2022, 109, 2S47-2S58.	0.6	0
1519	Therapeutic sequencing in the era of first-line immune checkpoint inhibitor combinations, a novel challenge in patients with metastatic clear-cell renal cell carcinoma. <i>Bulletin Du Cancer</i> , 2022, 109, 2S31-2S38.	0.6	2
1520	Clinical activity of immunotherapy-based combination first-line therapies for metastatic renal cell carcinoma: the right treatment for the right patient. <i>Bulletin Du Cancer</i> , 2022, 109, 2S4-2S18.	0.6	3
1521	Surgical management in metastatic renal cell carcinoma. <i>Bulletin Du Cancer</i> , 2022, 109, 2S59-2S65.	0.6	0
1522	Metastatic renal cell cancer and first-line combinations: for which patients? (focus on tolerance and) Tj ETQq1 1 0.784314 rgBT /Over bo	0.6	0
1523	Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma. <i>JAMA Network Open</i> , 2022, 5, e2216379.	2.8	10
1524	High Grade Dermatologic Adverse Events Associated With Immune Checkpoint Blockade for Cancer. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	7
1525	Quantitative and qualitative changes in platelet traits of sunitinib-treated patients with renal cell carcinoma in relation to circulating sunitinib levels: a proof-of-concept study. <i>BMC Cancer</i> , 2022, 22, .	1.1	0
1526	Clinicopathologic and Immunohistochemical Characterization of Sarcomatoid Chromophobe Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2022, 46, 1171-1179.	2.1	4
1527	Cost-Effectiveness of Lenvatinib Plus Pembrolizumab or Everolimus as First-Line Treatment of Advanced Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
1528	Combination Immune Checkpoint Blockade Regimens for Previously Untreated Metastatic Renal Cell Carcinoma: The Winship Cancer Institute of Emory University Experience. <i>Journal of Immunotherapy and Precision Oncology</i> , 2022, , .	0.6	1
1529	Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1stâ€“2nd, 2021. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	4
1530	Precision Medicine: An Optimal Approach to Patient Care in Renal Cell Carcinoma. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	5
1531	Sunitinib-Induced Elevation of Mean Corpuscular Volume (MCV)â€”Exploring Its Possible Clinical Relevance in Cancer Patients. <i>Current Oncology</i> , 2022, 29, 4138-4147.	0.9	3
1532	An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 454-489.	157.7	13
1533	Metastatic Clear-Cell Renal Cell Carcinoma in the Era of Immune Checkpoint Inhibitors: Therapies and Ongoing Trials. <i>Cancers</i> , 2022, 14, 2867.	1.7	10
1534	Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 529-540.	21.5	134

#	ARTICLE	IF	CITATIONS
1535	Clinical evidence for synergy between immunotherapy and radiotherapy (<scp>SITAR</scp>). Journal of Medical Imaging and Radiation Oncology, 2022, 66, 881-895.	0.9	9
1536	A Study of Pazopanib Safety and Efficacy in Patients With Advanced Clear Cell Renal Cell Carcinoma and ECOG Performance Status 2 (Pazo2): An Open label, Multicentre, Single Arm, Phase II Trial. Clinical Genitourinary Cancer, 2022, 20, 473-481.	0.9	2
1537	Emerging Therapies in Penile Cancer. Frontiers in Oncology, 0, 12, .	1.3	1
1538	Cancer immunohistogram representing cancer-immunity cycle by immunohistochemistry predicts the efficacy of immune checkpoint inhibitors in urological cancer patients. Scientific Reports, 2022, 12, .	1.6	3
1539	Disparity in public funding of systemic therapy for metastatic renal cell carcinoma within Canada. Canadian Urological Association Journal, 2022, 16, .	0.3	3
1540	Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline. Journal of Clinical Oncology, 2022, 40, 2957-2995.	0.8	97
1541	Comprehensive Evaluation of the m6A Regulator Prognostic Risk Score in the Prediction of Immunotherapy Response in Clear Cell Renal Cell Carcinoma. Frontiers in Immunology, 0, 13, .	2.2	5
1542	Tivozanib in relapsed or refractory advanced renal cell carcinoma: a focus on US approval. Expert Review of Anticancer Therapy, 0, , 1-8.	1.1	0
1543	Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nature Medicine, 2022, 28, 1599-1611.	15.2	185
1545	Use of Circular RNAs in Diagnosis, Prognosis and Therapeutics of Renal Cell Carcinoma. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	5
1546	Successful Treatment of Metastatic Gallbladder Carcinoma with PD-L1 Expression by the Combination of PD-1 Inhibitor Plus Bevacizumab with Chemotherapy: A Case Report. OncoTargets and Therapy, 0, Volume 15, 629-636.	1.0	2
1547	Targeting Cardiovascular Adverse Events of Metastatic Renal Cell Carcinoma Therapies. JACC: CardioOncology, 2022, 4, 235-237.	1.7	1
1548	A Phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA). British Journal of Cancer, 2022, 127, 1051-1060.	2.9	17
1549	The prospect of targeting T cell immunoglobulin and mucin domain containing 3 in renal cell carcinoma immunotherapy. Scandinavian Journal of Immunology, 2022, 96, .	1.3	3
1550	Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy. European Journal of Cancer, 2022, 171, 124-132.	1.3	14
1551	Immune checkpoint inhibitor-based therapy for advanced clear cell renal cell carcinoma: A narrative review. International Immunopharmacology, 2022, 110, 108900.	1.7	13
1552	Advances in Targeted Therapy for Patients with Neuroendocrine Tumours. Touch Reviews in Oncology & Haematology, 2022, 18, 66.	0.1	0
1553	Mapping Single Cell Transcriptomes in the Intra-Tumoural and Associated Territories of Kidney Cancer. SSRN Electronic Journal, 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
1554	Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211086.	1.4	15
1555	Maximizing Immunotherapy in Sarcoma Using Histology, Biomarkers and Novel Approaches. <i>Touch Reviews in Oncology & Haematology</i> , 2022, 18, 73.	0.1	0
1556	Up-front Nivolumab With or Without Salvage Ipilimumab Across International Metastatic Database Consortium Risk Groups in Metastatic Clear Cell Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 0, , .	0.8	0
1557	Immunotherapy: an alternative promising therapeutic approach against cancers. <i>Molecular Biology Reports</i> , 2022, 49, 9903-9913.	1.0	17
1558	Lack of Efficacy of Immune Checkpoint Inhibitors in Cancer Patients Older Than 75?. <i>Journal of Immunotherapy</i> , 0, Publish Ahead of Print, .	1.2	0
1559	Charting roadmaps towards novel and safe synergistic immunotherapy combinations. <i>Nature Cancer</i> , 2022, 3, 665-680.	5.7	18
1560	Atlas of PD-L1 for Pathologists: Indications, Scores, Diagnostic Platforms and Reporting Systems. <i>Journal of Personalized Medicine</i> , 2022, 12, 1073.	1.1	36
1561	Association of Energy Expenditure and Efficacy in Metastatic Renal Cell Carcinoma Patients Treated with Nivolumab. <i>Cancers</i> , 2022, 14, 3214.	1.7	2
1562	RCC Real-World Data: Prognostic Factors and Risk Stratification in the Immunotherapy Era. <i>Cancers</i> , 2022, 14, 3127.	1.7	5
1563	A single-cell map of dynamic chromatin landscapes of immune cells in renal cell carcinoma. <i>Nature Cancer</i> , 2022, 3, 885-898.	5.7	20
1564	Evaluation of Provider Preferences in First-Line Metastatic Renal Cell Carcinoma: Comparison Between Dual Immunotherapy vs. Immunotherapy/Tyrosine Kinase Inhibitors. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 510-514.	0.9	0
1565	Efficacy and Safety of Immunotherapy-Based Combinations as First-Line Therapy for Metastatic Renal Cell Carcinoma in Patients Who Do Not Meet Trial Eligibility Criteria. <i>Targeted Oncology</i> , 2022, 17, 475-482.	1.7	4
1566	Cabozantinib in the treatment of patients with advanced renal cell carcinoma. <i>Journal of Modern Oncology</i> , 2022, 24, 184-190.	0.1	0
1567	Efficacy and Safety of Concomitant Proton Pump Inhibitor and Nivolumab in Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 488-494.	0.9	4
1568	A Cluster of Metabolic-Related Genes Serve as Potential Prognostic Biomarkers for Renal Cell Carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	5
1569	Does the Time to Start First-Line Treatment Influence the Survival of Favorable-Risk Patients With Metastatic Renal Cell Carcinoma? Results of the MetaSurvâ€UroCCR 79 Study. <i>Clinical Genitourinary Cancer</i> , 2023, 21, 194-202.	0.9	0
1570	Real-world efficacy and safety of nivolumab plus ipilimumab in untreated metastatic renal cell carcinoma, and the impact of previous nephrectomy on clinical outcome: Japanese multi-institutional retrospective study. <i>International Journal of Clinical Oncology</i> , 2022, 27, 1596-1604.	1.0	11
1571	Case report: treatment of metastatic renal cell carcinoma with nivolumab plus cabozantinib in routine clinical practice. <i>Malignant Tumours</i> , 2022, 12, 45-51.	0.1	0

#	ARTICLE	IF	CITATIONS
1572	Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma. <i>European Urology</i> , 2022, 82, 427-439.	0.9	15
1574	Case Report: A Durable Response to Camrelizumab and Apatinib Combination Therapy in a Heavily Treated Small Cell Carcinoma of the Ovary, Hypercalcemic Type. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
1575	The Risk of Opportunistic Infections and the Role of Antibiotic Prophylaxis in Patients on Checkpoint Inhibitors Requiring Steroids. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 800-807.e1.	2.3	5
1576	Tivozanib for the treatment of advanced renal cell carcinoma. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 1135-1142.	0.9	1
1577	Immune Checkpoint Inhibitors: The Unexplored Landscape of Geriatric Oncology. <i>Oncologist</i> , 2022, 27, 778-789.	1.9	2
1578	Trends in Incidence and Mortality of Kidney Cancer in a Northern Italian Province: An Update to 2020. <i>Biology</i> , 2022, 11, 1048.	1.3	1
1579	Mechanisms of resistance to immune checkpoint inhibitors. <i>Cancer Science</i> , 2022, 113, 3303-3312.	1.7	12
1580	DOCK4 as a Potential Biomarker Associated with Immune Infiltration in Stomach Adenocarcinoma: A Database Analysis. <i>International Journal of General Medicine</i> , 0, Volume 15, 6127-6143.	0.8	1
1582	A Profile of Avelumab Plus Axitinib in the Treatment of Renal Cell Carcinoma. <i>Therapeutics and Clinical Risk Management</i> , 0, Volume 18, 683-698.	0.9	2
1583	Therapeutic role of deferred cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab. <i>Japanese Journal of Clinical Oncology</i> , 0, , .	0.6	1
1584	Oncological Outcomes of Delayed Nephrectomy After Optimal Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma. <i>European Urology Oncology</i> , 2022, 5, 577-584.	2.6	19
1585	Facts and Hopes for Immunotherapy in Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 5013-5020.	3.2	8
1586	Complete response to an anti-programmed cell death 1 antibody following a combination therapy of an anti-programmed cell death ligand 1 antibody and a tyrosine kinase inhibitor for metastatic renal cell carcinoma. <i>Asian Journal of Urology</i> , 2023, 10, 103-105.	0.5	1
1587	Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	45
1588	Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	15
1589	Impact of modified Glasgow prognostic score on predicting prognosis and modification of risk model for patients with metastatic renal cell carcinoma treated with first line tyrosine kinase inhibitor. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 455.e11-455.e18.	0.8	2
1590	Identifying an Immune-Related Gene ST8SIA1 as a Novel Target in Patients With Clear-Cell Renal Cell Carcinoma. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	1
1591	The Multi-Kinase Inhibitor Lucitanib Enhances the Antitumor Activity of Coinhibitory and Costimulatory Immune Pathway Modulators in Syngeneic Models. <i>Journal of Immunotherapy</i> , 0, Publish Ahead of Print, .	1.2	3

#	ARTICLE	IF	CITATIONS
1592	The value measurement of emerging therapeutics in renal cell carcinoma: ASCO value framework and ESMO-MCBS. BMC Health Services Research, 2022, 22, .	0.9	3
1593	Dose Individualization of Oral Multi-Kinase Inhibitors for the Implementation of Therapeutic Drug Monitoring. Biological and Pharmaceutical Bulletin, 2022, 45, 814-823.	0.6	2
1594	Costâ€ effectiveness analysis of nivolumab plus cabozantinib versus sunitinib as first-line therapy in advanced renal cell carcinoma. Immunotherapy, 2022, 14, 859-869.	1.0	3
1595	Statin use improves the efficacy of nivolumab in patients with advanced renal cell carcinoma. European Journal of Cancer, 2022, 172, 191-198.	1.3	8
1596	Normalization of tumor vasculature: A potential strategy to increase the efficiency of immune checkpoint blockades in cancers. International Immunopharmacology, 2022, 110, 108968.	1.7	2
1597	Renal Tumors. , 2023, , 285-308.		0
1598	The Challenges of Novel Therapies in the Care of the Critically Ill Cancer Patient. , 2023, , 448-458.		0
1599	Current State of Cell Therapies for Genitourinary Malignancies. Cancer Journal (Sudbury, Mass), 2022, 28, 294-300.	1.0	4
1600	Two case reports of immune checkpoint therapy on chromophobe renal cell carcinoma with sarcomatoid differentiation. International Cancer Conference Journal, 0, , .	0.2	1
1601	Blockade of CD47 enhances the antitumor effect of macrophages in renal cell carcinoma through trogocytosis. Scientific Reports, 2022, 12, .	1.6	1
1602	Recent advances in the molecular basis of chemotherapy resistance and potential application of epigenetic therapeutics in chemorefractory renal cell carcinoma. WIREs Mechanisms of Disease, 2022, 14, .	1.5	1
1603	Knowledge mapping and research hotspots of immunotherapy in renal cell carcinoma: A text-mining study from 2002 to 2021. Frontiers in Immunology, 0, 13, .	2.2	15
1604	CABOSEQ: The Effectiveness of Cabozantinib in Patients With Treatment Refractory Advanced Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). Clinical Genitourinary Cancer, 2023, 21, 106.e1-106.e8.	0.9	7
1605	Evaluating the Optimal Duration of Immunotherapy in Kidney Cancer. Kidney Cancer, 2022, 6, 105-107.	0.2	2
1606	Distinct Predictive Immunogenomic Profiles of Response to Immune Checkpoint Inhibitors and IL2: A Real-world Evidence Study of Patients with Advanced Renal Cancer. Cancer Research Communications, 2022, 2, 894-903.	0.7	0
1607	Evaluation of Thyroid Dysfunction Associated with the Use of Molecular Targeted Antineoplastic Drugs Using the Japanese Adverse Drug Event Report Database. Iryo Yakugaku (Japanese Journal of) Tj ETQq1 1 0.784314 rgBT /Overl	0.7	0
1608	Disparities in Clinical Care and Research in Renal Cell Carcinoma. Kidney Cancer, 2022, 6, 147-157.	0.2	1
1609	Next Wave of Targets in the Treatment of Advanced Renal Cell Carcinoma. Current Oncology, 2022, 29, 5426-5441.	0.9	5

#	ARTICLE	IF	CITATIONS
1610	Case Report: Successful treatment of late-onset immune checkpoint inhibitor-associated membranous nephropathy in a patient with advanced renal cell carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
1611	Enhanced Inhibitory Effect of DC-CIK Cells on Lung Adenocarcinoma via Anti-Tim-3 Antibody and Antiprogrammed Cell Death-1 Antibody and Possible Mechanism. <i>Evidence-based Complementary and Alternative Medicine</i> , 2022, 2022, 1-11.	0.5	2
1612	Potential Ophthalmological Side Effects Induced by Anti-Neoplastic Regimens for the Treatment of Genitourinary Cancers: A Review. <i>Cureus</i> , 2022, , .	0.2	0
1613	Adverse Events of Axitinib plus Pembrolizumab Versus Lenvatinib plus Pembrolizumab: A Pharmacovigilance Study in Food and Drug Administration Adverse Event Reporting System. <i>European Urology Focus</i> , 2023, 9, 141-144.	1.6	2
1614	Clinical implications of epigenetics in Renal Cell Carcinoma. <i>Archives of Renal Diseases and Management</i> , 2022, 7, 008-013.	0.3	0
1615	Clinical outcome following checkpoint therapy in renal cell carcinoma is associated with a burst of activated CD8 T cells in blood. , 2022, 10, e004803.		15
1616	Clinical Benefit of Niraparib to TKI/mTORi-Resistance Metastatic ccRCC With BAP1-Frame Shift Mutation: Case Report and Literature Review. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
1617	Advantages of organ-sparing treatment approaches in metastatic kidney cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 3131-3137.	1.2	1
1618	PANK1 associates with cancer metabolism and immune infiltration in clear cell renal cell carcinoma: a retrospective prognostic study based on the TCGA database. <i>Translational Cancer Research</i> , 2022, 11, 2321-2337.	0.4	1
1619	Role of metastasectomy in the management of renal cell carcinoma. <i>Frontiers in Surgery</i> , 0, 9, .	0.6	6
1620	Weight and skeletal muscle loss with cabozantinib in metastatic renal cell carcinoma. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 0, , .	2.9	4
1621	Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study. <i>Onkourologiya</i> , 2022, 18, 39-57.	0.1	0
1622	Identification of ferroptosis-related signature with potential implications in prognosis and immunotherapy of renal cell carcinoma. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2022, 27, 946-960.	2.2	2
1623	Development of a SETD2-related immune prognostic signature in clear cell renal cell carcinoma. <i>Medicine (United States)</i> , 2022, 101, e29561.	0.4	0
1624	Hetero-bivalent agents targeting FAP and PSMA. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 4369-4381.	3.3	16
1625	Is Cytoreductive Nephrectomy Still Beneficial for Patients With Metastatic Renal Cell Carcinoma in the Contemporary Immunotherapy Era?. <i>The Korean Journal of Urological Oncology</i> , 2022, 20, 139-150.	0.1	0
1626	Anticancer Drugs: Recent Strategies to Improve Stability Profile, Pharmacokinetic and Pharmacodynamic Properties. <i>Molecules</i> , 2022, 27, 5436.	1.7	38
1627	Immune-based combination therapy to convert immunologically cold tumors into hot tumors: an update and new insights. <i>Acta Pharmacologica Sinica</i> , 2023, 44, 288-307.	2.8	14

#	ARTICLE	IF	CITATIONS
1628	Treatment of Metastatic Melanoma with a Combination of Immunotherapies and Molecularly Targeted Therapies. <i>Cancers</i> , 2022, 14, 3779.	1.7	18
1629	Molecular Mechanisms and Future Implications of VEGF/VEGFR in Cancer Therapy. <i>Clinical Cancer Research</i> , 2023, 29, 30-39.	3.2	53
1630	Synergistic effect of combining sunitinib with a peptide-based vaccine in cancer treatment after microenvironment remodeling. <i>Oncolimmunology</i> , 2022, 11, .	2.1	1
1631	IL-8 and its role as a potential biomarker of resistance to anti-angiogenic agents and immune checkpoint inhibitors in metastatic renal cell carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
1632	Concomitant Use of Statins, Metformin, or Proton Pump Inhibitors in Patients with Advanced Renal Cell Carcinoma Treated with First-Line Combination Therapies. <i>Targeted Oncology</i> , 0, .	1.7	4
1633	Improving survival in metastatic renal cell carcinoma (mRCC) patients: do elderly patients benefit from expanded targeted therapeutic options?. <i>World Journal of Urology</i> , 2022, 40, 2489-2497.	1.2	3
1634	The expanding role for small molecules in immuno-oncology. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 821-840.	21.5	50
1635	Insomnia in patients treated with checkpoint inhibitors for cancer: A meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
1637	Impact of Body Mass Index on Outcomes in an Asian population of Advanced Renal Cell Carcinoma and Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors. <i>Clinical Genitourinary Cancer</i> , 2023, 21, 136-145.	0.9	2
1638	2021 Consensus Statements on the Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma From the Korean Renal Cancer Study Group (KRCS). <i>The Korean Journal of Urological Oncology</i> , 2022, 20, 151-162.	0.1	1
1639	Iron accumulation typifies renal cell carcinoma tumorigenesis but abates with pathological progression, sarcomatoid dedifferentiation, and metastasis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
1640	Stereotactic Ablative Radiation for Systemic Therapy-naïve Oligometastatic Kidney Cancer. <i>European Urology Oncology</i> , 2022, 5, 695-703.	2.6	17
1641	Bayesian Treatment Screening and Selection Using Subgroup-Specific Utilities of Response and Toxicity. <i>Biometrics</i> , 2023, 79, 2458-2473.	0.8	5
1642	Case Report: Clinical complete response of advanced renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion by treated by camrelizumab and axitinib: A rare case report. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	2
1643	Real-world effectiveness of nivolumab plus ipilimumab and second-line therapy in Japanese untreated patients with metastatic renal cell carcinoma: 2-year analysis from a multicenter retrospective clinical study (J-cardinal study). <i>Japanese Journal of Clinical Oncology</i> , 0, .	0.6	1
1644	Improved Survival of Real-world Japanese Patients With Advanced Renal Cell Carcinoma Treated With Immuno-oncology Combination Therapy. <i>Anticancer Research</i> , 2022, 42, 4573-4580.	0.5	2
1645	Cuproptosis status affects treatment options about immunotherapy and targeted therapy for patients with kidney renal clear cell carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	20
1646	Protein Expression of immune checkpoints STING and MHCII in small cell lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 561-578.	2.0	5

#	ARTICLE	IF	CITATIONS
1647	Tyrosine Kinase Inhibitors in the Treatment of Metastasised Renal Cell Carcinomaâ€”Future or the Past?. <i>Cancers</i> , 2022, 14, 3777.	1.7	6
1648	Targeting <i>KRAS</i> : Crossroads of Signaling and Immune Inhibition. <i>Journal of Immunotherapy and Precision Oncology</i> , 2022, 5, 68-78.	0.6	6
1649	Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell Carcinomas. <i>Oncologist</i> , 2022, 27, 1041-1047.	1.9	10
1650	Immune checkpoint Inhibitorâ€”Induced diarrhea and Colitis: Incidence and Management. A systematic review and Meta-analysis. <i>Cancer Treatment Reviews</i> , 2022, 109, 102440.	3.4	28
1651	IL1R2 promotes tumor progression via JAK2/STAT3 pathway in human clear cell renal cell carcinoma. <i>Pathology Research and Practice</i> , 2022, 238, 154069.	1.0	5
1652	Comprehensive analysis of MFN2 as a prognostic biomarker associated with immune cell infiltration in renal clear cell carcinoma. <i>International Immunopharmacology</i> , 2022, 111, 109169.	1.7	4
1653	The application of 3D bioprinting in urological diseases. <i>Materials Today Bio</i> , 2022, 16, 100388.	2.6	17
1654	Development of a Simple and Objective Prognostication Model for Patients with Advanced Solid Malignant Tumors Treated with Immune Checkpoint Inhibitors: A Pan-Cancer Analysis. <i>Targeted Oncology</i> , 2022, 17, 583-589.	1.7	0
1655	Sarcomatoid-associated gene risk index for clear cell renal cell carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	3
1656	Evaluation of Antineoplastic Delayed-Type Hypersensitivity Skin Reactions In Vitro. <i>Pharmaceuticals</i> , 2022, 15, 1111.	1.7	1
1657	Dissociated response among multiple metastatic lesions in the patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors. <i>Japanese Journal of Clinical Oncology</i> , 0, , .	0.6	0
1658	Effect of Inferior Vena Cava Tumor Thrombus on Overall Survival in Metastatic Renal Cell Carcinoma Patients Treated with Cytoreductive Nephrectomy. <i>European Urology Open Science</i> , 2022, 44, 94-101.	0.2	2
1659	Inducing vascular normalization: A promising strategy for immunotherapy. <i>International Immunopharmacology</i> , 2022, 112, 109167.	1.7	2
1661	Pyroptosis-related gene expression patterns and corresponding tumor microenvironment infiltration characterization in ovarian cancer. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 5440-5452.	1.9	6
1662	Current and future perspectives on CAR-T cell therapy for renal cell carcinoma: A comprehensive review. <i>Investigative and Clinical Urology</i> , 2022, 63, 486.	1.0	7
1663	Available Immunotherapy Drugs in Oncology. <i>Current Clinical Pathology</i> , 2022, , 5-23.	0.0	0
1664	The role of gut microbiome in immune modulation in metastatic renal cell carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211227.	1.4	7
1665	Systemic Therapy for Pancreatic Neuroendocrine Tumors. <i>Clinical Colorectal Cancer</i> , 2023, 22, 34-44.	1.0	1

#	ARTICLE	IF	CITATIONS
1666	Clinical characteristics and outcomes of tyrosine kinase inhibitor-related lower GI adverse effects. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 3965-3976.	1.2	2
1667	Gemcitabine combined with apatinib and toripalimab in recurrent or metastatic nasopharyngeal carcinoma. <i>Med</i> , 2022, 3, 664-681.e6.	2.2	5
1668	Tumor vessel co-option: The past & the future. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	17
1669	Current Options for Second-Line Systemic Therapy in Metastatic Renal Cell Carcinoma. <i>Journal of Kidney Cancer and VHL</i> , 2022, 9, 29-40.	0.2	4
1670	Overcoming the cardiac toxicities of cancer therapy immune checkpoint inhibitors. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
1671	Chimeric Antigen Receptor (CAR) T-cell Treatment in Renal Cell Carcinoma: Current Clinical Trials and Future Directions. <i>Kidney Cancer</i> , 2022, 6, 159-168.	0.2	1
1672	Expression of nectin-4 in papillary renal cell carcinoma. <i>Discover Oncology</i> , 2022, 13, .	0.8	2
1673	Real World Data of Diagnosis, Survival, and Treatment Outcomes in Patients With Metastatic Non Clear Cell Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2023, 21, e35-e43.	0.9	1
1674	A radiogenomics biomarker based on immunological heterogeneity for non-invasive prognosis of renal clear cell carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
1675	Arborinine from <i>Glycosmis parva</i> leaf extract inhibits clear-cell renal cell carcinoma by inhibiting KDM1A/UBE2O signaling. <i>Food and Nutrition Research</i> , 0, 66, .	1.2	3
1676	Re: Jens Bedke, Brian I. Rini, Elizabeth R. Plimack, et al. Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma. <i>Eur Urol</i> . 2022;82:427-439. <i>European Urology</i> , 2022, , .	0.9	0
1677	Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	51
1678	Durable disease control and refractory bullous pemphigoid after immune checkpoint inhibitor discontinuation in metastatic renal cell carcinoma: A case report. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
1679	Integrated TCR repertoire analysis and single-cell transcriptomic profiling of tumor-infiltrating T cells in renal cell carcinoma identifies shared and tumor-restricted expanded clones with unique phenotypes. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
1680	A cuproptosis-related lncRNA signature identified prognosis and tumour immune microenvironment in kidney renal clear cell carcinoma. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	4
1681	Immunotherapy in advanced kidney cancer: an alternative meta-analytic method using reconstructed survival data in case of proportional hazard assumption violation. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
1682	Enhancing therapeutic anti-cancer responses by combining immune checkpoint and tyrosine kinase inhibition. <i>Molecular Cancer</i> , 2022, 21, .	7.9	5
1683	Grade 3/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell Carcinoma. <i>Oncologist</i> , 2023, 28, 72-79.	1.9	2

#	ARTICLE	IF	CITATIONS
1684	The Predictive Value of Three Variables in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-Based Combination Therapies in Randomized Clinical Trials: A Systematic Review and Meta-Analysis. <i>Journal of Oncology</i> , 2022, 2022, 1-12.	0.6	1
1685	Development and validation of a novel immunotype for prediction of overall survival in patients with clear cell renal cell carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
1686	Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC). , 2022, 10, e005413.		6
1687	Lenvatinib plus pembrolizumab combination therapy for adult patients with advanced renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 1049-1059.	1.1	5
1688	Resistance to tyrosine kinase inhibitors promotes renal cancer progression through MCP1P1 tumor-suppressor downregulation and c-Met activation. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	10
1689	Extensive plasma proteomic profiling revealed receptor activator of nuclear factor kappa- β ligand (RANKL) as emerging biomarker of nivolumab clinical benefit in patients with metastatic renal cell carcinoma. , 2022, 10, e005136.		7
1690	A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy. <i>Genome Medicine</i> , 2022, 14, .	3.6	11
1691	ImmunopET Imaging with ⁸⁹ Zr-Labeled Atezolizumab Enables <i><i>In Vivo</i></i> Evaluation of PD-L1 in Tumorgraft Models of Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 4907-4916.	3.2	7
1692	Management of Immune-Related Adverse Events from Immune-Checkpoint Inhibitors in Advanced or Metastatic Renal Cell Carcinoma. <i>Cancers</i> , 2022, 14, 4369.	1.7	4
1693	Effectiveness and Safety of Molecular-Targeted Therapy after Nivolumab Plus Ipilimumab for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter, Retrospective Cohort Study. <i>Cancers</i> , 2022, 14, 4579.	1.7	1
1694	V-Set and immunoglobulin domain containing (VSIG) proteins as emerging immune checkpoint targets for cancer immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
1695	Adrenal Insufficiency with Anticancer Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor: Analysis of the FDA Adverse Event Reporting System. <i>Cancers</i> , 2022, 14, 4610.	1.7	8
1696	Determining Front-Line Therapeutic Strategy for Metastatic Clear Cell Renal Cell Carcinoma. <i>Cancers</i> , 2022, 14, 4607.	1.7	2
1697	A signature based on chromatin regulation and tumor microenvironment infiltration in clear cell renal cell carcinoma. <i>Epigenomics</i> , 2022, 14, 995-1013.	1.0	0
1698	Molecular analysis and favorable clinical outcomes in real-world patients with metastatic renal cell carcinoma. <i>Acta Oncol</i> ³ <i>gica</i> , 2022, 61, 1268-1277.	0.8	2
1699	Systemic therapies for metastatic renal cell carcinoma in the second-line setting: A systematic review and network meta-analysis. <i>Medicine (United States)</i> , 2022, 101, e30333.	0.4	3
1700	Personalizing immunotherapy for renal cell carcinoma: how far have we come?. <i>Expert Opinion on Biological Therapy</i> , 0, , 1-5.	1.4	2
1701	The Emerging Role of Radiation Therapy in Renal Cell Carcinoma. <i>Cancers</i> , 2022, 14, 4693.	1.7	10

#	ARTICLE	IF	CITATIONS
1702	Evolution of precision oncologyâ€gguided treatment paradigms. WIREs Mechanisms of Disease, 2023, 15, .	1.5	5
1703	Immunogenic Cell Death: An Emerging Target in Gastrointestinal Cancers. Cells, 2022, 11, 3033.	1.8	21
1704	Bacterial outer membrane vesicle-based cancer nanovaccines. Cancer Biology and Medicine, 2022, 19, 1290-1300.	1.4	14
1705	Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma. Oncologist, 2023, 28, 157-164.	1.9	10
1707	Establishment of a ccRCC patient-derived chick chorioallantoic membrane model for drug testing. Frontiers in Medicine, 0, 9, .	1.2	3
1708	The relationship between systemic immune inflammation index and survival in patients with metastatic renal cell carcinomatreated with tyrosine kinase inhibitors. Scientific Reports, 2022, 12, .	1.6	7
1709	N6-methyladenosine long non-coding RNAs reveal novel tool to implicate overall survival and immune microenvironment in renal clear cell carcinoma. Journal of Cancer Research and Clinical Oncology, 0, , .	1.2	0
1710	Clinical impact of early response to firstâ€line <sc>VEGFRâ€TKI</sc> in patients with metastatic renal cell carcinoma on survival: A multiâ€institutional retrospective study. Cancer Medicine, 0, , .	1.3	1
1711	Risk of developing hypothyroidism with the use of tyrosine kinase inhibitors and immune checkpoint inhibitors. Cancer Epidemiology, 2022, 81, 102265.	0.8	2
1712	Cancer Immunotherapy Clinical Trials. , 2022, , 1-24.		0
1713	Cancer Immunodiagnosis in Upper Gastrointestinal Cancers. , 2022, , 1-33.		0
1714	Chemotherapeutic Protocols for the Treatment of Genitourinary Cancer. , 2022, , 201-231.		0
1716	Deferred cytoreductive nephrectomy in the management of metastatic renal cell carcinoma: A systematic review and meta-analysis. Urologic Oncology: Seminars and Original Investigations, 2022, , .	0.8	0
1717	Network <sc>Metaâ€Interpolation</sc> : Effect modification adjustment in network metaâ€analysis using subgroup analyses. Research Synthesis Methods, 0, , .	4.2	0
1718	Less is More? First Impressions From COSMIC-313. Cancer Investigation, 2023, 41, 101-106.	0.6	4
1719	Immune checkpoint inhibition in early-stage triple-negative breast cancer. Expert Review of Anticancer Therapy, 2022, 22, 1225-1238.	1.1	2
1720	A predictive signature based on enhancer RNA associates with immune infiltration and aids treatment decision in clear cell renal cell carcinoma. Frontiers in Oncology, 0, 12, .	1.3	0
1721	Prognostic Models for Renal Cell Carcinoma in the Era of Immune Checkpoint Therapy. Cureus, 2022, , .	0.2	0

#	ARTICLE	IF	CITATIONS
1723	Update on Immune Checkpoint Inhibitor Enterocolitis. <i>Current Gastroenterology Reports</i> , 2022, 24, 171-181.	1.1	5
1724	Initial active surveillance for patients with metastatic renal cell carcinoma: 10 years' experience at a regional cancer Centre. <i>Cancer Medicine</i> , 2023, 12, 5255-5264.	1.3	3
1725	Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	59
1726	A novel twelve-gene signature to predict neoadjuvant chemotherapy response and prognosis in breast cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
1729	Outcomes of High-Dose Stereotactic Ablative Radiotherapy to All/Multiple Sites for Oligometastatic Renal Cell Cancer Patients. <i>Current Oncology</i> , 2022, 29, 7832-7841.	0.9	4
1730	Immune-Checkpoint-Inhibitor Therapy Principles and Relevance of Biomarkers for Pathologists and Oncologists. <i>Advances in Anatomic Pathology</i> , 0, Publish Ahead of Print, .	2.4	0
1731	Small molecule inhibitors targeting the cancers. <i>MedComm</i> , 2022, 3, .	3.1	25
1732	Recurrent multiple liver metastases of clear cell renal cell carcinoma with a significant response to sunitinib after nivolumab treatment. <i>IJU Case Reports</i> , 0, , .	0.1	1
1733	IO-IO vs IO-TKI efficacy in metastatic kidney cancer patients: A structured systematic review over time. <i>Seminars in Oncology</i> , 2022, 49, 394-399.	0.8	2
1734	Location matters: LAG3 levels are lower in renal cell carcinoma metastatic sites compared to primary tumors, and expression at metastatic sites only may have prognostic importance. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	8
1735	Emerging Targets in Clear Cell Renal Cell Carcinoma. <i>Cancers</i> , 2022, 14, 4843.	1.7	10
1736	Potential of VEGFR2 expression as a predictive marker of PD-1 blockade in patients with advanced NSCLC. <i>Oncology Reports</i> , 2022, 48, .	1.2	4
1737	Immunoregulatory signal networks and tumor immune evasion mechanisms: insights into therapeutic targets and agents in clinical development. <i>Biochemical Journal</i> , 2022, 479, 2219-2260.	1.7	6
1738	Phase II study of multipeptide cancer vaccine IMA901 after single-dose cyclophosphamide in Japanese patients with advanced renal cell cancer with long-term follow up. <i>International Journal of Urology</i> , 0, , .	0.5	1
1739	Efficacy and safety of anlotinib combined with PD-1/PD-L1 inhibitors as second-line and subsequent therapy in advanced small-cell lung cancer. <i>Cancer Medicine</i> , 2023, 12, 5372-5383.	1.3	12
1740	Treatment of Refractory Metastatic Renal Cell Carcinoma. <i>Cancers</i> , 2022, 14, 5005.	1.7	10
1741	Longitudinal bioluminescence imaging to monitor breast tumor growth and treatment response using the chick chorioallantoic membrane model. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
1744	Cancer Immunotherapy: Harnessing the Immune System to Fight Cancer. <i>Journal of Clinical Medicine</i> , 2022, 11, 6356.	1.0	2

#	ARTICLE	IF	CITATIONS
1745	Optimal Choice of Adjuvant Treatment for Renal Cell Carcinoma Following Nephrectomy. <i>Cancer Management and Research</i> , 0, Volume 14, 3071-3081.	0.9	2
1746	Efficacy and safety of vorolanib plus everolimus in metastatic renal cell carcinoma: A three-arm, randomised, double-blind, multicentre phase III study (CONCEPT). <i>European Journal of Cancer</i> , 2023, 178, 205-215.	1.3	4
1747	Epigenetics in advanced renal cell carcinoma: Potential new targets. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 180, 103857.	2.0	2
1748	A Review of Immune Checkpoint Blockade for the General Surgeon. <i>Journal of Surgical Research</i> , 2023, 281, 289-298.	0.8	3
1749	Avelumab plus axitinib combination in treating metastatic renal cell carcinoma. <i>Onkologie (Czech)</i> Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.0	0
1750	Cabozantinib sensitizes microsatellite stable colorectal cancer to immune checkpoint blockade by immune modulation in human immune system mouse models. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
1751	LTB4R Promotes the Occurrence and Progression of Clear Cell Renal Cell Carcinoma (ccRCC) by Regulating the AKT/mTOR Signaling Pathway. <i>Cells</i> , 2022, 11, 3606.	1.8	3
1752	Immune Checkpoint Inhibitor (ICI) Genes and Aging in Clear Cell Renal Cell Carcinoma (ccRCC): Clinical and Genomic Study. <i>Cells</i> , 2022, 11, 3641.	1.8	2
1753	Contemporary Drug Therapy for Renal Cell Carcinomaâ€”Evidence Accumulation and Histological Implications in Treatment Strategy. <i>Biomedicines</i> , 2022, 10, 2840.	1.4	5
1755	Progression-free Survival After Second Line of Therapy for Metastatic Clear Cell Renal Cell Carcinoma in Patients Treated with First-line Immunotherapy Combinations. <i>European Urology</i> , 2023, 83, 195-199.	0.9	5
1757	Adjuvant therapy options in renal cell carcinoma â€” targeting the metastatic cascade. <i>Nature Reviews Urology</i> , 2023, 20, 179-193.	1.9	4
1758	A Seven-Autophagy-Related Long Non-Coding RNA Signature Can Accurately Predict the Prognosis of Patients with Renal Cell Carcinoma. <i>International Journal of General Medicine</i> , 0, Volume 15, 8143-8157.	0.8	0
1759	French AFU Cancer Committee Guidelines - Update 2022-2024: management of kidney cancer. <i>Progres En Urologie</i> , 2022, 32, 1195-1274.	0.3	11
1760	Emerging evidence of immunotherapy for colorectal cancer. <i>Annals of Gastroenterological Surgery</i> , 2023, 7, 216-224.	1.2	4
1761	Challenges in neoantigen-directed therapeutics. <i>Cancer Cell</i> , 2023, 41, 15-40.	7.7	27
1762	Computed tomographyâ€based radiomics prediction of <scp>CTLA4</scp> expression and prognosis in clear cell renal cell carcinoma. <i>Cancer Medicine</i> , 2023, 12, 7627-7638.	1.3	2
1763	Serum C-reactive Protein Level Predicts Overall Survival for Clear Cell and Non-Clear Cell Renal Cell Carcinoma Treated with Ipilimumab plus Nivolumab. <i>Cancers</i> , 2022, 14, 5659.	1.7	4
1764	[89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2023, 29, 592-601.	3.2	7

#	ARTICLE	IF	CITATIONS
1765	Atezolizumab plus tivozanib for immunologically cold tumor types: the IMMCO-1 trial. <i>Future Oncology</i> , 0, , .	1.1	0
1766	Dry and wet experiments reveal the significant role of FUT11 in clear cell renal cell carcinoma. <i>International Immunopharmacology</i> , 2022, 113, 109447.	1.7	2
1767	Cell-Surface Receptors: EGFR- and VEGFR-Targeted Agents. , 2022, , 153-172.		1
1768	Local Treatment of Recurrent Renal Cell Carcinoma May Have a Significant Survival Effect Across All Risk-of-recurrence Groups. <i>European Urology Open Science</i> , 2023, 47, 65-72.	0.2	4
1769	Therapeutic sequencing in advanced renal cell carcinoma: How to choose considering clinical and biological factors. <i>Critical Reviews in Oncology/Hematology</i> , 2023, 181, 103881.	2.0	3
1770	Can Molecular Classifications Help Tailor First-line Treatment of Metastatic Renal Cell Carcinoma? A Systematic Review of Available Models. <i>European Urology Open Science</i> , 2023, 47, 12-19.	0.2	1
1771	Frontline immune checkpoint inhibitor-based combination therapy in metastatic renal cell carcinoma patients with poor performance status. <i>European Journal of Cancer</i> , 2023, 180, 21-29.	1.3	2
1772	Current and Future Biomarkers in the Management of Renal Cell Carcinoma. <i>Urologic Clinics of North America</i> , 2023, 50, 151-159.	0.8	2
1773	Improved overall survival of metastatic renal cell carcinoma patients in the era of modern tyrosine kinase inhibitors and immune checkpoint inhibitors: results from a real-life, population-based Austrian study comprising three decades of follow-up. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211340.	1.4	1
1774	The Tumor Microenvironment in Pancreatic Cancer and Challenges to Immunotherapy. , 2022, , 381-401.		0
1775	PD-1 inhibitor plus anlotinib for metastatic castration-resistant prostate cancer: a real-world study. <i>Asian Journal of Andrology</i> , 2022, .	0.8	1
1776	Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2022, 7, 131-149.	0.4	3
1777	The Role of Immune Checkpoint Blockade in Acute Myeloid Leukemia. <i>Onco</i> , 2022, 2, 164-180.	0.2	1
1778	Incidence rate and treatment strategy of immune checkpoint inhibitor mediated hepatotoxicity: A systematic review. , 2023, 1, 46-55.		1
1779	Stereotactic body radiotherapy and tyrosine kinase inhibitors in patients with oligometastatic renal cell carcinoma: a multi-institutional study. <i>Strahlentherapie Und Onkologie</i> , 0, , .	1.0	1
1780	Cuprotosis Patterns Are Associated with Tumor Mutation Burden and Immune Landscape in Lung Adenocarcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-12.	0.6	4
1781	Prognostic significance of 18F-FDG PET/CT indices in metastatic renal cell cancer and evaluation of revised IMDC risk model by including 18F-FDG PET-CT parameters. <i>Acta Radiologica</i> , 2023, 64, 2040-2049.	0.5	2
1782	Immune combinations and complete response: a new hope for metastatic renal cell carcinoma. <i>Reports of Practical Oncology and Radiotherapy</i> , 0, , .	0.3	0

#	ARTICLE	IF	CITATIONS
1783	Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma. <i>Nature Reviews Urology</i> , 2023, 20, 133-157.	1.9	46
1784	Tumor-infiltrating immune cell status predicts successful response to immune checkpoint inhibitors in renal cell carcinoma. <i>Scientific Reports</i> , 2022, 12, .	1.6	1
1785	Takotsubo syndrome in a patient with metastatic renal cell carcinoma treated with pembrolizumab plus axitinib. <i>Immunotherapy</i> , 2022, 14, 1297-1305.	1.0	5
1786	A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03). <i>Tumori</i> , 2023, 109, 129-137.	0.6	16
1787	Drugs In The GIST Field (Therapeutic Targets And Clinical Trial Staging). <i>Current Drug Delivery</i> , 2022, 20, .	0.8	0
1788	Baseline Neutrophil-to-Eosinophil Ratio Is Associated with Outcomes in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. <i>Oncologist</i> , 2023, 28, 239-245.	1.9	1
1790	Mapping single-cell transcriptomes in the intra-tumoral and associated territories of kidney cancer. <i>Cancer Cell</i> , 2022, 40, 1583-1599.e10.	7.7	39
1791	Durable complete response for oligometastatic renal cell carcinoma with immune checkpoint inhibition and cytoreductive nephrectomy in a Jehovahâ€™s witness: A case report. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
1792	Proinflammatory activity of VEGF-targeted treatment through reversal of tumor endothelial cell anergy. <i>Angiogenesis</i> , 2023, 26, 279-293.	3.7	12
1793	Unfavorable immunotherapy plus tyrosine kinase inhibition outcome of metastatic renal cell carcinoma after radical nephrectomy with increased ADAM9 expression. <i>Immunogenetics</i> , 0, , .	1.2	1
1794	A Comparison of Alternative Network Meta-Analysis Methods in the Presence of Nonproportional Hazards: A Case Study in First-Line Advanced or Metastatic Renal Cell Carcinoma. <i>Value in Health</i> , 2023, 26, 465-476.	0.1	3
1795	Feasibility and tolerability of sintilimab plus anlotinib as the secondâ€line therapy for patients with advanced biliary tract cancers: An openâ€label, singleâ€arm, phase <sc>II</sc> clinical trial. <i>International Journal of Cancer</i> , 2023, 152, 1648-1658.	2.3	7
1796	Therapeutic Management of Metastatic Clear Cell Renal Cell Carcinoma: A Revolution in Every Decade. <i>Cancers</i> , 2022, 14, 6230.	1.7	3
1797	Active use of electronic patient-reported outcome in kidney cancer and effect on self-reported physical function: PRORECECA study protocol. <i>Acta Oncologica</i> , 2022, 61, 1473-1476.	0.8	1
1798	Long-term Clinical Outcomes of a Spanish Cohort of Metastatic Renal Cell Carcinoma Patients with a Complete Response to Sunitinib. <i>Clinical Genitourinary Cancer</i> , 2023, 21, e166-e174.	0.9	0
1799	Cancer Immunotherapy Beyond Checkpoint Blockade. <i>JACC: CardioOncology</i> , 2022, 4, 563-578.	1.7	1
1800	Immune Checkpoint Inhibitor Therapy in Oncology. <i>JACC: CardioOncology</i> , 2022, 4, 579-597.	1.7	25
1801	Immune Checkpoint Inhibitors in the Pre-operative Setting and Impact on the Primary Renal Tumor. <i>Kidney Cancer</i> , 2022, 6, 201-203.	0.2	1

#	ARTICLE	IF	CITATIONS
1802	Clinical potential of PD-1/PD-L1 blockade therapy for renal cell carcinoma (RCC): a rapidly evolving strategy. <i>Cancer Cell International</i> , 2022, 22, .	1.8	3
1803	APOBEC3G expression correlates with unfavorable prognosis and immune infiltration in kidney renal clear cell carcinoma. <i>Heliyon</i> , 2022, 8, e12191.	1.4	5
1804	Rational combinations of targeted cancer therapies: background, advances and challenges. <i>Nature Reviews Drug Discovery</i> , 2023, 22, 213-234.	21.5	69
1805	Clinical outcomes of nivolumab plus ipilimumab in patients with metastatic non-clear cell renal cell carcinoma: Real-world data from a Japanese multicenter retrospective study. <i>International Journal of Urology</i> , 2023, 30, 714-721.	0.5	3
1806	Prognostic pyroptosis-related lncRNA signature predicts the efficacy of immunotherapy in hepatocellular carcinoma. <i>Biochemistry and Biophysics Reports</i> , 2022, 32, 101389.	0.7	2
1807	Optimizing targeted drug selection in combination therapy for patients with advanced or metastatic renal cell carcinoma: A systematic review and network meta-analysis of safety. <i>Cancer Medicine</i> , 0, , .	1.3	0
1808	Case report and literature review: Small bowel intussusception due to solitary metachronous metastasis from renal cell carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
1809	Efficacy and Safety of Cabozantinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study. <i>Biomedicines</i> , 2022, 10, 3172.	1.4	2
1810	The prospect of tumor microenvironment-modulating therapeutical strategies. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
1811	Current and novel therapeutic strategies for optimizing immunotherapy outcomes in advanced non-small cell lung cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
1812	High Serum Levels of IL-6 Predict Poor Responses in Patients Treated with Pembrolizumab plus Axitinib for Advanced Renal Cell Carcinoma. <i>Cancers</i> , 2022, 14, 5985.	1.7	8
1813	Resistance to immune checkpoint inhibitors and the tumor microenvironment. <i>Experimental Dermatology</i> , 2023, 32, 240-249.	1.4	5
1814	Optimization of first-line systemic therapy in patients with advanced clear cell renal cell carcinoma. <i>International Journal of Urology</i> , 2023, 30, 705-713.	0.5	1
1815	Modulation of RNA splicing enhances response to BCL2 inhibition in leukemia. <i>Cancer Cell</i> , 2023, 41, 164-180.e8.	7.7	15
1816	Immune-based treatment re-challenge in renal cell carcinoma: A systematic review and meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
1817	The Continuing Question of Adjuvant Therapy in Clear Cell Renal Cell Carcinoma. <i>Cancers</i> , 2022, 14, 6018.	1.7	2
1818	Role of IDO expression in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy. <i>BMC Cancer</i> , 2022, 22, .	1.1	2
1819	Repurposing of Commercially Existing Molecular Target Therapies to Boost the Clinical Efficacy of Immune Checkpoint Blockade. <i>Cancers</i> , 2022, 14, 6150.	1.7	3

#	ARTICLE	IF	CITATIONS
1820	Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the <scp>CLEAR</scp> study. <i>Cancer Medicine</i> , 2023, 12, 6902-6912.	1.3	3
1821	Cutaneous adverse events in lung cancer patients on the therapy based on PD-1/PD-L1 inhibitors: A prospective observational cohort study. <i>Current Problems in Cancer</i> , 2022, , 100934.	1.0	0
1822	The iron-modulating hormone hepcidin is upregulated and associated with poor survival outcomes in renal clear cell carcinoma. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
1823	Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escape. <i>Genome Medicine</i> , 2022, 14, .	3.6	15
1824	Patient-reported experiences with side effects of kidney cancer therapies and corresponding information flow. <i>Journal of Patient-Reported Outcomes</i> , 2022, 6, .	0.9	2
1825	Comparison of the Impact of Immune-Related Adverse Events Due to Immune Checkpoint Inhibitor Dual Combination Therapy and Immune Checkpoint Inhibitor Plus Tyrosine Kinase Inhibitor Combination Therapy in Patients with Advanced Renal Cell Carcinoma. <i>Targeted Oncology</i> , 0, , .	1.7	1
1826	Cutaneous adverse events associated with PD-1 inhibitor-based therapy in patients with non-small-cell lung cancer. <i>Future Oncology</i> , 2022, 18, 3853-3861.	1.1	1
1827	The cuproptosis related genes signature predicts the prognosis and correlates with the immune status of clear cell renal cell carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	0
1828	Manipulation of Amino Acid Levels with Artificial Diets Induces a Marked Anticancer Activity in Mice with Renal Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 16132.	1.8	2
1829	Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma. , 2022, 10, e005445.		21
1830	CD70-Targeted Micelles Enhance HIF2 α siRNA Delivery and Inhibit Oncogenic Functions in Patient-Derived Clear Cell Renal Carcinoma Cells. <i>Molecules</i> , 2022, 27, 8457.	1.7	4
1831	Phase 1b/2 trial of fruquintinib plus sintilimab in treating advanced solid tumours: The dose-escalation and metastatic colorectal cancer cohort in the dose-expansion phases. <i>European Journal of Cancer</i> , 2023, 181, 26-37.	1.3	6
1832	Immune Cell Metabolism and Immuno-Oncology. <i>Annual Review of Cancer Biology</i> , 2023, 7, 93-110.	2.3	4
1833	Gonadal Function in Male Patients With Metastatic Renal Cell Cancer Treated With Sunitinib. <i>In Vivo</i> , 2023, 37, 410-416.	0.6	0
1834	Biomarkers of Inflammation and Progression During Immunotherapy in Patients With Metastatic Renal Cell Carcinoma. <i>In Vivo</i> , 2023, 37, 393-399.	0.6	0
1835	Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 1365-1379.	2.0	93
1837	Mechanisms of Resistance to Immunotherapies in Cancer. , 2023, , 1-30.		0
1838	Unraveling the Synergy between Atezolizumab and Bevacizumab for the Treatment of Hepatocellular Carcinoma. <i>Cancers</i> , 2023, 15, 348.	1.7	3

#	ARTICLE	IF	CITATIONS
1839	Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a). <i>International Journal of Molecular Sciences</i> , 2023, 24, 1096.	1.8	3
1840	Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cancer. <i>Cancers</i> , 2023, 15, 313.	1.7	3
1841	Cost-Effectiveness Analysis of Six Immunotherapy-Based Regimens and Sunitinib in Metastatic Renal Cell Carcinoma: A Public Payer Perspective. <i>JCO Oncology Practice</i> , 0, , .	1.4	0
1842	The Role of Immunotherapy in Renal Cell Carcinoma. , 2023, , 1-31.		0
1843	Increasing cure rates of solid tumors by immune checkpoint inhibitors. <i>Experimental Hematology and Oncology</i> , 2023, 12, .	2.0	17
1844	Bone Metabolism Effects of Medical Therapy in Advanced Renal Cell Carcinoma. <i>Cancers</i> , 2023, 15, 529.	1.7	3
1845	Immune Checkpoint Therapy Combinations in Adult Advanced MiT Family Translocation Renal Cell Carcinomas. <i>Oncologist</i> , 2023, 28, 433-439.	1.9	3
1846	Outcomes With Combination Pembrolizumab and Axitinib in Second and Further Line Treatment of Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2023, 21, 221-229.	0.9	2
1847	Adjuvant Therapy in Renal Cell Carcinoma: Are We Ready for Prime Time?. <i>Kidney Cancer</i> , 2023, 7, 1-11.	0.2	2
1848	The value of the multidisciplinary team in metastatic renal cell carcinoma: Paving the way for precision medicine in toxicities management. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
1849	Combining Sunitinib and Bevacizumab for the Management of Advanced Renal Cell Carcinoma: A Phase I/II Trial. <i>Oncologist</i> , 2023, 28, e254-e262.	1.9	3
1850	Exosome-Based Smart Drug Delivery Tool for Cancer Theranostics. <i>ACS Biomaterials Science and Engineering</i> , 2023, 9, 577-594.	2.6	57
1851	Proteomics Characterization of Clear Cell Renal Cell Carcinoma. <i>Journal of Clinical Medicine</i> , 2023, 12, 384.	1.0	1
1852	5-Methylcytosine (m5C) Modification Patterns and Tumor Immune Infiltration Characteristics in Clear Cell Renal Cell Carcinoma. <i>Current Oncology</i> , 2023, 30, 559-574.	0.9	2
1853	Cytoreductive nephrectomy for synchronous metastatic renal cell carcinoma. Is there enough evidence?. <i>Archivio Italiano Di Urologia Andrologia</i> , 2022, 94, 476-485.	0.4	1
1854	A comparative study on nivolumab and axitinib as secondary treatment in patients with metastatic renal cell carcinoma: A multi-institutional retrospective study in Japan. <i>International Journal of Urology</i> , 2023, 30, 723-729.	0.5	2
1855	Development of a TGF- β 2 signaling-related genes signature to predict clinical prognosis and immunotherapy responses in clear cell renal cell carcinoma. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	2
1856	Nivolumab plus cabozantinib for advanced renal cell carcinoma. <i>Future Oncology</i> , 0, , .	1.1	0

#	ARTICLE	IF	CITATIONS
1857	Clear Cell Renal Cell Carcinoma: From Biology to Treatment. <i>Cancers</i> , 2023, 15, 665.	1.7	11
1858	Identification of IRF-associated molecular subtypes in clear cell renal cell carcinoma to characterize immunological characteristics and guide therapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
1859	Tumor immunology. , 2023, , 245-452.		0
1860	Endobronchial metastasis secondary to occulting renal cell carcinoma: literature review and a rare case report. <i>BMC Pulmonary Medicine</i> , 2023, 23, .	0.8	1
1861	Adjuvant Therapy for High-Risk Localized Renal Cell Carcinoma: Current Landscape and Future Direction. <i>OncoTargets and Therapy</i> , 0, Volume 16, 49-64.	1.0	1
1862	Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study. <i>European Urology Oncology</i> , 2023, 6, 437-446.	2.6	4
1863	Case report: Abolishing primary resistance to PD-1 blockade by short-term treatment of lenvatinib in a patient with advanced metastatic renal cell carcinoma. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
1865	Complete Response in Metastatic Clear Cell Renal Cell Carcinoma Patients Treated with Immune-Checkpoint Inhibitors: Remission or Healing? How to Improve Patientsâ€™ Outcomes?. <i>Cancers</i> , 2023, 15, 793.	1.7	6
1866	Genomic Instability and Protumoral Inflammation Are Associated with Primary Resistance to Antiâ€“PD-1 + Antiangiogenesis in Malignant Pleural Mesothelioma. <i>Cancer Discovery</i> , 2023, 13, 858-879.	7.7	4
1867	Multifunctional Dendritic Au@SPP@DOX Nanoparticles Integrating Chemotherapy and Low-Dose Radiotherapy for Enhanced Anticancer Activity. <i>Molecular Pharmaceutics</i> , 0, , .	2.3	0
1868	Expression of PD-L1 in renal cancer, prognostic features and clinical utility of its routine staining. <i>Actas UrolÃ³gicas EspaÃ±olas (English Edition)</i> , 2023, 47, 271-278.	0.2	0
1869	Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study. <i>Journal of Clinical Oncology</i> , 2023, 41, 2571-2582.	0.8	17
1870	Outcomes from treatment of metastatic renal-cell carcinoma following failure of first-line anti-VEGF/VEGFR therapy: real-life evidence on the change of the treatment paradigm. <i>Anti-Cancer Drugs</i> , 2023, 34, 413-421.	0.7	2
1871	Immune checkpoint inhibitors combined with tyrosine kinase inhibitors or immunotherapy for treatment-naïve metastatic clear-cell renal cell carcinomaâ€”A network meta-analysis. Focus on cabozantinib combined with nivolumab. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
1872	Management of immune-mediated toxicities and their implications in the outcomes of advanced kidney cancer. <i>Immunotherapy</i> , 2023, 15, 397-400.	1.0	1
1873	Survival in Metastatic Renal Cell Carcinoma Treated with Immunotherapy and Stereotactic Radiation Therapy or Immunotherapy Alone: A National Cancer Database Analysis. <i>Advances in Radiation Oncology</i> , 2023, , 101238.	0.6	0
1874	ROS Scavenging Nanozyme Modulates Immunosuppression for Sensitized Cancer Immunotherapy. <i>Advanced Healthcare Materials</i> , 2023, 12, .	3.9	3
1875	Impact of Therapy Management on Axitinib-Related Adverse Events in Patients With Advanced Renal Cell Carcinoma Receiving First-Line Axitinib+Checkpoint Inhibitor. <i>Clinical Genitourinary Cancer</i> , 2023, 21, e343-e351.	0.9	1

#	ARTICLE	IF	CITATIONS
1876	Evolving Treatment Options for Metastatic Renal Cell Carcinoma (mRCC). <i>Uro</i> , 2023, 3, 117-131.	0.3	2
1877	An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2023, 29, 2291-2298.	3.2	3
1878	Favorable Immunotherapy Plus Tyrosine Kinase Inhibition Outcome of Renal Cell Carcinoma Patients with Low CDK5 Expression. <i>Cancer Research and Treatment</i> , 0, , .	1.3	0
1879	Integrating Surgery in the Multidisciplinary Care of Advanced Renal Cell Carcinoma. <i>Urologic Clinics of North America</i> , 2023, 50, 311-323.	0.8	2
1880	Multicentre real-world data of ramucirumab plus docetaxel after combined platinum-based chemotherapy with programmed death-1 blockade in advanced non-small cell lung cancer: NEJ051 (REACTIVE study). <i>European Journal of Cancer</i> , 2023, 184, 62-72.	1.3	9
1881	Adaptive Immunity in Genitourinary Cancers. <i>European Urology Oncology</i> , 2023, 6, 263-272.	2.6	3
1882	Radiation Therapy in the Treatment of Localized and Advanced Renal Cancer. <i>Urologic Clinics of North America</i> , 2023, 50, 325-334.	0.8	1
1883	Two is company, is three a crowd? Triplet therapy, novel molecular targets, and updates on the management of advanced renal cell carcinoma. <i>Current Opinion in Oncology</i> , 2023, 35, 206-217.	1.1	1
1884	The Promise of Neoadjuvant and Adjuvant Therapies for Renal Cancer. <i>Urologic Clinics of North America</i> , 2023, 50, 285-303.	0.8	5
1885	The Changing Role of Renal Mass Biopsy. <i>Urologic Clinics of North America</i> , 2023, 50, 217-225.	0.8	0
1886	Exploration of 68Ga-labelled prostate-specific membrane antigen-11 PET/CT parameters for identifying PBRM1 status in primary clear cell renal cell carcinoma. <i>Clinical Radiology</i> , 2023, 78, e417-e424.	0.5	1
1887	Future indications and clinical management for fecal microbiota transplantation (FMT) in immuno-oncology. <i>Seminars in Immunology</i> , 2023, 67, 101754.	2.7	4
1888	An update on safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma. <i>Expert Opinion on Drug Safety</i> , 2023, 22, 279-291.	1.0	4
1889	Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma. <i>Management of Urology</i> , 2022, , 237-245.	0.0	0
1890	Hypertransaminasemia in metastatic renal cell carcinoma patients receiving immune-based combinations: a meta-analysis. <i>Immunotherapy</i> , 2023, 15, 117-126.	1.0	2
1891	Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2023, 84, 109-116.	0.9	15
1892	Monitoring and Modulating Diet and Gut Microbes to Enhance Response and Reduce Toxicity to Cancer Treatment. <i>Cancers</i> , 2023, 15, 777.	1.7	3
1893	Immune Checkpoint Inhibitors in Urological Cancers. , 2023, , 1-25.		0

#	ARTICLE	IF	CITATIONS
1894	Life-threatening hemoptysis in patients with metastatic kidney cancer. <i>Clinical Genitourinary Cancer</i> , 2023, 21, 497-506.	0.9	0
1895	Radiomics to predict immunotherapy efficacy in advanced renal cell carcinoma: A retrospective study. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	1.4	2
1896	HÄmatologische Neoplasien und solide Tumore. , 2022, , 85-151.		0
1897	Pathological Complete Response of Metastatic Clear Cell Renal Carcinoma with Pembrolizumab and Axitinib: A Case Report and Review of Literature. <i>Case Reports in Oncology</i> , 0, , 30-35.	0.3	0
1898	The Efficacy and Safety of Immune Checkpoint Inhibitor and Tyrosine Kinase Inhibitor Combination Therapy for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Real-World Cohort Study. <i>Cancers</i> , 2023, 15, 947.	1.7	3
1899	Immunotherapy in Genitourinary Cancers: Role of Surgical Pathologist for Detection of Immunooncologic Predictive Factors. <i>Advances in Anatomic Pathology</i> , 2023, 30, 203-210.	2.4	0
1900	The role of immunotherapy in non-clear cell renal cell carcinoma. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	5
1902	Immunohistochemical Detection of 5T4 in Renal Cell Carcinoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2023, 31, 135-144.	0.6	1
1903	Modulation of oxidative phosphorylation and mitochondrial biogenesis by cigarette smoke influence the response to immune therapy in NSCLC patients. <i>Lung Cancer</i> , 2023, 178, 37-46.	0.9	0
1904	Real-world Treatment Patterns and Clinical Outcomes for Metastatic Renal Cell Carcinoma in the Current Treatment Era. <i>European Urology Open Science</i> , 2023, 49, 110-118.	0.2	12
1905	Antibody-Based Therapeutics for the Treatment of Renal Cell Carcinoma: Challenges and Opportunities. <i>Oncologist</i> , 2023, 28, 297-308.	1.9	1
1906	The Combination of Immune Checkpoint Blockade with Tumor Vessel Normalization as a Promising Therapeutic Strategy for Breast Cancer: An Overview of Preclinical and Clinical Studies. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3226.	1.8	3
1907	Combinations of Anti-Angiogenic Agents and Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Best Option?. <i>Cancers</i> , 2023, 15, 1048.	1.7	1
1908	LITESPARK-011: belzutifan plus lenvatinib vs cabozantinib in advanced renal cell carcinoma after anti-PD-1/PD-L1 therapy. <i>Future Oncology</i> , 2023, 19, 113-121.	1.1	7
1909	Clinical and molecular features of pulmonary NUT carcinoma characterizes diverse responses to immunotherapy, with a pathologic complete response case. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 6361-6370.	1.2	3
1910	Baseline and Dynamic Changes in Hemoglobin Levels Predict Treatment Response and Prognosis in Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Study. <i>Clinical Genitourinary Cancer</i> , 2023, 21, e242-e251.	0.9	2
1911	EHBP1L1 Drives Immune Evasion in Renal Cell Carcinoma through Binding and Stabilizing JAK1. <i>Advanced Science</i> , 2023, 10, .	5.6	5
1912	The emerging landscape of neo/adjuvant immunotherapy in renal cell carcinoma. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	1.4	4

#	ARTICLE	IF	CITATIONS
1913	Comprehensive Genomic Profiling of <i>NF2</i> -Mutated Kidney Tumors Reveals Potential Targets for Therapy. <i>Oncologist</i> , 0, , .	1.9	3
1914	Development and validation of a nomogram to evaluate the therapeutic effects of second-line axitinib in patients with metastatic renal cell carcinoma. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
1915	Crystallin zeta serves as a prognostic biomarker for patients with kidney renal clear cell carcinoma. <i>Asian Journal of Surgery</i> , 2023, , .	0.2	0
1916	Approaches to Oligometastatic Renal Cell Carcinoma. <i>Current Oncology Reports</i> , 2023, 25, 251-256.	1.8	0
1917	Fibroblast growth factor receptor type 4 as a potential therapeutic target in clear cell renal cell carcinoma. <i>BMC Cancer</i> , 2023, 23, .	1.1	1
1918	Stereotactic body radiation therapy to the kidney for metastatic renal cell carcinoma: A narrative review of an emerging concept. <i>Cancer Treatment and Research Communications</i> , 2023, 35, 100692.	0.7	2
1919	The Changing Landscape of Immunotherapy for Advanced Renal Cancer. <i>Urologic Clinics of North America</i> , 2023, 50, 335-349.	0.8	2
1920	New Phenylspirodrimanes from the Sponge-Associated Fungus <i>Stachybotrys chartarum</i> MUT 3308. <i>Marine Drugs</i> , 2023, 21, 135.	2.2	2
1921	Tumor Vasculature as an Emerging Pharmacological Target to Promote Anti-Tumor Immunity. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4422.	1.8	3
1922	Multidisciplinary Team (MDT) Discussion Improves Overall Survival Outcomes for Metastatic Renal Cell Carcinoma Patients. <i>Journal of Multidisciplinary Healthcare</i> , 0, Volume 16, 503-513.	1.1	2
1923	A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma. <i>European Urology Oncology</i> , 2023, 6, 339-348.	2.6	4
1924	Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study. <i>Lancet Oncology</i> , The, 2023, 24, 228-238.	5.1	35
1925	Targeted Therapies: A Molecular Overview. <i>Åæroonkoloji BÃ¼lteni</i> , 2023, 22, 1-14.	0.1	0
1926	The role of cytoreductive nephrectomy and systemic therapy in the management of tumour thrombus in patients with metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 2023, 128, 1888-1896.	2.9	3
1927	Stereotactic ablative radiotherapy for unresectable inferior vena cava tumor thrombus in a patient with renal cell carcinoma: a case report. <i>Strahlentherapie Und Onkologie</i> , 2023, 199, 420-424.	1.0	3
1928	Characterization and Management of Adverse Reactions From the CLEAR Study in Advanced Renal Cell Carcinoma Treated With Lenvatinib Plus Pembrolizumab. <i>Oncologist</i> , 2023, 28, 501-509.	1.9	3
1929	Study of the action of peripheral blood T-lymphocytes on renal cell carcinoma cells in model systems. <i>Onkourologiya</i> , 2023, 18, 15-24.	0.1	0
1931	The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF. <i>European Journal of Pharmacology</i> , 2023, 949, 175586.	1.7	27

#	ARTICLE	IF	CITATIONS
1932	Pseudoprogression and Mixed Responses in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab: A Retrospective Analysis. <i>Clinical Genitourinary Cancer</i> , 2023, 21, 442-451.	0.9	0
1933	Is It Time to Integrate Frailty Assessment in Onconeurology?. <i>Cancers</i> , 2023, 15, 1674.	1.7	0
1934	Current Advances in Immune Checkpoint Therapy. , 0, , .		0
1935	Phase II Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma. <i>Journal of Clinical Oncology</i> , 2023, 41, 2843-2851.	0.8	10
1936	Navigating and adapting care integrating immunotherapy, antiangiogenic therapy, and combinations in patients with advanced renal cell carcinoma. , 2023, 11, e006361.		1
1937	A New Signature That Predicts Progression-Free Survival of Clear Cell Renal Cell Carcinoma with Anti-PD-1 Therapy. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5332.	1.8	1
1938	Patients'™ Perceptions Regarding the Relevance of Items Contained in the Functional Assessment of Cancer Therapy Kidney Symptom Index-19. <i>Oncologist</i> , 2023, 28, 494-500.	1.9	2
1939	Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies. , 2023, 11, e005923.		4
1940	Patient-reported outcomes in metastatic renal cell carcinoma trials using combinations versus sunitinib as first-line treatment. <i>Nature Reviews Urology</i> , 2023, 20, 420-433.	1.9	4
1941	Anlotinib combined with Sintilimab is win-win cooperation for primary squamous cell carcinoma of the thyroid: A case report and literature review. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	2
1942	A case of metastatic renal cell carcinoma successfully treated with deferred cytoreductive nephrectomy following lenvatinib plus pembrolizumab combination therapy. <i>IJU Case Reports</i> , 0, , .	0.1	0
1943	Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1). <i>Clinical Genitourinary Cancer</i> , 2023, 21, e309-e319.e1.	0.9	4
1944	Comparison of Outcomes Between Therapeutic Combinations Based on Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitor Monotherapy for First-Line Therapy of Patients with Advanced Renal Cell Carcinoma Outside of Clinical Trials: A Real-World Retrospective Multi-Institutional Study. <i>Targeted Oncology</i> , 2023, 18, 209-220.	1.7	4
1945	Cardiovascular profile of contemporary treatments of renal cell carcinoma: A single-center prospective study. <i>International Journal of Cardiology</i> , 2023, 380, 40-46.	0.8	1
1946	Aging microenvironment and antitumor immunity for geriatric oncology: the landscape and future implications. <i>Journal of Hematology and Oncology</i> , 2023, 16, .	6.9	5
1947	Treatment strategies for clear cell renal cell carcinoma: Past, present and future. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	6
1948	Phase I Trial of Combination Therapy With Avelumab and Cabozantinib in Patients With Newly Diagnosed Metastatic Clear Cell Renal Cell Carcinoma. <i>Oncologist</i> , 2023, 28, 737-e693.	1.9	2
1949	Evaluating Trials of Adjuvant Therapy: Is There Benefit for People With Resected Renal Cancer?. <i>Journal of Clinical Oncology</i> , 2023, 41, 2713-2717.	0.8	10

#	ARTICLE	IF	CITATIONS
1950	Prognostic impact of CD73/adenosine 2A receptor (A2AR) in renal cell carcinoma and immune microenvironmental status with sarcomatoid changes and rhabdoid features. <i>Pathology Research and Practice</i> , 2023, 244, 154423.	1.0	1
1951	Predictive value of CXCL10 for the occurrence of immune-related adverse events in patient with renal cell carcinoma. <i>Microbiology and Immunology</i> , 0, , .	0.7	1
1952	Perioperative Complications and Oncologic Outcomes of Nephrectomy Following Immune Checkpoint Inhibitor Therapy: A Multicenter Collaborative Study. <i>European Urology Oncology</i> , 2023, 6, 604-610.	2.6	5
1953	Impact of sex on prognosis in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitors. <i>Japanese Journal of Clinical Oncology</i> , 0, , .	0.6	0
1954	Tailoring treatment with cabozantinib or pazopanib in patients with metastatic renal cell carcinoma: does it affect outcome?. <i>Expert Review of Anticancer Therapy</i> , 2023, 23, 545-554.	1.1	1
1955	Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study. <i>EClinicalMedicine</i> , 2023, 58, 101917.	3.2	12
1956	Ultrasensitive Circulating Tumor DNA Pilot Study Distinguishes Complete Response and Partial Response With Immunotherapy in Patients With Metastatic Renal Cell Carcinoma. <i>JCO Precision Oncology</i> , 2023, , .	1.5	3
1957	<scp>HMOX1</scp> pathway signature predicts clinical benefit from immunotherapy plus tyrosine kinase inhibitor therapy in advanced renal cell carcinoma. <i>Cancer Medicine</i> , 2023, 12, 10512-10525.	1.3	3
1958	The value of PET/CT for the diagnosis and evaluation of immunotherapy in occult primary renal cell carcinoma: a case report. <i>Journal of International Medical Research</i> , 2023, 51, 030006052311624.	0.4	0
1959	Pembrolizumab plus lenvatinib for radically unresectable or metastatic renal cell carcinoma in the Japanese population. <i>Expert Review of Anticancer Therapy</i> , 2023, 23, 461-469.	1.1	1
1960	High levels of baseline serum IL-10 are associated with reduced clinical benefit from first-line immune checkpoint inhibitor therapy in advanced renal cell carcinoma. <i>Journal of Cancer</i> , 2023, 14, 935-942.	1.2	1
1961	Vascular mimicry induced by m6A mediated IGFL2-AS1/AR axis contributes to pazopanib resistance in clear cell renal cell carcinoma. <i>Cell Death Discovery</i> , 2023, 9, .	2.0	4
1962	Targeting angiogenesis in oncology, ophthalmology and beyond. <i>Nature Reviews Drug Discovery</i> , 2023, 22, 476-495.	21.5	43
1963	BAP1-related signature predicts benefits from immunotherapy over VEGFR/mTOR inhibitors in ccRCC: a retrospective analysis of JAVELIN Renal 101 and checkmate-009/010/025 trials. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 2557-2572.	2.0	2
1964	Immune checkpoint therapy—current perspectives and future directions. <i>Cell</i> , 2023, 186, 1652-1669.	13.5	114
1965	Sensitivity of cytology in liver tumor biopsy and its significance in the prompt clinical diagnosis of non-hepatocellular carcinoma. <i>Cancer Medicine</i> , 0, , .	1.3	0
1966	Pathological angiogenesis: mechanisms and therapeutic strategies. <i>Angiogenesis</i> , 2023, 26, 313-347.	3.7	50
1967	Tumor heterogeneity in VHL drives metastasis in clear cell renal cell carcinoma. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	7

#	ARTICLE	IF	CITATIONS
1968	Update on combined immunotherapy for the treatment of advanced renal cell carcinoma. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	1.4	4
1969	SAA1 Has Potential as a Prognostic Biomarker Correlated with Cell Proliferation, Migration, and an Indicator for Immune Infiltration of Tumor Microenvironment in Clear Cell Renal Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7505.	1.8	0
1970	Targeting programmed cell death protein 1 (PD-1) for treatment of non-small-cell lung carcinoma (NSCLC); the recent advances. <i>Pathology Research and Practice</i> , 2023, 246, 154470.	1.0	0
1971	Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics. <i>Pharmaceuticals</i> , 2023, 16, 614.	1.7	18
1972	Targeted therapy. , 2023, , 205-411.		0
1973	Exome-Based Genomic Markers Could Improve Prediction of Checkpoint Inhibitor Efficacy Independently of Tumor Type. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7592.	1.8	1
1974	NeoAdjuvant pembrolizumab and STereotactic radiotherapy prior to nephrectomy for renal cell carcinoma (NAPSTER): A phase II randomised clinical trial. <i>Contemporary Clinical Trials Communications</i> , 2023, 33, 101145.	0.5	1
1988	Immunotherapy and Cancer: The Pharmacistsâ€™ Perspective. , 2023, , 1-34.		0
1993	Role of the gut microbiota in anticancer therapy: from molecular mechanisms to clinical applications. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	27
2001	The clinical application of immuno-therapeutics. , 2024, , 237-288.e7.		0
2023	Immune Checkpoint Inhibitors and Anti-Angiogenic Therapy for Cancer. , 2023, , 1-21.		0
2028	Understanding tumour endothelial cell heterogeneity and function from single-cell omics. <i>Nature Reviews Cancer</i> , 2023, 23, 544-564.	12.8	14
2035	Interleukin-1-mediated immune suppression and resistance to immunotherapy in cancer. , 2023, , 87-98.		0
2037	Re: Bradley McGregor, Daniel M. Geynisman, Mauricio Burotto, et al. A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma. <i>Eur Urol Oncol</i> . 2023;6:339â€“348. <i>European Urology Oncology</i> , 2024, 7, 172.	2.6	0
2050	Statistical Considerations on the Use of RWD/RWE for Oncology Drug Approvals: Overview and Lessons Learned. <i>Therapeutic Innovation and Regulatory Science</i> , 2023, 57, 899-910.	0.8	1
2062	Understanding and integrating cytoreductive nephrectomy with immune checkpoint inhibitors in the management of metastatic RCC. <i>Nature Reviews Urology</i> , 2023, 20, 654-668.	1.9	2
2066	Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	24
2069	From mucosal infection to successful cancer immunotherapy. <i>Nature Reviews Urology</i> , 0, , .	1.9	2

#	ARTICLE	IF	CITATIONS
2071	A Podcast Discussion on the Current Treatment Landscape for Renal Cell Carcinoma. <i>Advances in Therapy</i> , 0, , .	1.3	0
2076	The contribution of automated cytometry in immuno-oncology. <i>Methods in Cell Biology</i> , 2023, , .	0.5	0
2086	Medikamentöse Therapie des metastasierten Nierenzellkarzinoms. <i>Springer Reference Medizin</i> , 2023, , 551-559.	0.0	0
2107	Adult genitourinary cancer: Renal and testicular. , 2024, , 635-670.e2.		0
2120	Checkpoint inhibitors and anti-angiogenic agents: a winning combination. <i>British Journal of Cancer</i> , 0, , .	2.9	2
2123	Heterogeneity of the tumor immune microenvironment and clinical interventions. <i>Frontiers of Medicine</i> , 2023, 17, 617-648.	1.5	0
2136	Perspective Chapter: An Update on Renal Cell Carcinoma. , 0, , .		0
2141	Relapsing cytokine release syndrome in a patient with metastatic renal cell carcinoma treated with pembrolizumab and axitinib therapy. <i>International Cancer Conference Journal</i> , 0, , .	0.2	1
2154	Case Report: Exceptional response to nivolumab plus cabozantinib in a patient with extrarenal clear cell renal cell carcinoma. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
2158	Management of Metastatic Renal Cell Carcinoma. , 2023, , 41-52.		0
2159	Adjuvant Treatment and Follow-Up of Clinically Localized Renal Cell Carcinoma. , 2023, , 53-70.		0
2162	PD-1 and PD-L1 inhibitors in cold colorectal cancer: challenges and strategies. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 3875-3893.	2.0	4
2171	Molecular insight into renal cancer and latest therapeutic approaches to tackle it: an updated review. , 2023, 40, .		0
2172	Pulmonary Toxicity Associated with Immune Checkpoint Inhibitors-Based Therapy: Current Perspectives and Future Directions. <i>Drug Safety</i> , 2023, 46, 1313-1322.	1.4	1
2184	Novel Targets in Development for Advanced Renal Cell Carcinoma. , 2023, , 309-342.		0
2185	Predictive Biomarkers in Advanced Renal Cell Carcinoma. , 2023, , 251-268.		0
2186	Prognostic Factors in Advanced Renal Cell Carcinoma. , 2023, , 233-250.		0
2187	Neoadjuvant Therapy in Locally Advanced Renal Cell Carcinoma. , 2023, , 195-229.		0

#	ARTICLE	IF	CITATIONS
2188	Role of Primary and Metastasis-Directed Stereotactic Radiation Therapy for Advanced Renal Cell Carcinoma. , 2023, , 343-357.		0
2189	First-Line Systemic Treatment Options for Advanced Renal Cell Carcinoma. , 2023, , 269-292.		0
2205	Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations. Nature Reviews Immunology, 0, , .	10.6	2
2211	Current status and future perspective of immunotherapy for renal cell carcinoma. International Journal of Clinical Oncology, 0, , .	1.0	0
2258	Updated systematic review and network meta-analysis of first-line treatments for metastatic renal cell carcinoma with extended follow-up data. Cancer Immunology, Immunotherapy, 2024, 73, .	2.0	0
2272	Malignome des Urogenitaltrakts. , 2024, , 801-864.		0
2280	HÄmatologische Neoplasien und solide Tumore. , 2023, , 99-174.		0